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Abstract. 
Skin graft contracture is a problem facing many burns patients treated with skin 
grafts. Currently grafts under suspicion of contraction are treated with pressure 
garments to prevent contractures progressing. Patients may have to wear these for 
many months however once contractures have formed surgical intervention is 
commonly required. 
The aim of this project was to develop a hydrogel drug delivery system to prevent or 
reduce skin graft contracture. Two potential anti-contraction agents, identified based 
on prior work from our laboratory were initially examined for their effectiveness in 
preventing contracture formation using two 3D models of contraction - collagen I 
gels and a reconstructed human skin model. p-aminopropionitrile (PAPN). a non-
competitive lysyl oxidase inhibitor significantly reduced contraction in the 
reconstructed skin model but not the collagen gel model while 4-methyl 
umbelliferone (4-MU) reduced contraction in both models. 
For hydrogel drug delivery poly(N-vinylpyrrolidinone) (PNVP) hydrogels were 
developed with material properties suitable for use as a non-cytotoxic wound 
dressing. Two cross linked PNVP's were investigated, one crosslinked with ethylene 
glycol dimethacrylate (EGDMA) and the other crosslinked with diethyleneglycol bis 
allylcarbonate (DEGBAC). The different crosslinkers led to hydrogels with different 
mechanical and slightly different biological properties. Although neither hydrogel 
proved to be suitable for culturing cells on, indirect contact with both showed them 
to be biocompatible and in some cases stimulatory to fibroblasts. These hydrogels 
were evaluated for their uptake and release of PAPN and 4-MU. Hydrogels were 
then used to deliver PAPN and 4-MU to reduce skin cell contraction in both collagen 
gels and the reconstructed skin model with some promising preliminary results 
showing hydrogels releasing 4-MU to reduce contraction in the 3D collagen gel 
model. 
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1. Introduction. 
In the UK approximately 250,000 people suffer bum injuries per annum of these 
175,000 attend an accident and emergency department. 13,000 people are 
subsequently admitted to hospital. 1000 patients have bums severe enough to require 
fluid resuscitation and 50% of these are children under 12 years. On average 300 
deaths occur per annum from bums (Hettiaratchy and Dziewulski 2004a). Globally 
more than 6 million patients require grafts for bum injuries per annum. More than 
30% of these will subsequently suffer hypertrophic scarring and graft contracture 
(Harrison and MacNeil Submitted for publication). 
Skin graft contracture is a major clinical problem associated with healing of grafted 
bums patients. Over the past 15 years the group of Professor Sheila MacNeil at the 
University of Sheffield have been investigating the causes of skin graft contracture, 
developing in vitro models and investigating methods of blocking skin graft 
contracture. 
1.1 Skin morphology. 
Before introducing skin graft contracture it is necessary to briefly introduce skin, its 
structure and function, the normal wound healing process and what happens when 
wounds do not heal correctly. 
Skin is often referred to as the largest organ in the body having a surface area of 1.5-
2 m2• It has many functions, sensing its surroundings i.e. sensing touch and 
temperature; it also provides a protective barrier against environmental insult i.e. 
ultraviolet radiation and pathogens (Marte, Finkelstein et al. 2007). One of the more 
important aspects of the skins barrier function is the control skin exerts over the loss 
of water from the body (Paranteau, Hardin-Young et al. 2000). Skin is split into two 
main layers the epidermis and dermis. A schematic diagram showing the gross 
morphology of skin is shown in figure 1.1. 
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Figure 1.1 Schematic diagram of skin obtained from http://www.wikipedia.org. 
The epidermis presents a physical barrier between the body and the external 
environment. It is composed primarily of keratinocytes forming a stratified 
squamous epithelium and is subdivided into four further layers the stratum corneum, 
stratum granulosum, stratum spinosum and stratum basale. Proliferative cells are 
found in the stratum basale, and anchor the epidermis to the dermis. These cells 
continually replenish the cells of the epidermis. As cells move upwards towards the 
surface of the epidermis they terminally differentiate until they integrate into the 
stratum corneum. This is a layer of dead cells that provides the physical barrier of the 
skin. This outermost layer is continually being sloughed off the surface of the skin . 
As cells progress upwards from the stratum basale they stop being proliferative, 
Keratin filaments and desmosomes increase the strength and integrity of the 
intermediate layers (stratum granulosum and stratum spinosum). During the later 
stages of differentiation lipids are extruded into the intercellular space. The nuclei 
and organelles inside the cells breakdown and a highly crosslinked protein envelope 
is formed inside the cell membrane. This envelope is connected to a network of 
intracellular keratin filaments increasing the strength of the epidermis. In addition to 
keratinocytes which are the main cell population in the epidermis, Langerhans ' cells; 
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dendritic cells of the immune system, melanocytes; which produce and distribute 
melanin to neighbouring keratinocytes, and merkel cells; which act as sensory 
receptors can be found (Paranteau, Hardin-Young et al. 2000). 
Between the epidermis and dermis is the basement membrane. This is not visible to 
the naked eye or even under a light microscope. It is a specialized complex 
arrangement of extracellular matrix (ECM) proteins, namely collagen IV, VII and 
laminin that attaches epithelial cells to the underlying dermal matrix (Ghosh, Boyce 
et al. 1997; Ralston, Lay ton et al. 1999). The basement membrane appears to be 
produced by both fibroblasts and keratinocytes. It promotes keratinocyte attachment, 
proliferation and differentiation (MacNeil 1994). 
Below the basement membrane is the dermis. As the epidermis can be divided into 
regions so can the dermis. The papillary dermis, directly below the epidermis and the 
reticular dermis directly below that see figure 1.2 below. The upper surface of the 
papillary dermis forms ridges which interlock with similar ridges on the base of the 
epidermis; these ridges are called Rete ridges. The main difference between the 
papillary dermis and reticular dermis is the structure of the collagen bundles found 
there. The papillary dermis contains loose bundles of collagen whilst the reticular 
dermis contains dense bundles of collagen and elastin and it provides skin with its 
overall strength and elasticity. Within the dermis are many different inclusions, hair 
follicles, sebaceous glands, sweat glands etc. The dermis also contains blood vessels, 
nerves and lymphatic vessels The primary cell population in the dermis is the 
fibroblast which secretes large amounts of collagen, they can secrete enzymes such 
as collagenases and other proteases that can 'remodel' the dermis (Ramos-E-Silva 
and Ribeiro De Castro 2002). Other cells found in the dermis include endothelial 
cells which are found lining blood vessels, mast cells which contain granules rich in 
histamine and heparin and are involved in inflammation, macrophages and 
Iymphocytes. 
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Figure 1.2 Histology slide illustrating the epidennis, papillary dennis and reticular 
dennis. Image obtained from http://www.bu.edu/histology/p/0820310a.htm. 
1.2 Wound healing. 
As wound healing is a complex process involving multiple cell types, growth factors , 
cytokines, peptides etc. and many different processes a brief overview will be given 
here. There are many factors that affect the wound healing process especially in 
major wounds such as bums, age, nutrition, infection, associated illness and 
cytotoxic treatments all impact in either a positive or negative way. Wound healing 
is traditionally divided into three phases, inflammation, proliferation and 
remodelling or maturation (Broughton, Janis et at. 2006). These three phases of 
wound repair are not mutually exclusive but rather overlap in time (Clark 1995). The 
primary goals of wound treatment are rapid wound closure and a functional and 
aesthetically satisfactory scar. Recent advances in cellular and molecular biology 
have expanded the body of knowledge of the biological processes involved in wound 
healing and tissue regeneration and have led to improvements in wound care (Singer 
and Clark 1999). 
1.2.1 Inflammation. 
The skin serves as a protective barrier against the outside world. Any break in this 
barrier must therefore be mended rapidly. Most cutaneous wounds result in trauma to 
the blood vessels in the dennis, but this is not always the case. If haemorrhage does 
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occur then a temporary repair is achieved in the form of a clot or scab that plugs the 
defect (Martin 1997). This clot enables haemostasis to be re-established and provides 
ECM which aids cell migration into the wound bed. The clot that forms is made of 
collagen, platelets, thrombin, and fibronectin. The cytokines and growth factors 
released by the platelets initiate the inflammatory response (Broughton, Janis et al. 
2006). Chemotactic growth factors released by the platelets in the clot such as 
transforming growth factor-!3 (TGF-!3) and platelet derived growth factor (POGF) are 
among the triggers for leukocyte recruitment to the wound bed. 
Neutrophils are the most abundant leukocytes in the early stages of healing 
(Mutsaers, Bishop et al. 1997). Activation of inflammatory cells is important, 
activated macrophages mediate angiogenesis (the formation of new blood vessels). 
fibroplasia (formation of fibrous tissue) and synthesis of nitric oxide. Neutrophils 
clear the wound of invading bacteria, cellular debris and non-viable tissue. 
Neutrophils can generate oxygen free radicals and secrete proteases with either broad 
specificity i.e. elastase, or matrix metalloproteinase's (MMP's) which have greater 
specificity. Both of these destroy the existing wounded ECM, protease inhibitors 
protect unwounded ECM but this protection can be overwhelmed and penetrated if 
the inflammatory response is extremely robust from a massive release of proteases 
(Broughton, Janis et at. 2006). Neutrophils not only clear the wound bed of wounded 
ECM but clear the wound bed of invading bacteria. They are also a source of pro-
inflammatory cytokines that serve as some of the earliest signals to activate local 
fibroblasts and keratinocytes. Unless a wound is grossly infected, the neutrophil 
infiltration ceases after a few days, expended neutrophils are then phagocytosed by 
invading macrophages (Martin 1997). 
Macrophages are vital for normal wound healing and appear to have a pivotal role in 
the transition between inflammation and repair (Singer and Clark 1999). They act 
with neutrophils to phagocytose wound debris and invading bacteria and other 
pathogenic microorganisms. They are also a source of growth factors and cytokines 
such as POGF, TGF-!31,2&3, transforming growth factor-u (TGFu), heparin binding 
epidermal growth factor (HB-EGF), fibroblast growth factors 1,2 and 4 (FGF 1,2&4), 
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vascular endothelial growth factor (VEGF) and tumour necrosis factor-a (TNFa) 
(Martin 1997; Mutsaers, Bishop et al. 1997). 
1.2.2 Proliferation. 
The proliferation phase or tissue formation phases contains epithelialisation, 
angiogenesis and provisional matrix formation (Broughton, Janis et al. 2006). To aid 
keratinocyte migration MMP secretion is up regulated in migrating keratinocytes and 
those close to the wound edge. MMP's up regulated include MMP-9 (gelatinase B). 
MMP-I (interstitial collagenase) and MMP-I0 (stromelysin-2), these quickly start to 
remove wounded tissue and clotted blood from the wound bed (Martin 1997; Singer 
and Clark 1999). Keratinocyte growth factor (KG F) is synthesised and secreted by 
fibroblasts in close proximity to the wound bed. This and the presence of HB-EGF 
and other growth factors such as TGFa and FGF stimulates keratinocytes to migrate 
into the wound bed in a leapfrog like fashion (Clark 1995). Keratinocytes migrate 
from the margins of the wound and the linings of any dermal inclusions i.e. hair 
follicles within the wound bed. Keratinocytes immediately behind the migrating 
keratinocytes begin to proliferate but not differentiate and as reepithelialisation 
progresses basement-membrane proteins reappear in an ordered fashion from the 
margin of the wound inward (Clark 1995; Martin 1997; Singer and Clark 1999; 
Broughton, Janis et al. 2006). Once the wound surface has been covered by a 
monolayer of keratinocytes migration ceases, this is probably caused by contact 
inhibition. From this point on a new stratified squamous epithelium complete with 
basement membrane is established from the wound margin inward. Coincident with 
the synthesis of the basal lamina (the uppermost portion of the basement membrane), 
keratinocyte MMP expression is 'shut off, and new hemidesmosomal adhesions to 
the basal lamina reassemble (Martin 1997). 
Angiogenesis or neovascularisation is the formation of new blood vessels within the 
healing wound and it is necessary to sustain the newly forming granulation tissue. 
Many factors are implicated in angiogenesis the release of growth factors such as 
FGF2, TGFp, and VEGF at the wound margin, and low oxygen tension and elevated 
lactic acid promote angiogenesis (Martin 1997; Singer and Clark 1999; Broughton. 
Janis et al. 2006). Angiogenesis is a complex process that relies on an appropriate 
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ECM in the wound bed as well as phenotype alteration, stimulated migration, and 
mitogenic stimulation of endothelial cells (Clark 1995). Proliferating microvascular 
endothelial cells both adjacent to and within the wound bed deposit fibronectin and 
begin to form new capillary tubes (Singer and Clark 1999; Broughton, Janis et at. 
2006). However once the wound is filled with granulation tissue angiogenesis ceases 
and many of the new blood vessels disintegrate as a result of apoptosis (Singer and 
Clark 1999). 
Fibroplasia consists of granulation tissue components that arise from fibroblasts 
(Clark 1995) and provides provisional support for the migrating epithelium (Linares 
2002). Granulation tissue begins to invade the wound approximately four days after 
injury. The molecules of newly formed ECM contribute to granulation tissue 
formation by providing a scaffold for cell migration into the wound. These 
molecules include fibrin, fibronectin and hyaluronic acid (Singer and Clark 1999). 
Skin fibroblasts are normally sessile and quiescent, but shortly after wounding they 
become activated (Grinnell 1994). Fibroblasts synthesise a matrix comprising mainly 
of collagen. In uninjured skin collagen 80-90% of the collagen is collagen 1 with 10-
20% collagen Ill. In granulation tissue collagen III comprises 30% of the total 
collagen (Broughton, Janis et at. 2006). 
1.2.3 Wound remodelling. 
Clinically, the maturation and remodelling phase is perhaps the most important 
(Broughton, Janis et at. 2006). The main features of this phase are the deposition and 
organisation of ECM in the wound bed, cell maturation and cell apoptosis (Clark 
1995). This third phase overlaps with tissue formation but can proceed for months 
after the wound appears to be healed. Remodelling of the ECM and maturation of 
the neoepidermis, fibroplasia and neovasculature begin at the wound margin while 
granulation tissue is still invading the wound space in all but the smallest of wounds 
(Clark 1995). Remodelling of the collagen meshwork in the wound bed includes 
increased crosslinking, breakdown activity of collagenases, decrease In 
glycosaminoglycans, regression of the capillary neovasculaturity, maintenance of an 
adequateI:IIl collagen ratio, and reorientation of collagen fibres in response to 
mechanical stress (Linares 2002). The degradation of collagen in the wound is 
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controlled by MMP's secreted by macrophages, epidermal cells and endothelial cells 
as well as fibroblasts (Singer and Clark 1999). Along with efforts to reepithelialise 
the wound spatial reduction in the size of the wounded area is also attempted. This 
occurs by means of centripetal movements of the surrounding skin and shrinkage of 
the wound contents (Linares 2002). Wound contraction is the relatively rapid 
mechanical reduction in the size of a wound (Greenhalgh 2002). Any. significant loss 
of dermis tends to contract and distort the skin producing a scar (Ramos-E-Silva and 
Ribeiro De Castro 2002). Collagen remodelling during the transition from 
granulation tissue to scar is dependent on continued synthesis and catabolism of 
collagen at a low rate (Singer and Clark 1999). Clinically, the original redness, 
elevation, and firm consistency of the new scar tissue gradually evolves into a pale, 
flat, soft scar tissue which is level with the adjacent skin surface. This phase of 
'maturation' includes a gradual replacement of the original scar tissue over a period 
of at least six months. A resulting scar may be depressed with respect to the normal 
skin level. show hypotrophic or even atrophic tissue features. be darker or lighter 
than the surrounding skin, or become hypertrophic (Linares 2002). Healed wounds 
never attain the same breaking strength as uninjured skin, at one week, the wound 
only has 3% of its final strength; at three weeks it is 30% and at three months and 
beyond it is approximately 80% (Singer and Clark 1999; Broughton. Janis et al. 
2006). Van Zuijlen et al. (2003) looked to see if there was any difference in the 
collagen morphology or collagen orientation in normal skin and in scar tissue 
especially in scars around joints. Despite their original hypothesis that collagen 
bundles align in a parallel fashion in the direction of mechanical tension during 
scaring, no difference could be found between collagen orientation for joints and 
control areas with respect to the mechanical forces acting on the skin. They 
concluded therefore that mechanical tension caused by joint mobility does not affect 
collagen structure and subsequently questioned whether tensional load is a causative 
factor for wound healing complications, such as contracture. However the collagen 
morphology of scar tissue differed significantly from that of normal skin, as collagen 
bundles of scar tissue were orientated in a more parallel fashion with respect to 
action of the mechanical forces than in normal skin (van Zuijlen, Ruurda et al. 2003). 
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1.2.4 Wound contraction, contracture and the myofibroblast. 
Wound contraction is often attributed to the presence of myofibroblasts in 
granulation tissue. The myofibroblast phenotype is characterised by large bundles of 
a smooth muscle actin containing microfilaments disposed along the cytoplasmic 
face of the plasma membrane of the ceIls, and by ceIl-cell and cell-matrix linkages 
(Martin 1997; Singer and Clark 1999). Myofibroblasts are also characterised by an 
indented nuclear envelope and weIl developed stress fibres (Scott, Ghahary et al. 
2002). According to GrinneIl et al. (1994) research performed in the 1950's 
implicated "connective tissue ceIls" in wound contraction and that subsequently, 
Gabbiani in 1972 demonstrated that granulation tissue could undergo a "smooth 
muscle-like" contraction in vitro. The cells in this granulation tissue exhibited some 
features of smooth muscle cells such as actin filament bundles or stress fibres. These 
'myofibroblasts' were therefore proposed to be responsible for force generation, and 
their presence has turned out to be a general feature of tissues undergoing 
contraction (GrinneIl 1994). In a normaIly healing wound when contraction stops 
and the wound is fuIly epithelialised myofibroblasts disappear in the scar. This could 
be due to myofibroblasts becoming quiescent when the wound is closed or 
myofibroblasts disappearing through apoptosis (Desmouliere 1995). It has been 
noted that hypertrophic scar tissue, but not keloid tissue, contains elevated numbers 
ofmyofibroblasts (Scott, Ghahary et al. 2002; Desmouliere, Chaponnier et al. 2005). 
Therefore, the presence of myofibroblasts has been considered a marker for fibrous 
tissue that is prone to undergo contracture. Keratinocytes have also been implicated 
in contracture formation. Work in the MacNeil group at the University of Sheffield 
has shown that keratinocytes are the primary cell type responsible for contraction of 
tissue engineered skin (Ralston, Lay ton et al. 1999; Chakrabarty, Heaton et at. 2001; 
Harrison, Gossiel et at. 2006c; Thomton, Harrison et at. ProvisionaIly accepted; 
Harrison and MacNeil Submitted for publication). Erdag and Sheridan (2004) 
showed that the addition of fibroblasts to a cultured skin substitute prepared from 
acellular dermis seeded with keratinocytes reduced contraction, increased 
vascularisation and produced a better epidermis (Erdag and Sheridan 2004). 
However the addition ofkeratinocytes to fibroblast populated coIlagen gels increased 
contraction (Oshita, Lee et at. 2006). Souren et al. (1989) showed that keratinocyte 
mediated contraction of collagen gels was more effective when the cells were seeded 
21 
on top of the gel rather than when they were dispersed through it. It has also been 
shown that inhibition of keratinocyte differentiation inhibits reconstructed skin 
contraction (Thornton, Harrison et at. Provisionally accepted). This correlates with 
Lillie et al. (1988) who suggested that contraction occurs in the stratum spinosum. 
The ability of keratinocytes to contract collagen gels or dermis is closely related to 
the concentration of collagen in the gel (Lillie, MacCallum et al. 1988) or the 
pliability of the dennis (Chakrabarty, Heaton et at. 200 I; Harrison, Gossiel et al. 
2006c). It has been shown that contraction ultimately becomes irreversible and 
appears to be maintained by collagen crosslinking (Harrison, Gossiel et al. 2006c). In 
a recent review Harrison and MacNeil state that it is clear that despite 50 years of 
research in this area, the treatment and prevention of graft contraction have 
progressed very little and understanding of the underlying mechanism remains poor 
(Harrison and MacNeil Submitted for publication). 
Most likely, the process of contraction evolved as a rapid and efficient way to close 
an open wound (Greenhalgh 2002). Loose-skinned animals possess a subcutaneous 
muscle layer called the panniculus carnosus which enables the skin to glide smoothly 
over the underlying tissues leading to wound closure with little scaring or loss of 
function. However, in man, this muscular layer is absent and the skin is more finnly 
attached, so the consequences of wound contraction are less beneficial. ranging from 
a minimal cosmetic scar in some cases to defonnity or disability in others (Gennain, 
Jean et at. 1994; Grinnell 1994; Harrison and MacNeil Submitted for publication). It 
is therefore necessary to distinguish between contraction as a nonnal, integral part of 
the wound healing process and excessive contracture the abnonnal result of the 
wound healing process resulting in significant scaring, disfigurement or loss of 
mobility. Scar contractures occur when the scar is not fully matured and often tend to 
be hypertrophic. They are common after burn injury across joints or skin concavities 
(Bayat, McGrouther et at. 2003). 
1.2.5 Pharmacological methods to reduce contraction - p-aminopropionitrile 
and 4-methyl umbelliferone. 
p-aminopropionitrile (PAPN) is a specific non competitive Iysyl oxidase inhibitor 
isolated from the sweet pea (Arem, Madden et at. 1975). Lysyl oxidase enzymes are 
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a family of enzymes involved in the crosslinking of collagen. It has been shown that 
fibroblasts treated with 0.25 and 0.5 mM PAPN have reduced migration however no 
alteration in cell proliferation or collagen synthesis was observed (Nelson, 
Diegelmann et al. 1988). Harrison et al. (2006a) showed that treatment of 
keratinocyte and fibroblast mono and co-cultures with PAPN increased production of 
PINP the amino terminated procollagen tripeptide. This drug was subsequently 
shown to decrease the contraction of the MacNeil group tissue engineered skin 
model from 60% of original area to approximately 20% of original area at a 
concentration of 200 J.!g.mr1 in Greens medium (Harrison, Gossiel et al. 2006c). 
This is in good agreement with research which showed that treatment of fibroblast 
populated collagen gels with PAPN at a concentration of 1 mM decreased 
contraction (Redden and DooIin 2003). 
Chakrabarty (2001) and Ralston (1997) showed that contraction of the reconstructed 
skin model was primarily driven by keratinocytes. It has also been shown that the 
more differentiated the keratinocytes were the more the skin contracted (Thornton, 
Harrison et al. Provisionally accepted). Reducing the hyaluronan concentration 
around the keratinocytes, temporarily reducing the differentiation of the 
keratinocytes could therefore reduce contraction. Rilla et al. (2005) reported that 
excessive epidermal HA was implicated in the hyperproliferation and disturbed 
terminal differentiation ofkeratinocytes. 4-methyl umbelliferone (4-MU) inhibits the 
synthesis of hyaluronan by suppressing the expression of hyaluronan synthase 
(HAS) enzymes on the plasma membrane of keratinocytes (Rilla et al. 2005). Rilla et 
al. 2005 also showed that decreasing HA synthesis by treating keratinocyte cultures 
with 4-MU strongly inhibited cell proliferation. In monolayer cultures treated with 
0.5 mM 4-MU cell proliferation was completely, but reversibly, blocked. In a more 
physiologically relevant model keratinocytes were grown on a collagen gel at an air-
liquid interface to create a fully differentiated normal epidermis. 4-MU did not affect 
the structure or the differentiation pattern of the cultures (Rilla, Pasonen-Seppanen et 
al. 2004). 4-MU has also been shown to increase mRNA expression for MMP-} 
(Interstitial collagenase) resulting in activation of MMP-2 (Gelatinase A / Type IV 
collagenase) in cultured human skin fibroblasts (Nakamura, Ishikawa et al. 2002). 
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Hyaluronan (HA) is a negatively charged extracellular glycosaminoglycan (GAG) 
that accumulates in wound beds. Allison and Grande-Allen (2006) reviewed the uses 
of HA in tissue engineering where it has been used in applications as far ranging as 
tissue engineering scaffolds and drug delivery devices. This review indicates that HA 
is crucial in embryo development, tissue organisation, wound healing and 
angiogenesis. It is most widely known, however for its effects on the biomechanical 
properties of tissues especially in cartilage. The presence of HA in wound beds 
increases keratinocyte migration (Karvinen, Pasonen-Seppanen et al. 2003; Allison 
and Grande-Allen 2006). HA also has an important role in cell adhesion, migration, 
proliferation and differentiation (Nag ira, Nagahata-Ishiguro et al. 2007). Nagira et al. 
(2007) investigated how sulphated HA (sHA) influenced the adhesion of fibroblasts 
and keratinocytes. Nagira et al. also investigated how sHA affected keratinocyte 
proliferation. Differentiation was investigated by analysis of Wnt4, Wnt5a, Wnt6, 
Wnt7a, Notch I, Notch2 and Notch3 expression. This study showed that sHA 
promoted keratinocyte differentiation by increasing the expression of Wnt4 and 
Wnt6 mRNA's. Conversely Notch! expression was down regulated whilst Notch2 
expression remained unchanged and Notch3 expression increased. Fibroblasts 
showed low adhesion to sHA coated surfaced whilst keratinocytes showed high 
adhesiveness to the same coated surfaces. HA interacts with cell surfaces via cell-
surface receptors such as CD44 (Allison and Grande-Allen 2006). It was stated in 
this paper that the interaction of HA with CD44 promotes cell migration, 
extracellular matrix remodelling, promotes the inflammatory response and can 
inhibit cell adhesion. 
Reducing the hyaluronan concentration around the keratinocytes, by treatment with 
4-MU, might temporarily reduce the differentiation of the keratinocytes and reduce 
contraction in the reconstructed skin model. 
1.2.6 Burns wounds. 
Bum trauma to the skin can occur through a variety of methods, flames, scalds, 
contact, electrical, chemical, friction and sunburn (Benson, Dickson et al. 2006). 
Bum depth is traditionally divided into four categories; first degree bums affect the 
epidennis only. Second degree bums extend into the dermis whilst third degree 
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bums extend into the subdermal fat. Fourth degree bums extend beyond the 
subdermal fat into the fascia, bone, tendon, muscle or other tissue, this is illustrated 
in figure 1.3 (Greenhalgh 2002). 
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Figure 1.3 Illustration of bum depth in relation to the gross morphology of skin. 
Image obtained from http://www.burn-recovery.org/treatment.htm. 
Bum injuries can also be divided into three zones, the zone of coagulation, zone of 
stasis and zone of hyperaemia (Quinn, Courtney et al. 1985). The zone of 
coagulation is the most severely affected part of the bum. Here there is irreversible 
tissue loss due to the coagulation of the ECM proteins. The zone of stasis surrounds 
the zone of coagulation. Here the tissue is potentially salvageable, however this zone 
is characterised by decreased tissue perfusion. The zone of hyperaemia is the 
outermost zone and here tissue perfusion is increased. The tissue here will usually 
recover (Hettiaratchy and Dziewulski 2004b). Bums are peculiar injuries because 
they force an organism into a tremendous biological task of equilibrating its 
deranged internal homeostasis and, at the same time, reconstructing its destroyed 
protective barrier against the external environment (Linares 2002). However the bum 
wound is a dynamic living environment that will alter depending on both intrinsic 
factors (inflammation, bacterial contamination etc.) and extrinsic factors 
(dehydration, systemic hypotension, cooling etc.) (Papini 2004). 
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Healing of burn wounds follows the same principles as general wound healing. The 
type of healing that is involved changes, depending on the depth of the wound 
(Greenhalgh 2002). Superficial burns usually heal primarily by reepithelialisation 
within fourteen days and leave minimal scarring. Deep burns have a prolonged 
healing time and usually require surgical intervention i.e. excision and skin grafts 
(Benson, Dickson et al. 2006). When epithelialisation is delayed beyond three 
weeks, the incidence of hypertrophic scarring increases from 33% to 78% (Papini 
2004). Split-thickness skin autografts from uninjured skin remain the mainstay of 
treatment for many patients. However autologous skin has limited availability, is 
associated with additional scarring and unfortunately severe burn patients invariably 
lack sufficient adequate skin donor sites (Atiyeh, Hayek et a!. 2005). If this is the 
case then STSG's can be combined with cadaveric skin or artificial skin substitutes 
(Benson, Dickson et al. 2006). 
According to Bombaro et a!. (2003) hypertrophic scarring following burn injury 
continues to be a real concern and clinical challenge. It is common for burn survivors 
to wear pressure garments in an attempt to reduce hypertrophic scarring. When 
reviewing the prevalence of hypertrophic scaring following burns Bombaro et al. 
(2003) noted that 67% ofthe group examined presented with hypertrophic scars. The 
group was split by race into white versus non-white and the results are shown in 
table 1.1 below. 
Table 1.1 Prevalence of hypertrophic scarring after burns taken from (Bombaro, 
Engrav et a!. 2003) 
Age 1 Years White (%) Non-white (%) 
<15 (n=13) 6/8 (75%) 5/5 (100%) 
15-44 (n=48) 19/32 (60%) 12/16 (75%) 
45-65 (n=23) 13/19 (68%) 3/4 (75%) 
>65 (n=2) 0/2 (0%) -
These results correlate with studies performed by Deitch et a!. and McDonald and 
Deitch (De itch, Wheelahan et al. 1983; McDonald and Deitch 1987) who showed 
that non-white patients were more likely to have hypertrophic scaring after burns 
(Deitch, Wheelahan et al. 1983) or in burns that had been treated with a skin graft 
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(McDonald and Deitch 1987). Children, under 14 years of age, were also more likely 
to have hypertrophic scars after bums than adults especially in grafted sites 
(McDonald and Deitch 1987). As mentioned previously the current gold standard for 
bums wound treatment is the addition of an autologous split thickness skin graft 
(STSG) to the wound bed. However treatment with STSG's is not problem free, 
STSG's have been shown to produce hypertrophic scars and contractures (McDonald 
and Deitch 1987). Stephenson et al. (2000) therefore investigated the effect of full 
thickness skin grafts (FTSG's) on contraction. Unfortunately these grafts still 
contracted significantly despite the initial thought that FTSG's should contract less. 
However there was no comparison made between FTSG's and STSG's in this study. 
Currently problematic scars can be treated with non-invasive treatment, invasive 
treatment or be left alone and managed. Non-invasive treatments include pressure 
therapy i.e. pressure garments, splitting, acrylic casts, masks and clips, various oils, 
drugs, creams and lotions. Hydrotherapy and massage therapy are also used. Invasive 
treatments can involve surgical excision and revision, steroid injections, fluorouracil 
injections, interferon-y, bleomycin, radiotherapy, laser therapy and cryosurgery 
(Bayat, McGrouther et al. 2003). Pressure garments have been the major form of 
treatment for hypertrophic scars and potential contractures since the early 1970's. 
Specific references to treating hypertrophic scars with pressure go as far back as the 
early 1800's (Edgar and Brereton 2004; Macintyre and Baird 2006). Macintyre et al. 
(2006) when reviewing pressure garments suggest that the pressure exerted by 
pressure garments controls collagen synthesis, reduces collagen production and 
encourages realignment of collagen bundles already present. They suggest that these 
effects could increase scar maturation, reduce the incidence of contractures and thus 
the need for surgical intervention. A reduction in the itchiness and pain that is 
associated with active hypertrophic scars is a fortunate side effect of the application 
of pressure to scars (Macintyre and Baird 2006). However, although pressure therapy 
has been used for more than three decades in the management of hypertrophic and 
bum scars, so far scientific evidence is limited. Recommendations about the amount 
of pressure and duration of the therapy are merely based on empirical observations, 
although, there is consensus that the early application of pressure is necessary for an 
optimal outcome (WilIiams, Knapp et al. 1998; Van Den Kerckhove, Stappaerts et 
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al. 2005). Van Den Kerckhove et al. did show a significant difference in the 
thickness of post-burn scars that were preventively treated with garments that were 
delivering pressures with a mean value of 15 mmHg compared to scars treated with 
garments delivering a lower mean pressure (Van Den Kerckhove, Stappaerts et al. 
2005). 
1.3 Wound healing and contraction models. 
Several different contraction models are available for use; they vary from simple 
collagen gel models to in vivo animal models. All of these models have positives and 
negatives. The collagen gel model is very popular especially when populated with 
fibroblasts. It is relatively easy to cast collagen gels into the required shapes for 
mechanical loading (Berry, Shelton et al. 2003), for clamping to allow cellular 
contractile forces to be measured (Freyman, Yannas et al. 2002) or for clamping for 
microscopy (Freyman, Yannas et al. 2001). Collagen gels contract rapidly and 
experiments have been performed over time periods varying from 3 hours (Deveci, 
Gilmont et al. 2005) to 28 days (Helary, Giraud Guille et al. 2005; Helary, Ovtracht 
et al. 2006). Models based on dermal equivalents or reconstructed skin are also used 
and are especially popular in the MacNeil group at the University of Sheffield. In 
this group a model based on sterilised acellular human dermis has been used since 
the mid 1990's. Its uses vary from investigating skin graft contraction (Ralston, 
Lay ton et al. 1997; Chakrabarty, Heaton et al. 2001; Harrison, Gossiel et al. 2006c; 
Thornton, Harrison et al. Provisionally accepted) and other wound healing processes 
(Dawson, Goberdhan et al. 1996; Harrison, Heaton et al. 2006b) to investigating 
melanoma invasion through the basement membrane (Eves, Layton et al. 2000; Eves, 
Katerinaki et at. 2003) and studies of skin pigmentation. The uses of this model have 
recently been reviewed by MacNeil (2007). Animal models could also be used 
although there are complications associated with the presence of the panniculus 
carnosus allowing for the free movement of the skin over the underlying tissue. 
1.3.1 Collagen gels. 
Several in vitro models of wound contraction have been developed using fibroblasts 
cultured in collagen or fibrin matrices (Grinnell 1994). The majority of research into 
28 
contraction has been performed using fibroblast populated collagen gels. The 
fibroblast populated collagen gel model was introduced by Bell and Ivarsson in 1979 
and has since been widely used for investigating contraction, (Bell, Ivarsson et al. 
1979; Bellows, Melcher et al. 1982; Schaffer, Tantry et al. 1997; Enever, Shreiber et 
al. 2002; Howling, Oettmar et al. 2002; Berry, SheIton et al. 2003; Gentleman, 
Nauman et al. 2004). However collagen matrix contraction requires serum and can 
be stimulated by individual extracellular factors, including TGFpl and POGF or 
inhibited by factors such as epidermal growth factor (EGF) (Schaffer, Tantry et al. 
1997). When fibroblasts are cultured within an extracellular matrix such as collagen 
or fibrin, fibroblasts experience a richer, more complex physical environment and 
markedly different geometry which is more physiologically relevant than cells on 20 
surfaces (Bellows, Melcher et al. 1982; Grinnell 2003). 
According to Grinnell (2003), Paul Weiss showed that fibroblasts cultured in a blood 
plasma clot varied in shape from stellate to bipolar depending on the orientation of 
the fibrous network of the clot. In free floating collagen gels where there is little 
resistance to cellular force fibroblasts can project an elaborate dendritic network of 
extensions interconnected by gap junctions. If the matrix is constrained then tension 
develops within the matrix and the collagen fibrils become orientated in response to 
the force exerted by the cells (Grinnell 2003). It is thought that changes in celI 
proliferation and biosynthetic activity after stress relaxation provide insight into the 
possible mechanism of myofibroblast disappearance at the end of wound healing. As 
long as the tissue is under mechanical stress, cell proliferation and biosynthetic 
activity will persist. Once mechanical stress is relieved, usually by a combination of 
wound contraction and biosynthetic activity, cells will switch to a non-proliferative 
phenotype. Thus fibroblasts in floating gels and those in anchored collagen gels 
show profound differences in celI proliferation (Grinnell 1994). 
Germain et al. (1994) used collagen gels to compare the contractile properties of 
fibroblasts obtained from samples of granulation tissue and dermal fibroblasts. It was 
noted that collagen gels prepared with dermal fibroblasts contracted by 25% of their 
original area over the first 24 hours whilst the gels seeded with wound healing 
fibroblasts contracted by 50% of their original area over the first 24 hours. However 
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after fourteen days in culture there was no significant difference in the surface area 
of the two gels (Germain, Jean et al. 1994). Schliffer et al. (1997) and Moulin et al. 
(1998) also showed that wound healing myofibroblasts contract collagen gels more 
than dermal fibroblasts. Wound fluid also increased the contraction of collagen gels 
populated with dermal fibroblasts but had no effect on the contraction of collagen 
gels populated with wound healing fibroblasts (Schaffer, Tantry et al. 1997). The 
concentration of collagen in the gel can also affect fibroblast behaviour with the rate 
of gel contraction varying inversely with the collagen concentration (Bell, Ivarsson 
et al. 1979). Helary et al. prepared collagen gels with collagen concentrations of 
5 mg.mr l and 40 mg.mr l • The gels with low collagen concentration showed weak 
myofibroblast proliferation and no apoptosis, however the cells migrated easily. In 
gels with a high collagen concentration, cell proliferation and apoptosis occurred and 
the cells spread more than in the loose matrices (Helary, Ovtracht et al. 2006). 
Expression of a smooth muscle actin (aSMA) and MMPI (collagenase 1) did not 
differ between the 5 mg.mr l and 40 mg.mr l matrices. However, expression of 
MMP2 (gelatinase A) was increased in the high density (40 mg.mr l ) matrices 
(Helary, Giraud Guille et al. 2005). Pullar and Isseroff (2005) used fibroblast 
populated collagen gels to investigate the role of the adrenergic signalling system in 
contraction. Treatment of the gels with a J3-agonist delayed contraction in a 
concentration dependent manner whilst treatment with a J32-adrenergic receptor 
specific antagonist reduced the delay in contraction. The authors report that the J32-
adrenergic receptor is therefore solely responsible for the delay in contraction and 
further showed that this is via a cyclic adenosine monophosphate (cAMP) 
mechanism (Pullar and Isseroff 2005). 
Shannon et al. (2006) used collagen gels to compare buccal mucosa and dermal 
fibroblasts. Collagen gel contraction, as MA expression, growth factor production 
and the effects of TGF-J31&3 were investigated. In this study oral fibroblasts 
contracted collagen gels significantly more than the dermal fibroblasts. The presence 
of TGF-J31 significantly increased collagen gel contraction in a concentration 
dependent manner in both cultures. TGF-J33 significantly increased collagen gel 
contraction in both cultures. In collagen gels populated with oral fibroblasts this was 
in a concentration dependent manner but this was not the case in collagen gels 
30 
populated with dermal fibroblasts (Shannon, McKeown et al. 2006). TGF-p has also 
been shown to increase contraction of fibroblast populated collagen gels in a 
concentration dependent manner by Grinnell and Ho (2002). The addition of 
keratinocytes into fibroblast populated collagen gels also leads to an increase in 
contraction (Oshita, Lee et al. 2006). 
Collagen gel models are especially popular for investigating the effects of various 
drugs on fibroblast biology and contraction. Redden and Doolin produced fibroblast 
populated collagen gels containing both a high and a low concentration of 
fibroblasts. These gels were treated with the lathyrogen p-aminopropionitrile 
(PAPN) fumarate. The PAPN reduced the contraction of both of the collagen gels 
(Redden and Doolin 2003). Howling et al. investigated the effect of adding chitosan, 
chitin and hyaluronan to the culture medium surrounding the fibroblast populated 
collagen gels. Adding chitosan to the medium inhibited contraction whilst chitin and 
hyaluronan had no significant effect (Howling, Dettmar et al. 2002). Moulin et al. 
(1998) treated collagen gels populated with both wound healing and dermal 
fibroblasts with TGF-PI and interferon-y (IFNy). Treating both collagen gel 
populations with TGF-PI initially increased contraction in both cell populations but 
this increase was stronger with the wound healing fibroblasts. The effect of treatment 
with IFNy was the same for both fibroblast populations. Contraction was reduced 
during the initial 24 hours and then stopped completely thereafter, this also proved to 
be reversible as once the IFNy was removed from the culture system after a 2 day 
delay contraction resumed in the dermal fibroblast populated gels. In wound healing 
fibroblast populated gels very little, if any, contraction was observed when the IFNy 
was removed (Moulin, Castilloux et al. 1998). 
Whilst the collagen gel model is simpler, cheaper and less time consuming collagen 
gels are limited by their lack of dermal architecture and basement membrane. A 
number of factors can influence the effectiveness of this assay. The concentration of 
the collagen in the gel, being a major factor. Personal experience also illustrated that 
the age of the cells particularly the age of the keratinocytes had implications on the 
success of the experiment. Keratinocytes that had been subjected to more than two 
passages struggled to attach to the gels and therefore these gels did not contract as 
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much as gels seeded with lower passage number keratinocytes. However these 
factors do not alter the fact that this model is the accepted model for investigating 
contraction. The time taken to run the experiments, six or seven days, is much 
shorter than the time taken to run other contraction model experiments i.e. 
reconstructed skin models. This makes collagen gels a useful screening tool to 
quickly investigate the effects of a range of drugs at a wide range of concentrations 
on contraction. The addition of keratinocytes to the standard fibroblast populated 
collagen gels makes the model more of a reconstructed skin model but the absence of 
a basement membrane and dermal architecture cannot be overcome and this should 
be taken into consideration when reviewing the data. 
1.3.2 Tissue engineered skin equivalents. 
Skin equivalents for contraction studies have been produced using a variety of 
different methods. Most of the skin or dermal equivalents are produced using 
acellular dermis and primary skin cells, dermal fibroblasts and keratinocytes. It is 
possible to produce acellular dermal matrices in a variety of methods. Erdag and 
Sheridan (2004) report the production of an acellular dermal matrix by rapidly freeze 
thawing cadaver skin. These matrices were seeded with fibroblasts and / or 
keratinocytes and transplanted onto mice. The presence of fibroblasts in these 
matrices reportedly produced a thicker epidermis, reduced contraction and enhanced 
angiogenesis compared to matrices seeded with keratinocytes alone (Erdag and 
Sheridan 2004). Dawson et al. (1996) and Ralston et al. (1997) report the production 
of a sterilised deepithelialised acellular dermis (DED) using increasing 
concentrations of glycerol. Ralston et al. (1997) used this composite to illustrate that 
whilst fibroblasts can contract this composite slightly, when keratinocytes are added, 
composite contraction is more pronounced. Ghosh et at. (1997) investigated how 
changing sterilisation methods affected the quality of the resulting skin composites. 
Glycerol sterilisation and lyophilisation were used to render the skin acellular. 
Ethylene oxide treatment and gamma irradiation were used to sterilise the skin. 
Deepidermisation was carried out by immersion of the skin in 1 M sodium chloride 
solution, phosphate buffered saline (PBS) or dispase solution. It was noted in this 
study that skin can be reconstructed based on either glycerol or ethylene oxide 
treatment but the ethylene oxide treatment produced composites with poorer 
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epidermis' than the glycerol treated composites (Ghosh, Boyce et al. 1997). This 
model has subsequently been used to produce epidermal-dermal composites for 
clinical use and to investigate the mechanism of skin graft contraction especially the 
role of the keratinocyte (Chakrabarty, Dawson et at. 1999; Chakrabarty, Heaton et at. 
2001; Harrison, Heaton et at. 2006b; Harrison, Gossiel et at. 2006c; Thomton, 
Harrison et at. Provisionally accepted). Harrison et al. used this model to investigate 
pharmacological approaches to reduce contraction. Agents such as PAPN, <l2-
macroglobulin and catechin reduced contraction whilst estrone increased contraction 
(Harrison, Gossiel et al. 2006c). This model was also used by Eves et al. to 
investigate melanoma invasion in skin (Eves, Lay ton et al. 2000; Eves, Katerinaki et 
at. 2003). It has been shown that contraction of this skin composite can be affected 
by a number of factors summarised in table 1.2 
Ta bl 1 2 Effi f h f e ect 0 varIOUS agents on t e contractIOn 0 reconstructe d k· s tn. 
Agent Effect on contraction Reference 
Ascorbic acid-2-phosphate Increased (Chakrabarty, Heaton et 
at. 2001) 
Mannose-6-phosphate No significant effect (Chakrabarty. Heaton et 
at. 2001) 
Forskolin No significant effect (Chakrabarty. Heaton et 
at. 2001) 
Galardin Decreased (Chakrabarty. Heaton et 
at. 2001) 
Keratinocyte conditioned Decreased (Chakrabarty. Heaton et 
medium at. 2001) 
Glutaraldehyde pre-treatment Decreased (Harrison. Gossiel et at. 
2006c) 
Insulin like growth factor No significant effect (Harrison. Gossiel et at. 
2006c) 
Estrone or Estradiol Increased (Harrison. Gossiel et at. 
2006c) 
Dexamethasone No significant effect (Harrison, Gossiel et at. 
2006c) 
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Basic fibroblast growth factor No significant effect (Harrison, Gossiel et at. 
2006c) 
Tumour necrosis factor a No significant effect (Harrison, Gossiel et at. 
2006c) 
Prostaglandin-E2 No significant effect (Harrison, Gossiel et at. 
2006c) 
Catechin Decreased (Harrison, Gossiel et at. 
2006c) 
a2-macroglobulin Decreased (Harrison, Gossiel et at. 
2006c) 
p-aminopropionitrile Decreased (Harrison. Gossiel et at. 
2006c) 
Putrescine No significant effect (Harrison. Gossiel et at. 
2006c) 
NTU283 or NTU285* No significant effect (Harrison, Gossiel et at. 
2006c) 
*NTU283 and NTU285 are novel thioimidazolium transglutaminase inhibitors 
synthesised by Prof. M. Griffin at Nottingham Trent University. 
Ascorbic acid-2-phosphate is a stable form of vitamin C and stimulates procollagen 
synthesis. It is a cofactor for hydroxyproline and hydroxylysine (Chakrabarty, 
Heaton et at. 2001). Mannose-6-phosphate inhibits the effects of TGF-
p (Chakrabarty, Heaton et at. 2001). Forskolin stimulates adenylate cyclase and 
elevates cAMP (Chakrabarty, Heaton et at. 200 I). Galardin inhibits 
matrixmetalloproteinases (Chakrabarty, Heaton et at. 2001). Glutaraldehyde pre-
treatment reduces dermal pliability (Harrison, Gossiel et al. 2006c). Insulin like 
growth factor, Estrone and Estradiol stimulate collagen synthesis (Harrison, Gossiel 
et at. 2006c). Dexamethasone and basic fibroblast growth factor inhibit collagen 
synthesis (Harrison, Gossiel et at. 2006c). TNF-a also inhibits collagen synthesis it 
also inhibits keratinocyte proliferation (Harrison, Gossiel et at. 2006c). 
Prostaglandin-E2 inhibits collagen synthesis and stimulates keratinocytes 
proliferation (Harrison, Gossiel et al. 2006c). Catechin, an antioxidant, inhibits 
collagen degradation (Harrison, Gossiel et at. 2006c). a2-macroglobulin also inhibits 
34 
collagen degradation and inhibits MMP's (Harrison, Gossiel et al. 2006c). PAPN is a 
non-competitive lysyl oxidase inhibitor and inhibits collagen crosslinking (Harrison, 
Gossiel et al. 2006c). Putrescine is a competitive transglutaminase inhibitor, 
inhibiting collagen crosslinking (Harrison, Gossiel et al. 2006c). NTU283 is an 
irreversible transglutaminase inhibitor, NTU285, a competitive transglutaminase 
inhibitor (Harrison, Gossiel et al. 2006c). 
Investigation into the mechanism by which the reconstructed skin model contracts 
showed that collagen synthesis and degradation (Harrison, Gossiel et al. 2006c) had 
no effect on contraction whilst collagen crosslinking (Harrison, Gossiel et al. 2006c) 
and keratinocyte differentiation (Thornton, Harrison et al. Provisionally accepted) 
significantly affected contraction. Blocking the action of lysyl oxidase by the 
addition of PAPN to the composite culture medium significantly reduced contraction 
at PAPN concentration of200 ~g.mrl (Harrison, Gossiel et al. 2006c). 
Tissue engineered skin equivalents, especially those based on DED have three main 
advantages over collagen gels especially fibroblast populated collagen gels. These 
are namely the presence of basement membrane proteins, an appropriate dermal 
architecture and the presence of multiple cell types. The main disadvantage to this 
model is the lack of suitable skin that can be made into DED. Whilst this laboratory 
is lucky in the quantity of skin that it receives the vast majority of the skin is only 
suitable for cell isolation. Skin of sufficient quality and quantity for DED production 
is rarely obtained. These experiments also take a long time to run i.e. 28 days instead 
of the 6 or 7 days taken for collagen gel contraction experiments. However this 
contraction model is a useful model to verify the results obtained from the collagen 
gel experiments. Once the collagen gels have been used to identify drugs that could 
be used to block or reduce contraction and at what concentrations. 
1.3.3 Animal models. 
As mentioned in section 1.3 the presence of the panniculus carnosus in animals 
makes the majority of animals unsuitable for contraction studies. Selection of an 
animal model depends on a number of factors including availability, cost, ease of 
handling, investigator familiarity, and anatomical/functional similarity to humans 
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(Sullivan, Eaglstein et al. 2001). According to Middelkoop et al. (2004) small 
mammals, such as mice, rats, rabbits and guinea pigs are suitable for studies that 
require large numbers of animals or specific characteristics, such as availability of 
knockouts or transgenic animals (mainly available in mice) (Escamez, Garcia et al. 
2004) or a compromised immune system (athymic mice). Wound healing in rodents 
differs considerably from wound healing in humans as wounds in rodents heal 
primarily by contraction rather than migration of epidermal cells (Middelkoop, Van 
Den Bogaerdt et al. 2004). SuIlivan et al. evaluated a number of different wound 
healing models and compared them to wound healing in humans. The porcine model 
agreed with human studies 78% of the time whilst small mammals agreed with 
human studies 53% of the time and in vitro models 57% of the time (Sullivan, 
Eaglstein et al. 2001). SuIlivan et al. do state that because no model will completely 
replicate clinical human wound healing, it is essential that the model utilized be 
selected with care. For example guinea pigs are generally used to evaluate the effects 
of vitamin C deficiency on wound healing as guinea pigs, like humans, require 
vitamin C from dietary sources. Comparatively few other animals, such as pigs, 
synthesise their own vitamin C but the anatomy and physiology of pig skin is similar 
to human skin and neither mammal possesses a panniculus camosus (Sullivan, 
Eaglstein et al. 2001). This makes the porcine model more suitable for the evaluation 
of therapeutic agents that could, for example, be used to treat scarring. Middelkoop 
et al. (2004) report the use of a porcine bum model to evaluate the efficacy of 
various treatments whilst looking at reepithelialisation, inflammatory response, 
contraction and bacterial contamination. Horan et al. (2005) used mice to evaluate 
the effect of stress on wound contraction. The mice were restrained and deprived of 
food and water for set periods over the experiment. These mice showed delayed 
healing and reduced contraction compared to those mice just deprived of food and 
water for the same time periods but not restrained. Mirastschijski et al. (2004) used 
Sprague-Dawley rats to evaluate the effect of a broad spectrum MMP inhibitor on 
wound healing. The MMP inhibitor reduced wound contraction, decreased 
myofibroblast formation but impaired keratinocyte migration but not keratinocyte 
proliferation, and produced abnormal granulation tissue and blood vessel 
architecture. Spyrou and Naylor (2002) used Hooded Lister rats to investigate the 
effect of basic FGF (FGF2) on scarring. FGF2 was shown to inhibit the 
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differentiation of fibroblasts into myofibroblasts and improved the dermal 
architecture of the healing wound. 
Despite the limitations imposed by the differences in the anatomy and physiology of 
animal skin compared to human skin these animal models are still used to evaluate 
wound treatments. For the purpose of this project an animal model would not be 
required. However, if this wound dressing were to be taken forward to the clinic an 
animal model, ideally a porcine model, would be needed. 
1.4 Wound dressings and skin replacements. 
Mankind has been covering wounds with a variety of materials since the earliest 
written records. Historically, wounds have been treated with homemade remedies 
derived from ritualistic teachings and observation. According to Lionelli and 
Lawrence the ''three healing gestures" were described c2200 BC on an ancient clay 
tablet: 1. washing the wound, 2. making plasters (mixtures of herbs, ointments, and 
oils that were applied to wounds to aid in the healing process), and 3. bandaging the 
wound. References to early wound care are seen in the Bible, ancient Assyrian 
writings and ancient Greek texts such as The Iliad and The Odyssey by Homer and 
writings by Hippocrates in 400 BC (Ramos-E-Silva and Ribeiro De Castro 2002; 
Lionelli and Lawrence 2003) According to Ovington (2007) Sumerian cuneiform 
tablets from before 2000 BC describe the application of poultices formed of mud, 
milk and plants to wounds. Egyptian papyruses from 1550 and 1650 BC provide 
specific details of how to wash the wound, prepare and apply plasters of honey, plant 
fibres, and animal fat and then bandage the wound (Ovington 2007). In the Ebers and 
Edwin Smith papyri (1500-1600 BC) there are descriptions of a variety of dressing 
materials used in ancient Egypt, including bandages with grease which can be seen 
as precursors of tulle gras, one of the earliest non-adherent dressings, which was 
used during the First World War (Lawrence 1982; Lionelli and Lawrence 2003). 
Prior to the early 1960's however dressings had hardly advanced from those used in 
ancient times with dressings consisting primarily of dry non-occlusive gauze and 
non-woven cotton or wool (Cho and Lo 1998). 
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Immediate wound coverage is one of the cornerstones of wound management. Acute 
or chronic wounds can usually be covered by any of a number of synthetic and 
natural dressings (Singer and Clark 1999). However different sized wounds require 
different strategies for closure. The goal should always be to obtain the most 
cosmetic and functional wound closure the first time. Whilst small and clean wounds 
such as a small burn wound or scar can be treated with excision and sutures or 
staples resulting in a relatively narrow scar this is dependent on the size of the 
wound. If infection is suspected the wound can be left open and treated with dressing 
changes for 4-5 days and then closed (Greenhalgh 2002). It is not possible to treat 
larger wounds like this and so for larger areas of skin loss, skin grafts are usually 
used either as sheets or expanded by meshing. According to Greenhalgh (2002) there 
are three stages of graft healing, the first being the phase of imbibition, in this phase 
the graft' imbibes' or survives by diffusion of nutrients from the wound bed. During 
this phase which lasts approximately 2-3 days if there is any barrier to the diffusion 
of nutrients to the graft such as a blood clot, oedema, or nonviable tissue the graft 
will not 'take' and will therefore be lost. The second phase of graft healing is the 
phase of neovascularisation where new blood vessels invade the graft through 
angiogenesis and 'hook up' with those in the graft. The final stage is the phase of 
maturation where collagen bridges form between the graft and the wound bed. This 
phase closely mirrors the maturation phased in wound healing described in section 
1.2.3 (Greenhalgh 2002). The ideal biologic skin substitute or wound dressing has to 
meet a formidable list of criteria listed below which have been taken from 
Ehrenreich and Ruszczak (2006) and added to from Seal et at. (2001), Sheridan and 
Tompkins (2002) and Atiyeh et at. (2005): 
• Absence of antigenicity 
• Tissue compatible 
• Absence of local or systemic toxicity 
• Impermeable to exogenous microorganisms 
• Water vapour transmission similar to normal skin 
• Rapid and sustained adherence to the wound surface 
• Conform to surface irregularities 
• Elastic to permit motion of underlying tissue 
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• Tensile strength to resist fragmentation 
• Inhibition of wound surface flora and bacteria 
• Long shelf life, minimal storage requirements 
• Biodegradable (for permanent membranes) 
• Low cost 
• Minimise nursing care of wounds 
• Minimise patient discomfort 
• Translucent properties to allow direct observation of healing (for dressings) 
• Reduce heal ing time 
• Not increase rate of infection 
• Patient acceptance 
• Grow with a child 
• Can be applied in one operation 
• Prevent heat and fluid loss 
• Does not become hypertrophic or contract 
Currently there are no materials commercially available that meet all these criteria. 
However commercial products, such as Permaderm, are beginning to emerge to meet 
this need (MacNeil 2007), and whilst autologous skin grafts, especially STSG's are 
the current gold standard for treatment of large burns there are a number of problems 
associated with them. Among these are donor site morbidity and the lack of available 
skin especially in patients with extensive severe burns. In essence when skin for an 
autologous graft is taken the surgeon is increasing the total body surface area 
affected by the burn, therefore potentially increasing the problems associated with 
large wounds i.e. fluid loss, and increasing the chance of infection. It has therefore 
been necessary to look at various different methods for closing wounds that could 
either be used in the place of, or in conjunction with STSG's. Table 1.3 summarises 
some commercially available skin substitutes. 
Table 1.3 Table summarising the materials from which some commercially available 
epidermal, dermal and skin replacements are made. 
Trade name Materials used Cells included Reference 
Alloderm Acellular deepithelialised - (Jones, 
(Dennal substitute) cadaver dermis Currie et al. 
2002) 
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Apligraf Collagen Neonatal allogenic (Jones, 
(Skin replacement) fibroblasts & Currie et al. 2002) 
keratinocytes 
Biobrane Silicone, nylon mesh, 
-
(Jones, 
(Temporary skin collagen Currie et al. 
substitute) 2002) 
BioSeed-S Fibrin glue Cultured autologous (Enoch, 
(Epidermal keratinocytes Grey et al. 
substitute) 2006b) 
CellSpray 
-
Cultured autologous (Enoch, 
(Epidermal keratinocytes Grey et al. 
substitute) 2006b) 
Dermagraft Polyglycolic acid or Neonatal allogenic (Jones, 
(Dermal substitute) polyglactin-910 fibroblasts Currie et al. 2002) 
Epicel 
-
Cultured autologous (Jones, 
(Epidermal keratinocytes Currie et al. 
replacement) 2002) 
E-Z-Derm Chemically crosslinked 
-
(Ramos-E-
(Temporary skin porcine collagen Silva and Ribeiro De substitute) 
Castro 2002) 
Human Amniotic Allogenic human amnion - (Atiyeh, 
membrane Hayek et al. 2005) 
(Dermal substitute) 
Hyaff-NW Benzyl-esterified Autologous (Atiyeh, 
(Dermal substitute) hyaluronan derivative fibroblasts Hayek et al. 2005) 
Integra Silicone, collagen, - (Jones, 
(Dermal Substitute) glycosaminoglycans Currie et al. 2002) 
Laserskin Hyaluronic acid Cultured autologous (Jones, 
(Epithelial cover) keratinocytes Currie et al. 2002) 
MySkin PVC, acrylic acid Autologous (Heroon, 
(Epithelial cover) keratinocytes Dawson et 
al. 2006) 
OrCel Collagen Allogenic fibroblasts (Boyee and 
(Skin substitute) & keratinoeytes Warden 2002) 
Pelnac Silicone, collagen Autologous (Atiyeh, 
(Skin substitute) keratinocytes Hayek et al. 2005) 
Permacol Porcine skin - (MaeNeil 
(Temporary dermal 2007) 
substitute) 
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Permaderm Bovine collagen Autologous (MacNeil 
(Skin substitute) fibroblasts & 2007) 
keratinocytes 
PolyActive Polyethylenglycol Cultured autologous (Boyce and 
(Skin substitute) terepthalate, fibroblasts & Warden 2002), (Seal, 
polybutylene keratinocytes Otero et al. 
terephthalate 2001) 
Terumo Collagen Autologous (Atiyeh, 
(Skin substitute) keratinocytes Hayek et al. 2005) 
Tissue Tech Hyaluronic acid ester Autologous (Atiyeh, 
autograft system fibroblasts & 
Hayek et al. 
2005) 
(Skin substitute) keratinocytes 
TissuFleece Collagen foam - (Ng, Khor et 
(Dennal substitute) al. 2004) 
Transcyte Silicone, nylon mesh, Neonatal fibroblasts (Jones, 
(Temporary dennal collagen Currie et al. 
substitute) 2002) 
VivoDerm Hyaluronan Autologous (Ramos-E-
(Skin substitute) keratinocytes Silva and Ribeiro De 
Castro 2002) 
1.4.1 Epidermal replacements. 
In 1975 wound management was revolutionised by the development of a technique 
that used cultured human epidermal cells to form sheets suitable for grafting. This 
development was soon followed by the use of autologous cultured epidermal-cell 
grafts for the treatment of bums as well as other acute and chronic wounds (Singer 
and Clark 1999). The application of cultured epithelial autografts (CEAs) to bum 
wounds became an extremely useful and often life-saving adjunct in the management 
of severe bum injuries (Hemon, Harrison et al. In press). Cultured epithelial 
auto grafts (CEA's) are produced from confluent multilayer sheets of keratinocytes 
that have been detached from their culture dishes and attached to a backing dressing 
to aid the application of the CEA onto the wound bed. CEA's cannot be detached as 
an integrated sheet generally before nine days but once confluent they must be used 
within two to three days as beyond this point they begin to blister and detach from 
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the tissue culture plastic (TCP). Therefore once CEA culture starts plans must be 
made to use the CEA's within a very narrow window often to fourteen days or they 
lose the ability to attach to the wound bed. This narrow window where the CEA's 
can be applied means that if the patient's condition changes there can be significant 
wastage of cells. In a recent study Hernon et al. showed that nearly 50% of CEA's 
produced were wasted (Hernon, Dawson et al. 2006). However CEA's do provide a 
wide and permanent skin coverage method (Singer and Clark 1999). More recently 
several alternative methodologies for delivering keratinocytes to the wound bed have 
been explored ranging from spraying on cells to delivering cells on collagen coated 
membranes or chemically defined membranes such as MySkin ™ (Hemon, Harrison 
et al. In press). Wood et al. (2006) reviewed the use of CEA's in the treatment of 
bum injuries and discussed the main limiting factors in the production of and 
treatment with CEA's. The time taken to produce the CEA's, the reliability of 'take', 
vulnerability of grafts, long term durability and the cost implications of treatment 
were assessed. Whilst the study was inconclusive and unable to answer the question 
"do CEA's have a role in the treatment of major bums?" it is typical of the variation 
of opinion found in the literature (Wood, Kolybaba et al. 2006). MySkin™ is one 
example of a dressing being used in an attempt to overcome some of the limitations 
encountered in CEA production. Medical grade carrier polymers were treated with 
an acrylic acid plasma and primary keratinocytes were seeded onto these surfaces 
and could be cultured in serum free conditions, and transferred from these surfaces 
onto deepithelialised acellular dermis (Haddow, Steele et al. 2003; Higham, Dawson 
et al. 2003; Bullock, Higham et al. 2006). The use of this treatment clinically 
resulted in reduced wastage due to the flexibility in the timing of delivery of cells to 
the wound bed as the keratinocytes could be transferred to the wound bed whilst 
subconfluent. This also had the advantage that subconfluent keratinocytes in theory 
have a greater proliferative potential (Hernon, Dawson et al. 2006). 
1.4.2 Dermal replacements and skin substitutes. 
The historic standard for rapid closure of full-thickness wounds with a skin 
substitute is split-thickness, autologous skin applied either as a sheet, or expanded by 
meshing (Boyce and Warden 2002). Although split-thickness autografts remain the 
gold-standard they are not always available in sufficient quantity giving rise to the 
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clinical need for tissue-engineered alternatives (MacNeil 2007). The inclusion of a 
dermal component in skin substitutes helps prevent wound contraction and provides 
greater mechanical stability (Singer and Clark 1999). The production of a tissue 
engineered skin based on human dermis, often supplied by a skin bank, has met with 
some success with reconstructed skin being used clinically (Chakrabarty, Dawson et 
al. 1999) and in the laboratory for research purposes (Dawson, Goberdhan et al. 
1996; Ghosh, Boyce et al. 1997; Ralston, Lay ton et al. 1997; Ralston, Lay ton et al. 
1999; Eves, Layton et al. 2000; Chakrabarty, Heaton et al. 200 I; Eves, Katerinaki et 
al. 2003; Haddow, Steele et al. 2003; Higham, Dawson et al. 2003; Harrison, Dalley 
et al. 2005; Hernon, Dawson et al. 2006; Harrison, Gossiel et al. 2006a; Harrison, 
Heaton et al. 2006b; Harrison. Gossiel et al. 2006c; Thornton, Harrison et al. 
Provisionally accepted). Other materials used in the production of skin substitutes 
include collagen, glycosaminoglycans, hyaluronan, and various polymers (Boyce 
and Warden 2002; lones, Currie et al. 2002; Atiyeh, Hayek et al. 2005). 
Biosynthetic dressings were originally developed to provide temporary coverage to 
optimise wound healing. They were first introduced in 1979 for the treatment of 
donor sites (Bello and Falabella 2001). 
Allogenic materials such as an allograft from a skin bank can be used as a temporary 
wound dressing in bums treatment. Human allograft is generally used as a STSG 
after being procured from organ donors. When used in a viable fresh or 
cryopreserved state, it vascularises and remains the 'gold standard' of temporary 
wound closures (Sheridan and Tompkins 2002). An acellular allogenic dermal 
matrix such as AlIoderm, which was approved by the Food and Drug Administration 
(FDA) in 1992 provides a template with natural dermal porosity for regeneration and 
allows the use of thinner autografts (Ramos-E-Silva and Ribeiro De Castro 2002). 
The allogenic dermis still contains its basement membrane proteins and is intended 
to be combined with a thin epithelial autograft in full thickness bums and chronic 
wounds (Singer and Clark 1999; Jones, Currie et al. 2002; Ramos-E-Silva and 
Ribeiro De Castro 2002; Atiyeh, Hayek et al. 2005; Enoch. Grey et al. 2006b). The 
acellular nature of this product removes the specific immune response and so the risk 
of rejection but there is still a risk of disease transmission (Ng, Khor et al. 2004). 
Once applied to the wound bed it becomes repopulated with the patient's own cells, 
generally revascularises quickly and is incorporated into the healing tissue. It 
43 
reportedly has a good take rate and reduces the scarring associated with full 
thickness wounds (Jones, Currie et al. 2002; Atiyeh, Hayek et al. 2005). Some other 
commercial dermal matrices used in skin reconstruction are Apligraf, Dermagraft, 
Integra, and CrCel. 
Integra artificial skin is currently the most widely accepted synthetic skin substitute 
to be developed for use on burns patients (Jones, Currie et al. 2002). The FDA gave 
approval in 2002 for Integra to be used in "the postexcisional treatment of life-
threatening full-thickness or deep partial-thickness thermal injuries where sufficient 
autograft is not available at the time of excision or not desirable due to the 
physiological condition of the patient. Integra Dermal Regeneration Template is also 
indicated for the repair of scar contractures when other therapies have failed or when 
donor sites for repair are not sufficient or desirable due to the physiological 
condition of the patient" (Schultz 2002). Integra is a biopolymer tissue-engineered 
bilayer material consisting of a bovine collagen and shark chondroitin-6-sulfate 
dermal regeneration template with a temporary silicone epidermal layer (Jones, 
Currie et al. 2002; MacNeil 2007). The dermal regeneration template is 
approximately 2 mm thick and has a 70-200 Ilm pore size that allows for the matrix 
to become vascularised and for fibroblast invasion (Ramos-E-Silva and Ribeiro De 
Castro 2002; Sheridan and Tompkins 2002). Neovascularisation usually occurs 
within 28 days at which point the silicone layer is removed and replaced with a 
STSG or epidermal autograft (Singer and Clark 1999; Atiyeh, Hayek et al. 2005; 
MacNeil 2007). The direct application of cells to the dermal matrix was found to be 
problematic because the cells failed to attach securely (MacNeil 2007). Integra 
provides immediate permanent coverage for surgically excised full thickness burns 
and is also used in reconstructive surgery. It requires a healthy and non-infected 
wound bed (Enoch, Grey et al. 2006b). Case studies show that burn wounds treated 
with Integra show good cosmetic and functional results with softer scars compared to 
STSG's (Kremer, Lang et al. 2000; Papp and Harma 2003; Wisser and Steffes 2003; 
Wisser, RennekampfT et al. 2004). 
Apligraf is a bilayer of a neonatal fibroblast populated bovine collagen matrix seeded 
with neonatal keratinocytes. The exposure of Apligraf to an air-liquid interface 
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during production allows the fonnation of a stratified differentiated epithelium 
(Ehrenreich and Ruszczak 2006). Apligraf is available in a ready to use fonn with a 
five day shelf life and is primarily used in the treatment of chronic ulcers (Jones, 
Currie et al. 2002). It resembles human skin histologically (Ramos-E-Silva and 
Ribeiro De Castro 2002) and it appears to hasten healing especially in deep and 
chronic wounds (Jones, Currie et al. 2002). According to Ehrenreich and Ruszczak 
(2006) Apligraf was initially intended for use in bums treatment. Whilst meshed 
Apligraf over a meshed autograft did not improve the 'take rate' of the autograft, a 
better quality scar was achieved and bums treated in this manner were judged to 
have healed better than those treated with an autograft alone. Despite this promising 
study Apligraf use in bums is rare as Apligraf is only FDA approved for use in 
chronic wounds i.e. ulcers and not in bums (Ehrenreich and Ruszczak 2006). 
OrCel is composed of type I bovine collagen in which neonatal fibroblasts and 
keratinocytes are seeded. The fibroblasts are seeded within a porous collagen sponge 
whilst the keratinocytes are seeded on the nonporous side of the matrix. OrCel is not 
exposed to an air-liquid interface during production and therefore the epithelium is 
not tenninally differentiated (Ehrenreich and Ruszczak 2006). OrCel is commonly 
used in acute and chronic deep dennal ulcers, partial thickness bums and donor site 
wounds. Its main disadvantages are that it cannot be used on infected wounds or on 
patients allergic to bovine collagen (Enoch, Grey et al. 2006b). According to Supp 
and Boyce (2005) OrCel is designed for grafting to partial thickness wounds to 
provide a favourable matrix for host cell migration. Oreel has been indicated for use 
in the treatment of donor sites in patients with bums, and surgical wounds and donor 
sites in patients with epidennolysis bullosa (Supp and Boyce 2005). In a recent study 
comparing two skin equivalents OrCel and Biobrane-L in treating split-thickness 
donor sites in bums patients OrCel was shown to reduce healing time and scarring 
(Still, Glat et al. 2003). However, these findings were deemed not clinically 
meaningful by the FDA (Ehrenreich and Ruszczak 2006). 
Wound healing matrices can be produced using synthetic as well as natural 
materials. One such commercial matrix is Dennagraft which is prepared using 
cryopreserved neonatal fibroblasts seeded in a bioabsorbable polyglactin mesh and is 
usually combined with a meshed autograft (Atiyeh. Hayek et al. 2005; Supp and 
45 
Boyce 2005). The fibroblasts become confluent among the degrading polymer fibres, 
producing ECM proteins and secreting growth factors in the interstices of the mesh 
(Paranteau, Hardin-Young et al. 2000; Seal, Otero et al. 200 I; Jones, Currie et at. 
2002). Dermagraft has been shown to increase angiogenesis (Naughton 2000) and 
epithelisation but does not close the wound. It is approved by the FDA for use in full 
thickness diabetic foot ulcers but not for use in bums and had no significant effect on 
the 'take' of STSG's when STSG's were placed above Dermagraft in full thickness 
bums (Ehrenreich and Ruszczak 2006). 
Research into new and improved matrices for wound healing is ongoing. Ng and 
Hutmacher (2006) have produced dermal matrices using synthetic rather than natural 
materials. Weft-knitted poly(lactic-co-glycolic acid) mesh and starch dialdehyde-
crosslinked collagen-hyaluronic acid matrices were seeded with dermal fibroblasts 
and keratinocytes and were investigated for use as skin equivalents. In vitro these 
showed no sign of contracting. When cultured at an air-liquid interface a stratified 
keratinocyte layer resembling native epidermis was observed more readily on the 
starch-collagen-hyaluronic acid matrix than on the poly(lactic-co-glycolic acid) 
matrix. These matrices were subsequently transplanted onto the backs of rats and the 
wounds contracted to a similar degree as those treated with autografts with untreated 
wounds contracting the most (Ng and Hutmacher 2006). El Ghalbzouri et al. (2004) 
investigated the use of a polybutylene terephthalate I polyethylene oxide 
terephthalate (PBTIPEGT) (PolyActive) porous film as a dermal scaffold. ECM 
proteins such as collagen and fibrin could be incorporated later and keratinocytes 
could be seeded directly onto the matrix or a cultured epithelial sheet added. In 
serum free conditions at an air-liquid interface a full thickness skin equivalent with a 
differentiated epidermis could be produced which did not contract during the culture 
period and was easy to handle (El Ghalbzouri, Lamme et at. 2004). 
1.4.3 Dressings. 
Dressings have been used since antiquity to aid the healing process. The choice of 
which dressing to use for a particular wound requires an understanding of wound 
healing and the properties of the available dressings (Lionelli and Lawrence 2003). 
Over the past century, our understanding of wound healing has changed. Up until the 
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mid 1900's it was thought that wounds healed more quickly if they were kept dry 
and left uncovered. It is now understood that wounds heal faster and better when in a 
moist environment and occluded wounds have been shown to heal with cosmetically 
superior results (Menaker 2001). The idea of an occlusive dressing is not new. The 
Smith Papyrus of 1615 BC states that closed wounds heal more quickly than open 
wounds and describes the creation of a dressing made from linen strips covered with 
a gumlike substance. Hippocrates however stated that chronic wounds should not be 
closed as it was thought that chronic wounds were an indication that something 
harmful needed to leave the body and this attitude continued until the 19th century 
(Eaglstein 2001). In the early 1960's two articles were published in Nature (Winter 
1962; Hinnman and Maibach 1963) which showed in both a porcine model and in 
humans that acute. partial thickness excisional wounds experienced significant 
increases in reepithelialisation rates when the exposed tissues were maintained in a 
moist local environment by a semi-occlusive polyethylene film as opposed to being 
allowed to desiccate when uncovered. This lead to the introduction of semi-occlusive 
dressings for the treatment of chronic wounds in the 1970's (Ovington 2007). 
Traditionally wet-to-dry gauze has been used to dress wounds. Dressings that create 
and maintain a moist environment, however. are now considered to provide the 
optimal conditions for wound healing. Moisture under occlusive dressings not only 
increases the rate of epithelialisation but also promotes healing through moisture 
itself and the presence initially of a low oxygen tension (promoting the inflammatory 
phase). Traditional dressings such as gauze do not exhibit these properties; it may be 
disruptive to the healing wound as it dries and causes tissue damage when it is 
removed (lones. Grey et al. 2006). Occlusive dressings have been shown to be 
effective in the treatment of donor sites for STSG's (Wiechula 2003) and in the 
treatment of second degree bums (Field and Kerstein 1994; Wiechula 2003). 
According to Lionelli and Lawrence (2003) occlusive dressings can be divided into 
two classes, non-biologic and biologic. with non-biologic dressings further divided 
into alginates. films. foams. hydrocolloids and hydrogels (Eaglstein 200 I; Menaker 
2001; Lionelli and Lawrence 2003). The roles of human amnion. alginates. polymer 
films, polymer foams and hydrocolloids as wound dressings will be discussed here. 
With the role of hydrogels as wound dressings covered within the section on 
hydrogels in section 1.5.3. 
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An example of a biologic dressing is amnion. Since 1910 allogenic amnion has been 
used as a wound dressing and it has been claimed that it is one of the most effective 
biological dressings ever used in bum treatment. Its use has special appeal in 
developing countries particularly where religious barriers preclude the acceptance of 
bovine, porcine or cadaveric skin (Atiyeh, Hayek et al. 2005). It is used as a 
temporary dressing for clean superficial wounds such as partial thickness bums, 
donor sites, and freshly excised bums awaiting donor site availability (Sheridan and 
Tompkins 2002). Generally fresh amnion is used but according to Maral et al. (1999) 
the use of frozen, dried, irradiated and lyophilised amnion has also been reported. 
Whilst amnion has been shown to have low antigenicity, be effective in eliminating 
pain, allowing wounds to dry faster and in promoting early reepithelialisation there 
are concerns associated with its use especially with regards to virus and disease 
transmission (Kane, Tompkins et al. 1996; Maral, Borman et al. 1999; Sheridan and 
Tompkins 2002; Atiyeh, Hayek et al. 2005). 
Alginates have their origin in the naturally occurring calcium and sodium salts of 
alginic acid found in the family of brown seaweed Phaeophyceae, kelp and algae 
(Menaker 200 I; Ramos-E-Silva and Ribeiro De Castro 2002; Jones, Grey et at. 
2006). They are composed of soft non-woven, twisted fibres and non-woven mats 
(Cho and Lo 1998; Ramos-E-Silva and Ribeiro De Castro 2002; Lionelli and 
Lawrence 2003). They generally fall into one of two categories, those containing 
100% calcium alginate and those containing both calcium and sodium alginate 
(usually 80:20 Ca:Na) (Jones, Grey et at. 2006). Alginates also contain galuronic and 
mannuronic acid. The amounts of these two compounds in the gel alter the material 
properties with high levels of galuronic acid resulting in firmer gels which maintain 
their shape. Dressings containing high amounts of mannuronic acid are 
correspondingly weaker (Ramos-E-Silva and Ribeiro De Castro 2002). Alginate gels 
release calcium ions and have haemostatic properties (Menaker 2001). According to 
Cho and Lo (1998) when the alginate dressing is applied, sodium from the wound 
exudate and calcium from the alginate fibres undergo an ion exchange reaction, 
forming a soluble sodium alginate gel. The free calcium ions produced during the ion 
exchange reaction act to amplify the clotting cascade, according the alginate 
dressings significant haemostatic properties (Cho and Lo 1998). The soluble sodium 
alginate gel produced during the ion exchange reaction creates an occlusive 
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environment that aids wound healing (Lionelli and Lawrence 2003). Alginates are 
best used in wounds with a moderate to heavy wound exudate and in granulating and 
reepithelialising wounds where some exudate is present. They are especially useful 
in packing exuding wounds and rope alginates are easy to apply. Several alginates 
have good wet strength and can be removed in one piece thus reducing trauma to the 
wound. However a second, protective dressing is always required and there is a risk 
of the dressing drying the wound bed and therefore alginate dressings are not 
recommended for wounds with a low volume of exudate (Eaglstein 200 I). Alginate 
dressings have been successfully used in chronic ulcers, partial and full thickness 
burns and STSG's (Cho and Lo 1998). Several alginate dressings are available 
commercially such as AIgiderm, Algisite, Algosteril, Carasorb, Curasorb Calcium 
Alginate Dressing, Kalginate, Kaltostat, Melgisorb, SeaSorb, Sorbsan, Tegagen. 
Urgosorb, (Menaker 2001; Ramos-E-Silva and Ribeiro De Castro 2002; Lionelli and 
Lawrence 2003; Jones, Grey et a1. 2006; Ovington 2007). 
Polymer films used as wound dressings especially in the early stages of burns 
treatment can be as simple as Clingfilm (polyvinylchloride sheeting) which would 
normally be found covering food in a kitchen (Benson, Dickson et al. 2006). Film 
dressings are typically clear polyurethane or copolyester membranes, usually about 
0.2mm thick coated on one side with an adhesive (Cho and Lo 1998; Menaker 200 I; 
Ramos-E-Silva and Ribeiro De Castro 2002; Lionelli and Lawrence 2003). 
According to Cho and Lo these dressings are highly elastic and transparent, allowing 
continuous inspection of the wound. They are semi occlusive dressings as they are 
permeable to oxygen, carbon dioxide and water vapour but are impermeable to 
wound fluids and bacteria (Cho and Lo 1998). Film dressings have little absorptive 
capacity, so frequent dressing changes are needed (Menaker 2001). Unfortunately 
they can adhere to wounds and so retard wound healing by removing new epithelium 
during dressing changes (Cho and Lo 1998; Menaker 2001). Film dressings are best 
used in donor sites, shallow wounds, superficial burns, partial thickness wounds with 
minimal exudate and abrasions (Eaglstein 2001; Menaker 200 I) Commercially 
available film dressings include Acu-Derm, Bioclusive Transparent Dressing, 
Blisterfilm Transparent Dressing, Carrafilm, Hi/Moist Transparent, Mefilm, 
Omniderm, Opsite Wound Dressing, Polyskin 11 Transparent Dressing, Silon TSR 
(temporary skin replacement), Tegaderm Transparent Dressing, Transeal, Transite 
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Exudate Transfer Film, Transparent Adhesive, Uniflex Transparent Dressing, Visi 
Derm 11 by Medline (Cho and Lo 1998; Eaglstein 200 I; Ramos-E-Silva and Ribeiro 
De Castro 2002; Lionelli and Lawrence 2003). 
Foam dressings tend to be composite materials. They are usually composed of a 
polyurethane or silicone foam mesh inner layer and an outer semi permeable 
membrane of polyurethane, polyester, silicone, or Gore-Tex surrounding a 
polyoxyethylene glycol foam (Cho and Lo 1998; Ramos-E-Silva and Ribeiro De 
Castro 2002; lones, Grey et a!. 2006). Early foam dressings were custom 
polymerised or cut for individual wounds. Foam dressings are both absorbent and 
nonadherent, they are permeable to both water and gases and they can expand and 
conform to wounds with unusual proportions. They are comfortable and can be 
removed easily for cleaning (Cho and Lo 1998; Lionelli and Lawrence 2003). They 
aid the dispersion of wound exudate throughout the absorbent layer and the presence 
of the semi permeable backing dressing prevents leakage (lones, Grey et a!. 2006). 
Disadvantages of polymer foams as wound dressings includes their opacity so the 
wound cannot be visualised, additional dressings are required to secure the foam, the 
dressing needs to be changed every three days, they cannot be used on dry wounds 
and they can become incorporated into the wound (Cho and Lo 1998; Menaker 2001; 
Ramos-E-Silva and Ribeiro De Castro 2002). Foam wound dressings are usually 
used in heavily exudating and partial thickness wounds, especially during the early 
inflammatory phase following debridement and sloughing when drainage is at its 
peak, they are also used as pressure relief, packing in deep cavity wounds and in 
venous leg ulcers (Eaglstein 2001; Menaker 2001). Some commercially available 
foam dressings include Allevyn, Cutinova plus, Flexzan, Flexzan Extra, Optifoam, 
PolyMemn, Revitaderm, Silastic foam, Sof-Foam and Tielle (Eaglstein 200 I; 
Menaker 2001; Ramos-E-Silva and Ribeiro De Castro 2002; Ovington 2007). 
The term hydrocolloid is used to describe a family of dressings containing a 
hydrocolloid matrix composed of such materials as gelatin, pectin, and 
carboxymethylcellulose (Lionelli and Lawrence 2003). Hydrocolloid dressings are 
compound formulations usually composed of an outer polyurethane foam bonded to 
a middle hydrocolloid gelling agent, usually sodium carboxymethylcellulose, and an 
inner adhesive layer (Cho and Lo 1998; Ramos-E-Silva and Ribeiro De Castro 
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2002). Hydrocolloid dressings are available as adhesive wafers, sheets or as pastes or 
powders and were derived from materials used initially as ostomy barrier products 
(Cho and Lo 1998; Lionelli and Lawrence 2003; Jones, Grey et at. 2006). 
Hydrocolloid dressings are impermeable to oxygen, carbon dioxide, water vapour 
and bacteria (Ramos-E-Silva and Ribeiro De Castro 2002; Lionelli and Lawrence 
2003). Other advantages include enhanced angiogenesis and an ability to conform to 
wound contours (Menaker 200 I). The dressing absorbs wound exudate well, and 
upon absorbing the exudate the matrix swells and liquefies forming a viscous, 
colloidal gel that prevents adherence of the dressing to the wound bed (Cho and Lo 
1998; Lionelli and Lawrence 2003). Hydrocolloid dressings are used in wounds 
draining low to moderate amounts of exudate, bums, partial or full thickness wounds 
and pressure ulcers. They have also been used in skin disorders such as psoriasis and 
epidermolysis bullosa and are used to prevent blisters in athletes and diabetics (Cho 
and Lo 1998; Eaglstein 200 I; Menaker 200 I). Hydrocolloid dressings are 
particularly good for use on hands and other small areas of superficial or partial 
thickness bums, although they leave a 'skim' of exudate that needs to be removed to 
allow appropriate assessment of the wound (Senson, Dickson et at. 2006). 
Hydrocolloids cannot be used in wounds with a moderate to heavy exudate, they are 
impermeable to oxygen, and they can break down resulting in time consuming 
removal of the hydrocolloid residue from the wound (Eaglstein 200 I). They should 
not be used on infected wounds and are opaque making visualisation of the wound 
difficult (Ramos-E-Silva and Ribeiro De Castro 2002). Some commercially available 
hydrocolloid dressings include Alione, CombiDERM, CombiDERM N, Corn feel, 
Comfeel Plus, Cutinova Hydro, Cutinova Thin, DuoDERM, Extra Thin, Granuncx, 
Hydrocol, Hyprapad, Intact, Intrasite wound dressing, J & J ulcer dressing, NuDenn, 
Orahesive, RepliCare, Restore, Sween-A-Peel, Tegasorb, Tegasorb Thin and Ultec 
(Cho and Lo 1998; Eaglstein 2001; Lionelli and Lawrence 2003; Jones, Grey et at. 
2006; Ovington 2007). 
Wound dressings continue to develop with more coming onto the market annually, a 
recent study states that in a recent issue of a wound care products buyer's guide lists 
more than 400 individual advanced wound dressings including 25 alginates, 55 
foams, 50 hydrocolloids, 51 hydrogels and 24 transparent films (Ovington 2007). 
Many specialist dressings are available especially for bums wounds. However, the 
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prevention of infection is a major problem encountered in wound healing. 
Systemically administered antibiotics should be reserved for treating invasive 
infection whilst topical antibacterials are used for superficial, local management of 
an open wound surface. Antibacterials have been used for centuries and are still in 
widespread use (Leaper 2006). Antimicrobials are among many additives being 
incorporated into wound dressings to aid healing. According to Leaper, the 
introduction of silver into wound care as an antibacterial, particularly in burns is 
relatively recent. There is a growing number of silver dressings commercially 
available these include creams such as Flamazine, foams, hydrogels, hydrocolloids 
and polymeric films and meshes (Hudspith and Rayatt 2004). Dressings containing 
the nanocrystalline form of silver appear to have the best evidence of consistency in 
relation to clinical outcomes. These dressings significantly reduce the bacterial 
burden in chronic wounds and there may be further benefit in reducing infection in 
the management of bums (Leaper 2006). Silver has been incorporated into 
poly(ethylene glycol) hydrogels. This study showed that the muItifunctional 
properties of silver allowed for a simplified polymer that was biocompatible, as 
showed by in vitro testing with fibroblasts and keratinocytes and was still 
antimicrobial (Babu, Zhang et al. 2006). Another antimicrobial incorporated into 
wound dressings is poly(vinylpyrrolidinone)-iodine (PVP-I). Vogt et al. (2006) 
produced a PVP-I hydro some and hydrogel which was shown to prevent infection, 
promote wound healing, improve the quality of healing and increase graft 'take' in 
smokers and on wounds with increased bacterial load. The incorporation of 
curcumin, an antioxidant, into collagen gels for use as wound dressings has also been 
recently shown to increase cell migration towards the wound and so speed up the 
wound healing cascade of inflammation, proliferation and scar formation (Gopinath, 
Ahmed et al. 2004). EGF has also been successfully incorporated into chitosan gels 
to improve wound healing in bums (Alemdaroglu, Degim et al. 2006). 
1.5 Hydrogels. 
Hydrogels as defined by Peppas and Mikos (1986) are water-swollen networks 
(crosslinked structures) of hydrophilic homopolymers and copolymers. They are 
three-dimensional and the cross links can be formed by covalent or ionic bonds. 
Often, weaker forces such as van der Waals forces and hydrogen bonds can serve as 
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crosslinks, thus forming swollen networks which behave as hydrogels. Finally. semi-
crystalline, uncrosslinked hydrophilic polymers may form hydrogels upon swelling 
since the crystallites act as physical cross links and do not dissolve in water (Peppas 
and Mikos 1986). Hydrogels may absorb from 10-20% (an arbitrary lower limit) up . 
to thousands of times their dry weight in water (Hoffman 2001). Hydrophilic 
polymers include poly(ethylene oxide), poly(acrylamide), poly(ethylene glycol) or 
poly(vinylpyrrolidinone) (Ramos-E-Silva and Ribeiro De Castro 2002). According 
to Peppas et al. (2006) the polymer engineer can design and synthesise polymer 
networks with molecular-scale control over structure such as crosslinking density 
and with tailored properties, such as biodegradation, mechanical strength, and 
chemical and biological response to stimuli (Peppas, Hilt et al. 2006). Physical 
hydrogels can be formed in many ways, these include warming or cooling of 
polymer solutions to form gels and changing the pH of polymer solutions to form 
gels (Hoffman 2001; Hoffman 2002). Chemical hydrogels can also be formed in a 
variety of different methods. Polymer solids or solutions can be crosslinked with 
radiation, chemical crosslinkers or multi-functional reactive compounds. Monomers 
and crosslinkers can be copolymerised as can monomers and multi functional 
macromers. Interpenetrating networks can be formed via the polymerisation of a 
monomer within a different solid polymer and hydrophobic polymers can be 
converted chemically to hydrogels (Hoffman 2001; Hoffman 2002). 
1.5.1 Polymer synthesis. 
By far the most common method of network synthesis involves conventional free 
radical polymerisation (Patrickios and Georgiou 2003). Free radical polymerisation 
reactions can be separated into three stages initiation, propagation and termination 
reactions. According to Cowie (1991) a free radical is an atomic or molecular 
species whose normal bonding system has been modified such that an unpaired 
electron remains associated with the new structure. The radical is capable of reacting 
with an olefinic monomer to generate a chain carrier which can retain its activity 
long enough to propagate a macromolecular chain under the appropriate condition 
(Cowie 1991). The distinguishing characteristic of chain polymerisation, where the 
reactive species is a free radical, cation or anion, is that polymer growth takes place 
by monomer reacting only with the reactive centre. By far the most common 
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example of chain polymerisation is that of vinyl monomers and this process can be 
depicted in the following manner modified from Odian (2004). 
H2C=CHY ~ 
R. • R-C-C· 
H2 ~ 
• 
termination 
• 
Each monomer molecule that adds to a reactive centre regenerates the reactive 
centre. Polymer growth proceeds by the successive additions of hundreds or 
thousands or more monomer molecules. The growth of the polymer chain ceases 
when the reactive centre is destroyed by one or more of a number of possible 
termination reactions (Odian 2004). Typically free radical polymerisation reactions 
can be carried out in one of four different ways I) with monomer on Iy (in bulk), 2) in 
a solvent (in solution), 3) with monomer dispersed in an aqueous phase (in 
suspension) and 4) or as an emulsion (Cowie 1991). 
An initiator is usually used to initiate free radical polymerisation reactions. Initiators 
are susceptible to homolytic fission when exposed to heat, electromagnetic radiation 
or a chemical reaction. a,a'-azobisisobutyronitrile (AIBN) is a commonly used 
initiator that decomposes when exposed to either electromagnetic radiation (360 nm) 
or heat (::::60°C) as follows, reaction scheme taken from Cowie (1991) 
(CH3}2 I N=N1 (CH3h 
CN CN 
The reaction then propagates in a stepwise manner with molecules adding onto the 
growing chain. Initially these will be monomers but as the reaction progresses 
dimers, trimers and larger macromers will be added. In theory the chain should 
continue to grow in this manner until all the mono mer in the system has been used 
up. However free radicals are very reactive and interact quickly to form inactive 
covalent bonds. This produces short chains in systems containing a high 
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concentration of initiator and long chains in systems containing a low concentration 
of initiator. Chain growth can terminate in one of three ways. Termination I) via the 
interaction of two active chains, 2) the reaction of an active chain end with an 
initiator radical or 3) termination by transfer of the active centre to another molecule 
which may be solvent, initiator, monomer, inhibitor or an impurity i.e. oxygen. 
Termination via the interaction of two active chains can occur in one of two ways, by 
the combination or by disproportionation. Termination by combination is where two 
chain ends combine to form one long chain. Termination by disproportionation is via 
hydrogen abstraction from one end to give an unsaturated group and two dead 
polymer chains Cowie (1991). These principles hold true for both homopolymers 
and copolymers. 
Copolymers are produced when more than one monomer is used during the 
synthesis. There are five types of copolymers, statistical, random, alternating, block 
or graft copolymers, some of these are illustrated below where M I and M2 are 
different monomers (Odian 2004). 
Statistical copolymers - there is a statistical distribution of one monomer within the 
other. 
Alternating copolymers - the two monomers alternate along the polymer chain. 
Block copolymers - there are blocks of both monomers in the polymer chain. 
Hydrogels are called permanent or chemical gels when they are covalcntly 
crosslinked networks (Hoffman 2001). Diene monomers are often used in 
copolymerisation reactions to obtain a crosslinked structure. When crosslinking 
occurs in the copolymerisation it depends on the relative reactivity of the two double 
bonds of the diene. The extent of crosslinking depends on the latter and on the 
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amount of diene relative to the other monomer. Several different cases can be 
distinguished depending on the type of diene. In most instances it is assumed that the 
diene is present at low concentrations (Odian 2004). When a crosslinked polymer is 
produced the dimensional stability is improved, the creep rate is lowered, it becomes 
less prone to heat distortion as the glass transition temperature (Tg) is raised and the 
resistance to solvents is increased (Cowie 1991). If the selected crosslinker is 
susceptible to degradation then it is possible to design polymers with predictable 
degradation profiles. These polymers are especially useful in drug delivery and tissue 
engineering applications. Controlling degradation behaviour has been one of the 
critical issues in general biomaterials research. Generally biomaterials need to be 
cleared from the body once they complete their roles in the body, and degradable 
materials could be ideal for this purpose. Two approaches are typically used to 
obtain degradable polymers and hydrogels. In the first, gelling polymers are 
designed such that their backbone is degradable by hydrolysis and I or enzymatic 
action. The second approach involves the introduction of degradable crosslinking 
points to systems that are comprised of non-degradable polymer chains (Lee, 
Bouhadir et al. 2004). Whilst degradable polymers are usually viewed as superior 
materials, they have to be approached with caution. The effects of the degradation 
products i.e. Iow molecular weight oligomers, charged molecular species or larger 
pieces of polymer, on surrounding tissues have to be evaluated. Changes in pH 
associated with the degradation of polymers such as poly(lactic acid) or 
poly(glycolic acid) can also have an adverse effect on the viability of surrounding 
tissues. The rates of degradation also have to be evaluated and the effects of the 
degradation on the material properties of the polymer. A rapidly degrading polymer, 
which lost the majority of its strength within a day or two, would not be suitable for 
a wound dressing which may need to stay in place for a week. 
When a greater degree of control is required over the final product i.e. when the 
molecular weight of the polymer needs to be well defined, living polymerisation 
routes can be used. These include atom transfer radical polymerisation CA TRP) and 
reversible addition fragmentation transfer polymerisation (RAFT) (Odian 2004). 
Living radical polymerisation allows the preparation of polymers with predetermined 
molecular weights, a narrow molecular weight distribution and tailored architecture 
(e.g. end-functional, block, star) and therefore offers a vast range of new and 
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advanced materials (Rizzardo, Chiefari et al. 2000). The molecular weights are 
predetennined by the reagent concentrations and conversion. The polymer products 
can also be reactivated for chain extension or block copolymer synthesis (Moad, 
Mayadunne et al. 2003). 
1.5.2 Hydrogels as biomaterials. 
Hydrogels are appealing for biological applications because of their hydrophilic 
character and potential for biocompatibility. In the last couple of decades, hydrogels 
have attracted a great deal of attention, and significant progress has been made in 
designing, synthesising, and using these materials for many biological and 
biomedical applications (Peppas, Hilt et al. 2006). Many biomaterials have been 
designed to meet particular biological and chemical requirements (e.g. 
biocompatibility, degradability, mediation of cell adhesion, etc.). Other design 
parameters, such as the physical properties of the biomaterial, were regarded with 
respect to the processing conditions, the mechanical load capacity, or the diffusivity 
of solutes, but not with respect to the biological response (Brandl, Sommer et al. 
2007). 
Neutral synthetic polymers can be generated from derivatives of poly(hydroxyethyl 
methacrylate) (PHEMA), poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA) 
and poly(N-vinylpyrrolidinone) (PNVP). Polymers that respond to stimuli such as 
changes in temperature or pH can also be produced. Responsive polymers include 
poly(acrylic acid) (PAA) which is sensitive to changes in pH and polymers based on 
poly(N-isopropylacrylamide) (PNIPAAm) which is sensitive to changes in 
temperature. (Peppas, Hilt et al. 2006). 
C)*+c-c-ol * D) +H -h-H H Tn • c-c • 2 2 I H n 
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Figure 1.4 Representative chemical structures for some synthetic polymers. Neutral 
polymers A) poly(hydroxyethyl methacrylate) (PHEMA), 8) poly(vinyl alcohol) 
(PVA) C) poly(ethylene glycol) (PEG) and D) poly(N-vinylpyrrolidinone) (PNVP). 
Responsive polymers E) poly(acrylic acid) (PAA) and F) poly(N-
isopropylacrylamide) (PNIPAAm). 
Hydrogels made from PEG and HEMA are normally neutral and relatively incrt to 
cell attachment (Schneider, English et al. 2004). PEG hydrogels are one of the most 
widely studied and used biomaterials. According to Peppas et al. (2006) PEG 
hydrogels are non-toxic, non-immunogenic, and approved by the US FDA for 
various clinical uses. In many cases PEG has been applied as a 'stealth material' to 
render materials invisible to biological molecules i.e. proteins (Peppas, Hilt et al. 
2006). 
PHEMA hydrogels are also widely used in biomedical applications. PHEMA is a 
common constituent in contact lenses. According to Hoffman (200 I) the hydrogel 
pioneer was a PHEMA hydrogel crosslinked with ethyleneglycol dimethacrylate 
(EGDMA). These hydrogels were first reported for biomedical applications in the 
journal Nature in 1960 and have since been successfully used as soft contact lenses. 
The original PHEMA contact lens was developed by Otto Wichterle in 1961 and 
contained 38% water, had excellent wetability and was much more comfortable to 
wear than the hard contact lenses. These contact lenses were subsequently modified 
by the addition of various hydrophilic monomers such as PNVP and glycerol 
methacrylate (GMA) (Lloyd, Faragher et al. 2001). HEMA has been copolymerised 
with other monomers such as methyl methacrylate to modify the gels material 
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properties i.e. the swelling and mechanical properties. These approaches have lead to 
PHEMA being used in drug delivery and tissue engineering applications (Peppas, 
Hilt et at. 2006). PHEMA based hydrogels have also been used in wound healing 
applications as wound dressings and skin substitutes and they have also been used in 
cartilage tissue engineering (Seal, Otero et at. 2001). 
Schneider et al. (2004) modified the charge of PHEMA and PEG hydrogels to 
produce positively and negatively charged gels as well as the normal neutral gels. 2-
sulfoethyl methacrylate was incorporated into the hydrogels to produce negatively 
charged gels. 2-methacryloxy ethyltrimethyl ammonium chloride was added to 
produce positively charged hydrogels. Gels were produced with fixed charges of 
200, 0 and +200 mM. GRGDS (Glycine - Arginine - Glycine - Aspartic acid -
Serine) adhesion sites were also covalently bound to the hydrogel surfaces. This 
study showed that murine MC3T3-EI osteoblasts and 3T3 fibroblasts preferred to 
attach to the positively charged surfaces instead of the negatively charged and 
neutral surfaces. The osteoblastic cells attached better to both gels than the 
fibroblastic cells. Both cell types preferred the HEMA gels than the PEG gels and 
the cells attached better to the positively charged gels than to the gels with GRGDS 
grafted to the surface (Schneider, English et al. 2004). This contrasts with the work 
of Chen et al. (2005) who showed that bovine foetal aorta endothelial cells 
preferentially attached and proliferated on negatively charged PAA, poly(sodium p-
styrene sulfonate) (PNaSS) and poly(2-acrylamido-2-methyl-I-propanesulfonic 
sodium) (PNaAMPS) hydrogels with zeta potentials between -20 m V and -35 m V 
over the neutral PVA and poly(acrylamide) (PAAm) hydrogels (Chen, Shiraishi et 
at. 2005). SoJtys-Robitaille et al. (2001) also demonstrated a link between the surface 
charge of contact lenses and protein adsorption. Cationic proteins such as lysozyme 
adsorbed preferentially to anionic polymers and anionic proteins such as human 
serum albumen adsorbed preferentially to cationic polymers. Nonionic polymers 
showed no detectable protein adsorption (Soltys-Robitaille, Ammon et al. 200 I). 
Kulik and Ikada (1996) showed that hydrogel charge also affected the adsorption of 
platelets to various hydrogels. They showed that platelets adsorbed preferentially 
onto the surfaces of cationic polymers, and reduced adsorption was seen on anionic 
polymers. This was explained by the anionic nature of the platelet cell membrane. 
Platelet adsorption was also reduced on polymers with large water contents i.e. 
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greater than 90% (Kulik and Ikada 1996). Nuttelman et al. (2001) showed that the 
water content of hydrogels affected the ability of proteins, specifically fibronectin to 
adhere to the hydrogel surface. This lack of protein adhesion made cell attachment 
difficult and therefore fibronectin was chemically attached to the surface of the PV A 
hydrogel used in this study to allow NIH3T3 fibroblasts to attach and migrate 
(Nuttelman, Mortisen et al. 2001). The link between the water content of hydrogels 
and cell attachment has also been illustrated by Haigh et al. (2002) and Rimmer et al. 
(2005). 
It appears that a number of factors affect the adhesion of cells to polymers namely 
the charge associated with the polymer surface, the water content of polymers and 
the cells themselves. It has been shown that cells cannot attach directly to polymers. 
Proteins such as fibronectin, laminin or vitronectin must be adsorbed to the polymers 
surface before cells can attach (Nuttelman, Mortisen et al. 2001). If the water content 
of the polymer is too high then the protein will not be able to attach to the surface as 
the surface will not be 'seen' by the protein. The adage of opposites attract is also 
true when looking at the adsorption of proteins to polymers with charged proteins 
adsorbing onto the surfaces of polymers with the opposite charge. Proteins not only 
need to be adsorbed onto the polymer but they need to be the correct proteins for cell 
attachment. According to Nuttelman et al. (2001) the driving force for protein 
adsorption to hydrophilic surfaces is enthalpic, conversely the driving force for 
protein adsorption to hydrophobic surfaces is entropic, and protein adsorption to 
hydrophobic surfaces is usually irreversible, opposed to the reversible adsorption of 
proteins to hydrophilic surfaces. Nuttelman et al. (200 I) also states that maximal cell 
adhesion to polymeric surfaces occurs on surfaces of moderate water wetability. 
Surfaces of high or low water wetabilities discourage cell adhesion. At this time it is 
impossible to decide which is the more important of the material properties i.e. 
surface charge or water content when it comes to cell attachment to polymers. 
I.S.2.1 Poly(vinylpyrrolidinone) 
Poly(vinylpyrrolidinone) (PNVP) which IS sometimes known as 
poly(vinylpyrrolidone) or povidone is the water-soluble homopolymer of N-vinyl-2-
pyrrolidone. PNVP was first developed in Germany at I.G. Farben by Professor 
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WaIter Reppe and his colleagues during the 1930's, PNVP was subsequently widely 
used as a blood-plasma substitute and extender during world war 11 (Robinson, 
Sullivan et al. 1990). However in 1978 the FDA determined that the use of PNVP in 
normal saline was unsafe for use as a plasma expander due to the risk of 
accumulation in the body causing the formation of granulomas. The FDA also stated 
that Povidone also interferes with blood coagulation, haemostasis. and blood typing 
and cross matching (FDA 1998). PNVP still has a wide range of use in biomedical 
applications especially in the pharmaceutical industry where it is used as a binder for 
tablets with the World Health Organisation (WHO) granting an acceptable daily 
intake of 0-50 mg.kg,l.day'1 for PNVP (Robinson, Sullivan et al. 1990). 
PNVP hydrogels are widely used in biomedical applications. PNVP is a common 
constituent in contact lenses where it is used to raise the water content of the lens 
(L1oyd. Faragher et al. 2001). Copolymers of PNVP have been investigated as 
adhesives for surgical wounds (Kao, Manivannan et al. 1997), wound dressings 
(Risbud, Hardikar et al. 2000; Razzak, Darwis et al. 200 I; Vogt, Hauser et al. 200 I ; 
Wu, Bao et al. 2001; Lopergolo, Lugao et a!. 2002; Lugao, Rogero et a!. 2002; Ali i. 
Othman et al. 2005; Sen and Avci 2005; Vogt, Reimer et a!. 2006) and for drug 
delivery applications (Berscht, Nies et al. 1994; Liu, Fullwood et al. 2000; Liu and 
Rimmer 2002a; Liu and Rimmer 2002b; D'Souza, Schowen et a!. 2004; Kaneda, 
Tsutsumi et a!. 2004; Kodaira, Tsutsumi et al. 2004; Bajpai and Dubey 2005; 
Devine, Devery et a!. 2006; Saxena, Mozumdar et al. 2006). PNVP is commonly 
encountered as an antiseptic when complexed with Iodine under the trade name 
Betadine. PNVP hydrogels have also been investigated by the group of T.V. Chirila 
for use as a vitreous substitute (Vijayasekaran, Chirila et al. 1996; Chirila. Ilong et 
al. 1998; Hong, Chirila et a!. 1998). These studies showed that PNVP hydrogels had 
the required material properties i.e. these hydrogels were injectable, had the correct 
optical properties and did not stimulate an excessive immune response 
(Vijayasekaran, Chirila et al. 1996; Hong, Chirila et al. 1998). However in vitro 
cytotoxicity testing showed that these PNVP based hydrogels could significantly 
increase fibroblast viability both in the presence and absence of serum. The extent to 
which cell viability altered when exposed to PNVP was affected by the crosslinkers 
used in the study (Hong, Chirila et al. 1997). The ability of PNVP based hydrogels to 
increase cell viability was confirmed by Risbud et al. (2000) who showed that cell 
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viability could be significantly increased when cells were grown on PNVP-chitosan 
hydrogels. 
PNVP is a common constituent in wound dressings, its extreme hydrophilicity 
means that cells find adhesion difficult. It has also been postulated that PNVP could 
be used in the place of poly(ethyleneglycol) (PEG) due to their similar "stealth" 
properties especially when coating nanopartic1es for infiltration into the body 
(Saxena, Mozumdar et aI. 2006). A series of PNVP polymers have been investigated 
by the group of T.V. Chirila for use as vitreous substitutes. During cytotoxicity 
testing of these polymers a growth promoting effect was observed. This was 
especially potent when 3T3 Swiss mouse fibroblasts were cultured with these 
polymers in the absence of serum, this was also shown to be dependent on the 
concentration of polymer in the medium (Hong, Chirila et aI. 1997). Gels crosslinked 
with Diethyleneglycol Dimethacrylate (DEGDMA) performed best in cytotoxicity 
testing. Cytotoxicity was assessed using the SRB assay, an assay for cell protein 
content. For all of the polymers the equilibrium water contents were between 95· 
98%. The polymers had material properties suitable for use as vitreous substitutes 
and for injecting through a large gauge needle (Hong, Chirila et aI. 1997). In vivo 
testing showed that PNVP was still present in the eyes 4 weeks after operation, the 
eyes however showed signs of giant cell infiltration (Vijayasekaran, Chirila et aI. 
1996). Risbud et aI. (2000) showed that poly(vinylpyrrolidinone-chitosan) hydrogels 
could increase the viability and proliferation, assessed by MTT-ESTA assay and 
image analysis, of both fibroblasts and SiHa epithelial cells. Medium that had been 
incubated in the presence of these polymers was also shown to increase cell viability. 
In the case of the SiHa cells the more conditioned medium was present. up to 30%, 
the greater the increase in viability. For fibroblasts at concentrations of 10 and 20% 
conditioned medium and increase in viability above the tissue culture plastic (TCP) 
control was seen, however once the concentration reached 30% the viability of the 
cells, whilst still greater than the control cells, dropped significantly from that of the 
cells cultured in 20% conditioned medium. 
PNVP has also been investigated for use as a vitreous substitute (Vijayasekaran, 
Chirila et al. 1996; Hong, Chirila et aI. 1997; Chirila, Hong et al. 1998; Ilong. 
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Chirila et al. 1998). In vitro biodegradation experiments indicated that there should 
be no biodegradation over the 4 week examination period. Further in vivo testing 
showed that 50% of the injected crosslinked hydrogel disappeared from the eye 
while over the same period 80% of the homopolymer was lost within the same 
period (Hong, Chirila et al. 1998). This loss of polymer could be a major concern. 
However PNVP has been shown to induce only minor storage-related functional 
changes to organs and this is influenced by molecular weight. Linear PNVP's with 
molecular weights of less than 70 kDa passively excreted by the kidneys (Chirila, 
Hong et al. 1998). Other biodegradation studies (Bruining, Koole et al. 1999) have 
shown that PNVP crosslinked with a novel carbonate crosslinker (figure 1.5) , with a 
crosslinker:NVP mole ratio of 1: I 0.5 was still stable after a week. However with 
decreasing crosslinker concentrations the degradation rate increased 1: 1 05 degraded 
in less than I day and 1:1000 degraded immediately at 37°C in phosphate buffered 
saline. There are no literature studies showing the degradation of P(NVP-co-
DEGBAC) hydrogels. However the similarities between the two crosslinkers suggest 
that the degradation profiles may be similar. The structure of DEGBAC is shown in 
figure 1.6 
~/"J/'V~/'Vyv~Jy 
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Figure 1.5 Novel carbonate crosslinker (Bruining, Koole et al. 1999) 
Figure 1.6 Structure of Diethylene glycol bisallylcarbonate 
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The material and chemical characterisation of poly(vinylpyrrolidinone), of both the 
homopolymer and various copolymers are well documented in the literature. The 
13C_NMR spectrum of uncrosslinked poly(vinylpyrrolidinone) in methanol-d4 is 
shown in 1.7. 
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Figure 1.7 I3C-NMR spectrum of Plasdone C-15 in methanol - d4. A commercially 
available linear homopolymer of poly(vinylpyrrolidinone) with molecular weight 
J 04 Da (Raith, Kuhn et aJ. 2002). 
Material characterisation of various poJy(vinyJpyrroJidinone) copolymers for various 
applications has been approached in different ways. Dynamic mechanical analysis 
(OM A) and differential scanning calorimetry have been used to probe the properties 
of poly(vinylpyrrolidinone)-poly(vinyl alcohol) blends (Cauich-Rodriguez, Deb et 
al. 1996a; Cauich-Rodriguez, Deb et al. 1996b) giving storage moduli , glass 
transition temperatures (T g) and stress-strain (a-E) behaviour. Equilibrium water 
content (EWC) measurements are commonly used to characterise hydrogels as the 
hydrophilicity or hydrophobicity of these polymers is important when polymers are 
considered for biomedical applications. Shantha et al. (2003) investigated how 
increasing N-vinyl pyrrolidinone content in a series of poly(lactose acrylate-N-vinyl-
2-pyrrolidinone) hydrogels and increasing crosslinker concentration affected the 
EWC of these hydrogels. Uniaxial tensile and compression testing of hydrogels is 
also possible. Poly(vinylpyrrolidinone)-gelatin hydrogels have been tested using 
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compression testing (Lopes and Felisberti 2003) whilst other hydrogels have been 
tested using specimens cast into dumbbell moulds for uniaxial tensile testing 
(Hinkley, Morgret et al. 2004). Swelling studies and Fourier transform infrared 
(FTIR) spectroscopy have been used along with differential scanning calorimetry 
(DSC) and other chromatography techniques to characterise 
poly(vinylpyrrolidinone-co-acrylic acid) hydrogels (Devine and Higginbotham 
200S). Rheometry can also be used to examine the material properties of polymers 
and is especially suitable for soft polymers like hydrogels. Devine et al. (200S) used 
rheometry to examine the material properties of a poly(vinylpyrrolidinone-co-acrylic 
acid) hydrogel allowing the shear modulus (G) to be calculated. However when 
examining the material properties of hydrogels, as with any polymer, a number of 
factors such as rubber elasticity theory, viscoelasticity and creep behaviour have to 
be taken into account when designing experiments (Anseth, Bowman et al. 1996). 
It has been shown that PNVP can be conjugated to a number of drugs to produce 
functionalised PNVP's which could be used in pharmaceutical applications (Liu. 
Fullwood et al. 2000; Liu and Rimmer 2002b; D'Souza, Schowen et al. 2004). Liu et 
al. synthesised a number of allyloxycarbonyloxymethyl-5-fluorouracil monomers 
that were subsequently successfully reacted with NVP producing polymers. These 
were slightly rich in NVP at low conversions and rich in S- fluorouracil (5-FU) 
monomer at the latter stages of the reaction and a reactivity ratio of rNVP = 0.97 was 
reported (Liu, Fullwood et al. 2000). Subsequent studies involved these 5-FU 
functionalised NVP oligomers being used in the synthesis of NVP membranes. The 
release of the S-FU from these membranes was highly non-Fickian with the release 
mechanism dominated by chemical degradation of carbonate groups present in the 
polymers (Liu and Rimmer 2002b). Cytotoxicity testing of these NVP/5-FU 
membranes showed that wells containing polymer with the 5-FU functionality were 
not viable. It was also apparent that cell proliferation but not viability was reduced in 
the presence of the polymers lacking the 5-FU group. 
Functional NVP oligomers have also been prepared. These oIigoNVP's with methyl 
ketone end groups could be subsequently transformed to produce oligoNVP's with 
si!yl enol ether end groups (Liu and Rimmer 2002a). It has been suggested that 
living polymerisation methods such as Reversible Addition Fragmentation Chain 
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Transfer (RAFT) polymerisation could be used to produce NVP oligomers with 
functional end groups and narrow polydispersities (Moad, Mayadunne et al. 2003). 
1.5.3 Hydrogels as wound dressings. 
Wound dressings as described in section lA have to meet a formidable list of criteria 
to be successful. Briefly they have to be tissue compatible, non-toxic, impermeable 
to exogenous microorganisms, have a rapid and sustained adherence to the wound 
surface, conform to surface irregularities, be elastic to permit motion of underlying 
tissue, have an appropriate tensile strength to resist fragmentation, have a long shelf 
life, minimal storage requirements, be low cost, minimise nursing care of wounds, 
minimise patient discomfort, be translucent to allow direct observation of healing, 
reduce healing time, and prevent heat and fluid loss (Seal, Otero et al. 2001; 
Sheridan and Tompkins 2002; Atiyeh, Hayek et al. 2005; Ehrenreich and Ruszczak 
2006). Polymers used in hydrogel wound dressings include poly(ethylene oxide), 
polyacrylamides, PNVP, chitosan, glycosaminoglycans, pluronic F127 (a block 
copolymer of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) 
(PEO-PPO-PEO)), PHEMA and PEG (Corkhill, Hamilton et al. 1989; Ramos-E-
Silva and Ribeiro De Castro 2002) 
Hydrogel dressings are available as either gels, sheets or impregnated gauze (Lionelli 
and Lawrence 2003). There are many advantages to gel dressings, they are soothing. 
they will follow the contours of the wound surface, are non-adherent, are semi-
transparent, are relatively easy to apply and remove, are permeable to oxygen and 
water, and antimicrobial agents can be incorporated within the material (Quinn, 
Courtney et al. 1985; Eaglstein 200 I; Menaker 200 I). This last point is especially 
useful as hydrogels are poor bacterial barriers. Therefore an antimicrobial agent can 
be used in conjunction with the hydrogel dressing, either a cream underneath the 
dressing or an antimicrobial agent such as penicillin or PNVP-I being incorporated 
into the dressing (Corkhill, Hamilton et al. 1989; Cho and Lo 1998). Hydrogels have 
an ability to cool the skin upon application. This cooling is a result of their high 
specific heat and this has been quantified at about 5°C. The ability of hydrogels to 
cool the skin upon application reduces pain and inflammation (Cho and Lo 1998; 
Ramos-E-Silva and Ribeiro De Castro 2002). Hydrogels, unlike alginates or 
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hydrocolloids do not need further wound secretions to attain a gelatinous 
consistency. Hydrogels as well as donating moisture to the wound are capable of 
absorbing surplus contaminated exudates and safely retaining them within the gel 
structure. The absorption of secretions causes an expansion of the crosslinks in the 
polymer chains making room for the inclusion of foreign bodies such as bacteria, 
detritus, and odour molecules that are irreversibly taken up with the liquid (Jones and 
Vaughan 2005). One of the major problems with hydrogels is their relatively poor 
mechanical properties. The underlying cause of the limited resistance to mechanical 
deformation and poor tear strength of hydrogels is the plasticizing effect of the water 
held within the polymer network, Ironically, it is this same feature that dominated 
the surface properties, permselectivity and permeability that give hydrogels their 
unique and interesting properties (Corkhill, Hamilton et al. 1989). The poor material 
properties mean that hydrogels tend to be used as part of a composite dressing or 
with a secondary dressing. Other disadvantages include the need for frequent 
dressing changes and the fact that hydrogels do not provide a very good barrier 
against bacteria and actually selectively permit the overgrowth of gram-negative 
organisms. Also as hydrogel dressings are non-adherent bacteria and other pathogens 
may gain entry to the wound from the edges of the dressing (Cho and Lo 1998; 
Ramos-E-Silva and Ribeiro De Castro 2002). Hence the need for antimicrobial 
agents mentioned earlier. 
Hydrogels are considered to be a standard form of management for sloughy or 
necrotic wounds. However, they are not recommended for wounds producing high 
levels of exudate or where there is evidence of gangrenous tissue. In this case the 
wound should be kept dry to reduce the risk of infection (Jones, Grey et al. 2006). 
They are also useful for painful wounds, post-dermabrasion, laser wounds, ulcers, 
chemical peels and partial thickness wounds, burns and scalds. Hydrogel dressings 
are also useful for rehydrating eschar and slough for easy removal from the wound 
surface. They are also useful for creating and maintaining a moist but not wet 
microenvironment over the healing wound (Eaglstein 2001; Ramos-E-Silva and 
Ribeiro De Castro 2002; Jones and Vaughan 2005). 
Examples of hydrogel dressings include Aquaform, Carrasyn, Curafil, Curagel, 
Flexderm, FlexiGel, Geliperm, GranuGel, Hydron Burn Bandage, Intrasite, Lamin, 
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Nu-Gel, Omniderm, Purilon, Skintegrity Hydrogel, SoloSite, Sterigel, Tegagel, and 
Vigilon (Quinn, Courtney et al. 1985; Corkhill, Hamilton et al. 1989; Eaglstein 
200 I; Lionelli and Lawrence 2003; Jones and Vaughan 2005; Jones, Grey et a!. 
2006; Ovington 2007). Of these dressings Geliperm (an agar and polyacrylamide 
gel) and Vigilon (a poly(ethylene oxide) hydrogel with a polyethylene backing film) 
have shown promise in the treatment of bums (Quinn, Courtney et al. 1985). 
1.5.4 Hydrogels in drug delivery applications. 
Hydrogels are commonly used vehicles for drug delivery applications. Drugs can 
range from small molecules such as 5-tluorouracil (5-FU), 4-methyl umbelliferone 
(4-MU) or J3-aminopropionitrile fumarate (I3APN) to larger molecules such as 
proteins, enzymes and DNA or RNA. According to Saltzman (2001) many decades 
after the first descriptions of biocompatible polymers for drug delivery, a handful of 
these are now approved for use in humans (Saltzman 2001). The selection of 
hydrogels used in pharmaceutical applications depends on the characteristics of the 
gel and on the application of the drug or protein. Hydrogels have several important 
characteristics involved in drug diffusion. These include the ionisation of the gel, the 
swelling ratio, and specific mesh or pore size. Functional groups along the polymer 
chain can also react to the external environment for example temperature, pH, ionic 
strength of the swelling agent or a combination of two or more factors (Devine, 
Devery et al. 2006). 
Drug release from polymeric materials has been extensively investigated in the 
literature. Model drugs varying from large proteins such as bovine serum albumen 
(BSA) (Anseth, Metters et al. 2002), lysozyme and IgG (Hennink, Talsma et al. 
1996) to small molecules such as 5-tluorouracil (Liu and Rimmer 2002b) have been 
used in these studies. The group of Peppas et al. studied the kinetics of polymer-
solvent-solute interactions extensively (Ritger and Peppas 1987a; Ritger and Peppas 
1987b; Brannon-Peppas and Peppas 1991; Braze I and Peppas 2000). Ritger and 
Peppas (1987a; 1987b) attempted to simplify the data analysis involved in the 
application of the existing Fickian diffusion equation, equation 1.1 which deals with 
the kinetics of drug release from polymers. 
Mt = Mass of drug released at time, t 
Moo = Mass of drug released as time approaches infinity 
n = Diffusional exponent 
D = Drug diffusion coefficient 
I = sample thickness 
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Equation 1.1 
The fractional release (MtlMoo) of the drug from polymers with varying geometries 
relates to the release time (t) using the proposed empirical, exponential expression 
MtfMoo=ktn where n = diffusional exponent and k = rate constant. Using this equation 
generally "Fickian diffusion is defined by n equal to 0.50 and non-Fickian by n 
greater than 0.50" (Ritger and Peppas 1987a). Fickian diffusion is defined as zero 
order release of the solute from the polymer i.e. steady state diffusion, no 
interactions between the solute and the polymer. Non-Fickian diffusion is indicative 
of interactions between the solute and the polymer. Sample geometry influences 
solute release. Ritger et al. (1987b) showed how the diffusion exponent varies for 
samples with different geometries in swellable systems. For cylindrical samples, 
such as the ones used in this study, Ritger states that for Fickian diffusion n=0.45, 
for anomalous (non-Fickian) transport n= 0.45<n<0.89 and for Case-II transport 
n=0.89. Whilst Case-J or Fickian diffusion is described by a diffusion exponent, 
Case-II transport is described by a characteristic relaxation constant. Brazel and 
Peppas (2000) used mathematical models to predict drug release profiles from 
polymers. These predictions showed that sample thickness, water and drug diffusion 
exponents and polymer viscoelastic response markedly change the release profiles. A 
small change in sample thickness can have a large effect on drug release behaviour. 
The controlled release of proteins from hydrogels has been extensively investigated. 
The release of model proteins such as lysozyme, bovine serum albumin (BSA) and 
immunoglobulin G (lgG) has been investigated from dextran based hydrogels 
(Hennink, Talsma et al. 1996; Meyvis, De Smedt et al. 2001). BSA has also been 
used as the model protein in release experiments from glycidyl methacrylate-
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hyaluronic acid and glycidyl methacrylate-hyaluronic acid PEG hydrogels (Leach, 
Bivens et al. 2003). In this study the protein was also loaded into the hydrogels in 
two forms. The BSA was mixed into the hydrogel monomer blend before 
crosslinking or loaded into PLGA microspheres which were mixed into the monomer 
blend before crosslinking. The presence of the microspheres was shown to extend 
the release of the BSA from the system from a few hours to a couple of weeks 
(Leach and Schmidt 2005). The use of microspheres of different types i.e. liposomes, 
hydrosomes, polymersomes are becoming more and more popular for drug delivery, 
especially for the delivery of fragile molecules such as proteins. Bos et al. (200 I) 
report the encapsulation of a wide variety of proteins into a variety of synthetic, i.e. 
PLGA, dextran methacrylate or dextran HEMA, microspheres which were 
subsequently incorporated into the PEGTIPBT copolymer polyActive and various 
hydrogels. These systems proved to be extremely versatile with systems for both 
prolonged and delayed release patterns being achieved (Bos, Verrijk et al. 2001). 
Crosslinked nanoparticles synthesised from PNVP have been designed for use as a 
vector for gene delivery. According to Saxena et al. (2006) it has been observed that 
PNVP uptake by cells and its effect on the intracellular enzymes was very limited. 
Moreover, PNVP is retained within the intracellular vesicles after its uptake. The 
PNVP nanoparticles synthesised in this study were able to evade the rough 
endoplasmic reticulum and therefore were able to remain in circulation for a 
considerable period of time and resulted in an 80% transfection efficiency (Saxena, 
Mozumdar et al. 2006). Drugs like 5-tluorouracil (5-FU) can be conjugated to allyl 
carbonate crosslinkers and then used to produce 5-FU releasing PNVP hydrogels 
(Liu and Rimmer 2002b). The 5-FU was released from these hydrogels by 
degradation of the carbonate groups. The release rates of the 5-FU (37°C and pH 7.4) 
from the PNVP hydrogels investigated in this study showed that the release is 
controlled by Fickian diffusion and interaction with the polymer chains with the 
expected contribution from the rate of crosslinker degradation. The diffusion 
exponents obtained for the release of 5-FU from PNVP hydrogels were between 0.13 
and 0.23 and increased with increasing amounts 'of the 5-FU functionalised 
crosslinker (Liu and Rimmer 2002b). Alternatively D'Souza et al. (2004) conjugated 
the drug para-nitroaniline (PNA) directly to the PNVP chain by opening the lactam 
ring and protection of the resulting amine with t-BOC prior to conjugation of the 
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opened ring with the PNA. The t-BOC could then be removed to produce a 
secondary amine. In the deprotected polymers approximately 35% of the PNA was 
released over a 30 day period (50°C and pH 7.5). The protected polymers released 
only 12% of the PNA in the same conditions and over the same time period. 
D'Souza et al. suggest that these PNVP-PNA conjugates could be suitable for 
controlled release applications due to the relatively slow release kinetics. Kaneda et 
al. (2004) successfully conjugated TNFa to PNVP via a reaction with 
methoxypolyethylene glycol-succinimidyl succinate. PNVP-TNFa after Lv. injection 
has a much longer retention time in the blood than native TNFa with a half life of 
360.1 min ± 45.7 min opposed to 4.6 min ± 2.2 min for native TNFa. PEG-TNFa 
was also synthesised and this had a half life 122.6 min ± 85.0 min. PNVP-TNFa was 
shown to have a more potent antitumor effect than the PEG-TNFa. These polymers 
also showed little sign of tissue accumulation. 
Shantha and Harding (2003) reported entrapment of propranolol hydrochloride 
(PPH) into poly(lactose acrylate-N-vinyl-2-pyrrolidinone) hydrogels. Release of 
PPH from the PNVP based hydrogels followed a characteristic release pattern over a 
period of 48 hours. There was a slight burst release during the first hour of the 
experiment explained by PPH adsorbed onto the hydrogel surface. Approximately 
54% of the entrapped drug was released by hour six. During this initial six hour 
period the release profile followed a near zero-order pattern. This is indicative of 
drug release via diffusion from the hydrogel matrix as it swells to equilibrium. 
PNVP has been copolymerised with polyacryJic acid and aspirin and paracetamol 
incorporated (Devine, Devery et al. 2006). NVP has also been copolymerised with 
itaconic acid and methylene blue incorporated as a model drug in this system (Sen 
and Guven 1999). Copolymerisation of PNVP with acrylic acid allowed for the 
incorporation of vitamin B\2 (Bajpai and Dubey 2005). These pH sensitive hydrogels 
showed maximum release at pH 6.8 with a minimum release at pH 1.2. 
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1.6 Aims. 
In summary whilst great strides have been taken in understanding wound healing and 
in developing wound dressings to aid healing, skin graft contracture is still a major 
problem facing burns patients. Recent work by others in the group had identified two 
candidate drugs for blocking skin contraction in tissue engineered skin. It was 
therefore proposed to develop a wound dressing based on the polymer PNVP that 
could be used to deliver the drugs and prevent or at the very least reduce skin graft 
contracture in burns patients. To develop this active hydrogel dressing a series of 
specific objectives were identified. 
1. To evaluate the cellular cytotoxicity of novel PNVP hydrogels. 
2. To examine the cytotoxicity of the drugs p-aminopropionitrile and 4-methyl 
umbelliferone. 
3. To determine whether p-aminopropionitrile and 4-methyl umbelliferone 
would prevent or reduce contracture in a collagen gel contraction model. 
(The p..-aminopropionitrile had been previously identified on the basis of its 
action on a 3D skin contraction model in this group and the 4-methyl 
umbelliferone on the basis of its action on fibroblast populated collagen gels 
in the group of M Edwards at the University of Glasgow). 
4. To determine if 4-methyl umbelliferone could prevent or reduce contracture 
in the reconstructed skin contraction model. 
5. To examine the loading and release of p-aminopropionitrile and 4-methyl 
umbelliferone into and from PNVP hydrogels. 
6. To examine to what extent hydrogels loaded with p-aminopropionitrile and 
4-methyl umbelliferone would prevent or reduce the contraction of the 
collagen gel contraction model and the 3D reconstructed skin model. 
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2. Materials and Methods. 
2.1 Polymer synthesis and characterisation. 
Materials. 
I-vinyl-2-pyrrolidinone (NVP), Ethylene glycol dimethacrylate (EGDMA), Acrylic 
Acid (AA) and Dimethyl sulfoxide (OM SO) were obtained from Aldrich, UK. 
Absolute Alcohol, Acetone, Ether, Dimethylformamide (OM F), Tetrahydrofuran 
(THF), Propan-2-01 (IPA), Dichloromethane (DCM) and Acetonitrile were obtained 
from Fisher UK. Diethylene glycol bisallylcarbonate (DEGBAC) was obtained from 
Greyhound chromatography, UK. 2.2'-Azobis(2-methylpropionitrile) (AIBN) was 
obtained from Fluka, UK. 100 J-lm poly( ethylene terephthalate) (PET) sheeting was 
obtained from HiFi Industrial Film Ltd. UK), Benzene Dithiobenzoate (BDTB) was 
synthesised by Or Steve Carter, Chemistry dept. University of Sheffield, UK 
synthesis unpublished, I-methoxyphenyl-l-(trimethylsilyloxy)ethylene (MPTMSE) 
was synthesised by Or Prodip Sarker, Chemistry dept, University of Sheffield, UK 
(Lang, Sarker et at. 2004). 
2.1.1 Synthesis of poly(vinylpyrrolidinone) oligomers. 
3 g distilled NVP was placed in a dried degassed flask with 30 mg AIBN. The 
reaction was performed at 60°C and slowly stirred for 5 minutes and then quenched 
with liquid nitrogen. The resulting foam was dissolved in dichloromethane and 
added slowly to gently stirring ether, the poly(vinylpyrrolidinone) oligomers 
precipitate out. The solution was filtered and the solid placed in a drying oven at 
room temperature overnight. 
2.1.2 Synthesis of benzene dithiobenzoate functionalised 
poly(vinylpyrrolidinone) oligomers. 
3 g distilled NVP was placed in a dried degassed flask with 0.464 g benzene 
dithiobenzoate and 30 mg AIBN. The reaction was performed at 60°C for 2 hours 
and then quenched with liquid nitrogen. The resulting oil was added slowly to gently 
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stirring ether, the poly(vinylpyrrolidinone) oligomers precipitate out. The solution 
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2.1.3 Synthesis of I-methoxyphenyl-l-(trimethylsilyloxy)ethylene functionalised 
poly(vinyJpyrrolidinone) oligomers. 
0.36 ml distilled NVP was placed in a dried degassed flask with 0.16 ml 1-
methoxyphenyl-l-(trimethylsilyloxy)ethylene and 65 mg AlBN. The reaction was 
performed at 60°C for 2 hours and then quenched with liquid nitrogen. The resulting 
oil was added slowly to gently stirring ether, the poly(vinylpyrrolidinone) oligomers 
precipitate out. The solution was filtered and the solid placed in a drying oven at 
room temperature overnight. 
2.1.4 Synthesis of poly(vinylpyrrolidinone) membranes in the presence of 
solvent. 
109 distilled NVP, 0.1 g of EGDMA, and 0.1 g of AlBN were placed into a beaker 
containing 4.4 g DMSO. The solution was gently stirred whilst dry nitrogen was 
bubbled through for 20 minutes. The monomer blend was then injected into a glass 
mould consisting of two glass tiles lined with 100 J.1m PET sheets sandwiching a 
PTFE I mm thick spacer. The volume of the mould was approximately 10 ml. The 
mould was then placed into an oven at 60°C for 24 hours. After 24 hours the glassy 
plaque was removed from the mould and placed into absolute alcohol. The alcohol 
was changed every 24 hours for 5 days. 
2.1.5 Synthesis of poly(vinylpyrrolidinone) membranes in the absence of 
solvent. 
Table 2.1 Formulations of monomer blends for the production of NVP hydroge1s 
with different crosslinker concentrations in the absence of solvent. 
Weight NVP I g Crosslinker I g AIBN I g 
crosslinker 
lwt% 
2wt% 
14.85 
14.7 
0.15 
0.3 
0.1 
0.1 
3wt% 
4wt% 
1 wt%+ 1 wt% 
AA 
14.55 
14.4 
14.7 
0.45 
0.6 
0.15 + 0.15 AA 
0.1 
0.1 
0.1 
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Distilled NVP, crosslinker(s) (1 - 4 wt%), and AIBN, in quantities detailed in table 
2.1 above, were placed into a beaker. The solution was gently stirred whilst dry 
nitrogen was bubbled through for 20 minutes. The monomer blend was then injected 
into a glass mould consisting of two glass tiles lined with 100 J..lm PET sheets 
sandwiching a PTFE 1 mm thick spacer. The mould was then placed into an oven at 
60°C for 24 hours. After 24 hours the glassy plaque was removed from the mould 
and placed into absolute alcohol. The alcohol was changed every 24 hours for 5 
days. 
2.1.6 Synthesis of poly(vinylpyrrolidinone) membranes incorporating 3-
aminopropionitrile fumarate. 
Table 2.2 Formulations of monomer blends for the production of NVP hydrogels 
containing 3-aminopropionitrile fumarate with different crosslinker concentrations in 
the presence or absence of water. 
Weight NVPI Crosslinker I AIBN I pAPN.F I Water 
crosslinker g g g mg 
lwt% 14.85 0.15 0.1 3,3.5, 10.5 0, 
1 ml 
lwt%+ 11.85 0.15 0.1 3,3.5, 10.5 3g 
20 wt% H20 
2wt% 14.7 0.3 0.1 3, 3.5, 10.5 0, 
1 ml 
3wt% 14.55 0.45 0.1 3,3.5, 10.5 0, 
1 ml 
4wt% 14.4 0.6 0.1 3,3.5, 10.5 0, 
1 ml 
Iwt%+ 14.7 0.15 + 0.1 3,3.5, 10.5 N/A 
1 wt%AA 0.15 AA 
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Distilled NVP, crosslinker(s), AIBN and water, in quantities detailed in table 2.2 
above, were placed into a beaker containing 3 mg, 3.5 mg or 10.5 mg of 3-
aminopropionitrile fumarate. The solution was gently stirred whilst dry nitrogen was 
bubbled through for 20 minutes. The monomer blend was then injected into a glass 
mould consisting of two glass tiles lined with 100 J.lm PET sheets sandwiching a 
PTFE 1 mm thick spacer. The mould was then placed into an oven at 60°C for 24 
hours. After 24 hours the glassy plaque was removed from the mould. 
2.1.7 Production of poly(vinylpyrrolidinone) xerogels. 
Alcohol swollen P(NVP-co-EGDMA) and P(NVP-co-DEGBAC) membranes were 
cut to size with a cork borer in sterile conditions. The hydrogel discs were placed 
into a Petri-dish and the lid was fastened with autoclave tape. The Petri-dish was 
then placed into a drying oven at 50°C for 48 hours. The xerogeJs thus formed were 
then stored in sterile containers at room temperature until needed. 
2.1.8 Equilibrium water content measurements. 
Phosphate buffered saline (PBS) swollen hydrogel membranes were stored at room 
temperature prior to measurements. The swollen membranes were cut with a size 3 
cork borer (diameter 7 mm). The excess solvent was gently removed from the 
hydrogels by gently dabbing the polymer with tissue. The polymer pieces were 
weighed and placed on a glass slide. The slide was placed into a vacuum oven at 
50°C for 24 hours. The polymer pieces were weighed again and the equilibrium 
water content calculated using the formula. 
Ewe = wet weight - dry weight x 100 
wet weight 
2.1.9 IH NMR. 
Approximately 5 mg of the sample was dissolved in 1 ml of the appropriate 
deuterated solvent. The I H NMR spectra were obtained using a Bruker AC250 
spectrometer at 250MHz and analysed using Spinworks 1.3 software. 
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2.1.10 I3C solid state NMR. 
BC solid state NMR analysis was kindly performed by Dr David Apperley at the 
University of Durham EPSRC solid state NMR service. A Varian Unity Inova 
Spectrometer with a 7.5 mm MAS probe was used. Approximately 500 mg of 
xerogel was sent to the University of Durham by first class post. At The University 
of Durham the samples were lightly ground in a mortar and pestle prior to analysis. 
2.1.11 Size exclusion chromatography (SEC). 
SEC was performed using 2 x 40 cm kiw molecular weight Styrogel™ 5 mm mixed 
gel columns at room temperature. The eluent was THF at a flow rate of 1.0 cm3.min' 
I. Calibration was performed using polystyrene standards and a combination of RI 
and UV detection was employed. RI detector was a ERC-7512 obtained from ERMA 
inc. and the UV detector was a Lambda-Max LC spectrophotometer model 481. 
Automated sampling used a Gilson auto injector. All detectors were attached to a PC 
running Cirrus ™ GPC software. 
2.1.12 Compression testing. 
Compression testing was performed on a BaSE electroforce 3200 attached to a PC 
running WinTest™ software. PBS swollen hydrogel discs of diameter 13.2 mm were 
cut with a cork borer. Compression testing was performed over a distance of 2 mm at 
a rate of 0.1 mm.s· l . 
2.1.13 Degradation studies. 
PNVP samples hydrated in PBS were placed in a sealed container with a known 
quantity of PBS. The container was then placed in an incubator at 37°C and samples 
were removed and EWCs calculated for up to 12 days. 
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2.2 Cell Culture. 
Materials. 
Dulbeccos' Modified Eagles Medium (DMEM) and Hams FI2 were obtained from 
Sigma, UK or Biowest Biosera. Foetal calf serum was obtained from Biowest 
Biosera. L-glutamine, amphotercin B, penicillin-streptomycin, human recombinant 
epidermal growth factor, hydrocortisone, cholera toxin, adenine, insulin, apo-
transferrin 3,3,S-tri-idothyronine (TT), trypsin-ethylene diamine tetra-acetic acid 
(EDT A) (O.OS% w/v trypsin! 0.02% w/v EDTA), 0.02% w/v EDT A, Collagenase A, 
0.4% w/v Trypan blue, Bovine Serum Albumen (BSA) and Fibronectin were 
obtained from Sigma, UK. Epilife medium and human corneal growth supplement 
were obtained from Cascade Biologies, UK. Phosphate buffered saline tablets 
(Dulbeccos' A) were obtained from Oxoid, UK. Collagen from rats tail was obtained 
from Fluka, UK. Trypsin 0.1 % w/v was obtained from Difco, UK. Mycoplasma 
removal agent (MRA) was obtained from Serotec, UK. 
Skin for cell isolation and production of de-epithelised acellular dermis (DED) was 
obtained from patients undergoing routine abdominoplasties and breast reductions at 
the Northern General Hospital, Sheffield. All patients gave full informed consent for 
skin to be used for research through a protocol approved by the Ethical Committee of 
the Northern General Hospital Trust, Sheffield, UK. 
Adenine O.S g of powder was dissolved in 20 ml of distilled water. I M HCI was 
added drop-wise to get the powder into solution and the volume made up to 80 ml 
with distilled water before being filter sterilised, 2 ml aliquots were stored at -20°C 
before use. Final concentration 1.85 x 10-4 M, 2 ml aliquot used in making up SOO ml 
medium. 
Cells The 12 clone of the NIH 3T3 strain of murine fibroblasts was donated by 
Professor Howard Green at the Massachusetts Institute of Technology, USA or 
isolated from split thickness skin as per section 2.2.6 and section 2.2.7. 
Cholera Toxin 1 mg of cholera toxin was dissolved in 1.18 ml of distilled water and 
stored at 4°C. 0.01 ml of this solution was added to 1 ml of medium containing 
serum to form a base stock 8.47 pg.mr', which was then stored at 4°C. O.S ml was 
used in making up SOO ml medium. 
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Collagenase A was prepared by dissolving Collagenase A powder in fibroblast 
culture medium in sterile conditions to make 0.05% (w/v) solution. 
'Difco Trypsin' 0.1 % w/v was prepared by the adding of 0.5 g of Difco Trypsin 
powder, 0.5 g D-glucose, and 0.5 ml phenol red to 500 ml PBS. This was adjusted to 
pH 7.45 using 2 M NaOH using a pH meter. This was filter sterilised and aliquots 
stored at -20°C until needed. 
Epidermal Growth Factor (Human Recombinant from E.coli) 0.1 mg of EGF 
was dissolved in 1 ml of 10% Greens medium. 0.05 ml aliquots were prepared and 
stored at -20°C until needed. 0.05 ml used in making up 500 ml Greens medium, 
final concentration 10 ng.mr l • 
Hydrocortisone 250 mg was dissolved in I ml 100% ethanol. I ml of this was 
dissolved in 9 ml of PBS to form a base stock and stored at 4°C. 0.08 ml of stock 
used in making up 500 ml medium. 
Insulin 0.0 I g was dissolved in I ml of 0.0 I M HCI and then added to 9 ml of 
distilled water. This was filter sterilised and stored at 4°C. 0.5 ml of stock used in 
making up 500 ml medium. 
PBS was prepared by adding 1 tablet per 100 ml of distilled water. This solution was 
autoclaved at 115°C for 15 minutes and left to cool before use. 
TransferrinIT3 13.6 mg T3 was dissolved in a minimum amount of 0.02 M NaOH 
and the volume made up to 100 ml. 250 mg apo-transferrin was dissolved in 30 ml 
PBS, 0.5 ml T3 added and volume made up to 50 m!. This was filter sterilised and 
0.5 ml aliquots stored at -20°. Final concentration T3 1.36 J,lgr l , transferrin 2.5 mg.r l 
0.5 ml used in making up 500 ml medium. 
Trypan Blue stock solution I: I mixture of 0.4% Trypan blue and PBS 
No. 22 scalpel blades were purchased from Swann-Morton, Sheffield, UK. Cell 
counts were performed using a modified Neubauer haemocytometer purchased from 
Weber Scientific International, UK. Stainless steel rings and grids were 
manufactured by the Department of Medical Physics at the Royal Hallamshire 
Hospital, Sheffield, UK. Plasticware for cell culture was obtained from Costar, UK. 
ThinCert™ cell culture inserts were purchased from Greiner, UK. All cells, tissues 
and sterile reagents were handled in Class 11 laminar flow hoods obtained from 
Walker Safety Cabinets, UK. Cell and tissue culture was performed at 37°C, 5% CO2 
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95% humidity, in Sanyo CO2 incubators. Light microscopy of cell cultures was 
performed using an Olympus CK40-F200 light and phase contrast microscope. Still 
photographs were taken using a Nikon Coolpix 990 digital camera. 
2.2.1 Fibroblast culture medium. 
DMEM high glucose (4500 mg.rl glucose) supplemented with 10% v/v foetal calf 
serum (FCS), 2 x 10-3 M I-glutamine, 0.625 J-lg.mr l amphotercin B, 100 l.U.mrl 
penicillin and 100 J-lg.mr l streptomycin. 
The above ingredients were mixed at room temperature in a class 11 laminar flow 
hood to make a total volume of 500 ml. Medium was stored at <4°C for a maximum 
of 6 weeks prior to use. An aliquot of medium was warmed to 37°C before use. 
2.2.2 Serum free fibroblast culture medium. 
DMEM high glucose (4500 mg.r l glucose) supplemented with 2 x 10-3 M 1-
glutamine, 0.625 J-lg.mr l amphotercin B, 100 I.U.mr' penicillin and 100 J-lg.mr l 
streptomyc in. 
The above ingredients were mixed at room temperature in a class 11 laminar flow 
hood to make a total volume of 500 ml. Medium was stored at <4°C for a maximum 
of 6 weeks prior to use. An aliquot of medium was warmed to 37°C before use. 
2.2.3 3T3 culture medium. 
DMEM high glucose (4500 mg.r' glucose) supplemented with 10% v/v new born 
calf serum (FCS), 2 x 10-3 M I-glutamine, 0.625 J-lg.mr l amphotercin B, 100 LU.mr' 
penicillin and 100 J-lg.mr l streptomycin. 
The above ingredients were mixed at room temperature in a class 11 laminar flow 
hood to make a total volume of 500 ml. Medium was stored at <4°C for a maximum 
of 6 weeks prior to use. An aliquot of medium was warmed to 37°C before use. 
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2.2.4 Greens medium. 
A clinically approved cell culture medium suitable for the culture of keratinocytes. 
However fibroblasts are also able to grow successfully in Greens medium (Sun, Mai 
et al. 2005). 
DMEM high glucose and Ham's FI2 medium in a 3:1 ratio supplemented with 10% 
v/v foetal calf serum (FCS), 10 ng.mr l human recombinant epidermal growth factor, 
0.4 J.1g.mr l hydrocortisone, 10.10 M cholera toxin, 1.8 x 10.4 M adenine, 5 mg.mr l 
insulin, 5 J.1g.mr l apo-transferrin, 2 x 10.7 M 3,3,5-tri-idothyronine, 2 x 10.3 M 
glutamine, 0.625 J.1g.mr l amphotercin B, 100 l.U.mr l penicillin and 100 J.1g.mr l 
streptomyc in. 
The above ingredients were mixed at room temperature in a class 11 laminar flow 
hood to make a total volume of 500ml. Medium was stored at <4°C for a maximum 
of 6 weeks prior to use. An aliquot of medium was warmed to 37°C before use. 
2.2.5 HCEC medium. 
Epilife was supplemented with Human Cornea growth supplement. 
2.2.6 Cell counts and viability assessment. 
Cell suspension, Trypan blue solution, Cell culture media. 
Cell counts and viability assessments were performed using trypan blue. Cells were 
suspended in a known volume of cell culture media. 20 J.1l of this cell suspension was 
removed and 20 III of Trypan blue stock solution was added. Non viable cells appear 
blue. Viable cells were counted using a Neubauer haemocytometer and the 
concentration of viable cells in suspension was calculated. 
2.2.7 Isolation and culture of keratinocytes from split thickness skin grafts. 
Split thickness skin from theatre (no more than 3 days old), PBS, 'Difco-Trypsin', 
Foetal calf serum, Greens medium, Trypan blue solution, 0.02% w/v EDTA solution, 
TrypsinlEDT A solution 
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Keratinocyte isolation, split thickness skin (STS) (approximately 2.5 cm2) was cut 
into thin pieces (approximately 0.5 cm x 1 cm) and placed into 10 ml 'Difco-
Trypsin'. This solution was incubated at 4°C overnight (typically 12-18 hours). 
Enzymatic activity was stopped after this time by the addition of 5 ml foetal calf 
serum. The skin strips were gently placed into a Petri dish containing a small amount 
(approximately 1 ml) of PBS. The epidermis was gently peeled off the dermis and 
the bottom of the epidermis and top of the dermis gently scraped to remove cells 
(keratinocytes, melanocytes etc). The PBS and cells were transferred to a universal 
containing a 50/50 mix PBS and FCS. Cells in PBS and FCS were spun down at 
1000 rpm for 5 minutes and then suspended in 10% Greens medium. A cell count 
was performed using trypan blue to highlight non viable cells. Cells were seeded at a 
density of;:::;: 4 x 106 in T75 flasks seeded approximately 1 hour earlier with 1 x 106 
i3T3. Cells were cultured at 37°C, 5% CO2 in a humidified atmosphere. The media 
was changed after 24 hours and subsequent media changes were performed every 2-3 
days and the desired 70-80% confluency was generally achieved in 5-7 days. 
Keratinocyte sub-culture, the media was rinsed away with PBS and the i3T3 cells 
were removed by incubation with 5 ml 0.02% w/v EDTA at 37°C. The flasks were 
examined by phase contrast microscopy every 5 minutes and gently tapped to 
encourage fibroblast detachment ensuring that the keratinocytes were still attached. 
The i3T3 containing EDT A solution was then removed and the flask rinsed with 
PBS. 2.5 ml TrypsinlEDTA was then added to the flask and incubated at 37°C. 
Keratinocyte detachment was encouraged by gentle tapping and confirmed by phase 
microscopy after 5 minutes. The cell suspension was added to 10 ml 10% Greens 
medium to neutralise the trypsin and spun down at 1000 rpm for 5 minutes. The 
resulting pellet was then suspended in a known volume of 10% Greens medium and 
a cell count was performed prior to use, again using trypan blue. Keratinocytes were 
used between passages 1 and 3. When keratinocytes were cultured without i3T3's 
the TCP was coated with 0.2 mg.mr l collagen I solution. 
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2.2.8 Isolation and culture of fibroblasts from split thickness skin grafts. 
Split thickness skin from theatre (no more than 3 days old), PBS, Collagenase A, 
Foetal calf serum, Fibroblast culture medium, Mycoplasma Removal Agent. 
Fibroblast isolation, the dermis left from keratinocyte isolation is minced up and 
placed into a Petri dish containing collagenase A solution and incubated at 37°C 
overnight. 10 ml of fibroblast culture medium is added to the Petri dish to stop 
collagenase. The cell solution was removed spun down at 2000 rpm for 10 minutes. 
The cells were then suspended in fibroblast culture medium containing mycoplasma 
removal agent and seeded in a T25 flask and incubated at 37°C, 5% C02 in a 
humidified atmosphere. The medium was changed after 24 hours then every 3-4 days 
until the cells were 80% confluent. 
Fibroblast sub-culture, 2 ml TrypsinlEDT A was added to the fibroblast containing 
flasks after thorough washing with PBS and incubated at 37°C. Fibroblasts were 
encouraged to detach by gentle tapping and detachment was confirmed by phase 
contrast microscopy. This generally took around 5 minutes. The cell suspension was 
added to 10 ml fibroblast culture medium to neutralise the trypsin, the cell 
suspension was then spun down at 1000 rpm for 5 minutes. The pellet was then 
suspended in a known volume of fibroblast culture medium and a cell count 
performed prior to use. Fibroblasts were used between passages 3 and 9. 
2.2.9 Culture of HaCaT cells. 
The HaCaT human keratinocyte cell line was kindly supplied by Professor N .E. 
Fusenig (Institute of Biochemistry, German Cancer Research Centre, Heildelberg, 
Germany) and cultured in fibroblast culture medium at 37°C, 5% C02 in a 
humidified atmosphere. 
Sub-culture Flasks containing HaCaT cells were washed thoroughly with PBS and 
then were incubated with 5 ml 0.02% w/v EDTA at 37°C for 5 minutes, 2 ml 
trypsinlEDT A was then added and cells were incubated for a further 5 minutes. 
HaCaT's were encouraged to detach by gentle tapping and detachment was 
confirmed by phase contrast microscopy. This generally took another 5 minutes. The 
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cell suspension was added to 10 ml fibroblast culture medium to neutralise the 
trypsin. The cell suspension was then spun down at 1000 rpm for 5 minutes. The 
pellet was then suspended in a known volume of fibroblast culture medium and a cell 
count performed prior to use. 
2.2.10 Culture of Human Corneal Epithelial Cells (HCEC). 
A HCEC line (10.014 pRSV-T) was obtained from ATCC, USA. HCEC's were 
cultured on tissue culture polystyrene (TCP) plates coated with a solution of Bovine 
Serum Albumin (0.01 mg.mr\ Fibronectin (0.01 mg.mr l ) and Collagen I 
(0.03 mg.mr l ), in HCEC medium. Cells were cultured in a humidified atmosphere 
at 37°C, 5% C02 and used between passages 45 and 47. 
Sub-culture After washing thoroughly with PBS flasks of HCEC cells were 
incubated with 2 ml trypsin/EDTA at 37°C for approximately 2 minutes. HCEC's 
were encouraged to detach by gentle tapping and detachment was confirmed by 
phase contrast microscopy. The cell suspension was added to 5 ml trypsin inhibitor 
and then spun down at 1000 rpm for 5 minutes. The pellet was then suspended in a 
known volume offibroblast culture medium and a cell count performed prior to use. 
2.2.11 3T3 murine fibroblast culture and irradiation. 
Irradiated 3T3 (i3T3) murine fibroblasts were used as a feeder layer during 
keratinocyte culture. A known number of proliferative 3T3's were stored at passage 
14 in cryovials containing 1 ml of cryopreservation medium (see section 2.3.1) in 
liquid nitrogen (-196°C). 
For production of i3T3 passage 14 3T3's were thawed and expanded using standard 
fibroblast sub-culture protocol (Section 2.2.8). Once sufficient cell numbers had 
been achieved (this was usually achieved at passage 17) the cells were then sub-
cultured again. However once in suspension the cells were irradiated by exposure to 
a cobalt-60 source. Cells of known concentration in 3T3 culture medium were 
placed into 25 ml Universal containers. They were then exposed to y-irradiation and 
received a total radiation dose of 25 Grays. 
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2.3 Cell cryopreservation. 
Materials. 
Foetal Calf Serum, (DMSO), Cellstar Cryovials were obtained from Greiner Bio-
one, UK, Nalgene ™ Cryo 1°C freezing container obtained from Nalgene Co., USA. 
2.3.1 Cryopreservation medium. 
1 ml dimethyl sulphoxide (DMSO) was added to 9 ml foetal calf serum to produce a 
10% solution of DMSO in FCS. This solution was made up fresh each time it was 
needed. 
2.3.2 Method of cryopreservation. 
Immediately prior to cryopreservation, the cells were detached from their culture 
flasks using trypsinlEDT A and suspended in a known volume of the appropriate 
culture medium. A cell count was performed and the cells were spun down at 
1000 rpm for 5 minutes. The cells were then suspended in cryopreservation medium 
to give a total cell count of 1-4 x 106 cells per ml depending on the cell type. The 
cryovials were placed in a Nalgene Freezing Container and placed into a -80°C 
freezer overnight. The cryovials, now containing frozen cells were then transferred 
to a Dewar bucket containing liquid nitrogen (-196°C). 
2.3.3 Thawing of cryopreserved cells. 
Cryovials were removed from the liquid nitrogen and defrosted in a water bath at 
37°C for few minutes. They were then added to 10 ml pre-warmed cell culture 
medium. The cells were then spun down at 1000 rpm for 5 minutes. The supernatant 
was then discarded and the cell pellet suspended in a known volume of cell culture 
medium. A cell count and viability assessment was then performed. 
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2.4 Mono-and co-culture of keratinocytes and fibroblasts on tissue-
culture plastic for drug cytotoxicity experiments. 
Materials. 
Costar™ 24-well tissue culture plates, were obtained from Coming, USA. 0.20 J.lm 
non-pyrogenic sterile filters were obtained from Sarstedt, Germany. Cells, Greens 
culture medium, fibroblast culture medium, 3-aminopropionitrile fumarate, 4-methyl 
umbeIliferone sodium salt. 
3-aminopropionitrile (PAPN) solution 3-aminopropioniriIe fumarate was dissolved 
in DMEM to produce a stock concentration of 10 mg.mr'. This was filter sterilised 
and stored at 4°C until needed (no more than 4 weeks). 
4-Methyl umbelliferone (4-MU) solution 4-MU sodium salt was dissolved in 
DMEM to produce a stock concentration of 0.1 M. This solution was filter sterilised 
and made fresh for each experiment. 
Keratinocytes were cultured as per section 2.2.7 and then plated into 24-well culture 
plates coated with 0.2 mg.mr' rat tail collagen at 5 x 104 cells in 1 ml Greens 
medium. Cells at passage 1 and 2 were used. Human skin fibroblasts were cultured 
as per section 2.2.8 and cells at passage numbers 3 to 8 were used. They were plated 
in fibroblast culture medium for monoculture experiments and Greens medium for 
co-culture experiments. Cells were plated in 24-well culture plates at 5 x 104 cells 
per well in 1 ml medium. For co-culture experiments, 1.25 x 104 fibroblasts and 
3.75 x 104 keratinocytes were plated together in a total of 1 ml Greens medium. 
Experiments were performed over 7 days. 
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2.5 Culture of cells in direct and indirect contact with PNVP 
polymers. 
Materials. 
Costar ™ 24-well tissue culture plates, Costar ™ 12-well tissue culture plates, Greiner 
ThinCert™ cell culture inserts, stainless steel rings, cells, cell culture medium, 
PNVP polymers. 
A 
Medium level 
Cells 
Polymer 
Figure 2.1 Cartoon depicting a) indirect contact culture system and b) direct contact 
culture system. 
2.5.1 Culture of cells in direct contact with PNVP polymers. 
A cartoon illustrating the experimental set up is shown in figure 2.I .A. Basically 
PNVP hydrogels were placed into ThinCert™ PET tissue culture inserts with 8 ).1m 
pores and suspended in 24 well plates. Cells were seeded at 5 x 104 cells per well in 
10 ).11 of medium into the ThinCert on top of the hydrogel. This ensured contact 
between the cells and the PNVP. Alternatively to ensure contact between the cells 
and the hydrogels, hydrogel discs of 18 mm diameter were cut and placed into 12 
well Costar™ plates. Stainless steel rings, internal diameter 10 mm were placed on 
top of the gels and cells were seeded into each ring. A tissue culture plastic (TCP) 
control was always included. In the case of experiments performed with 
keratinocytes and HCEC cells the TCP was coated with the appropriate proteins (see 
section 2.2.7 and 2.2.10). Once seeded, cells were placed in the incubator for I hour 
and then extra medium was gently added. Cells were cultured in direct contact with 
PNVP for 4 days. 
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2.5.2 Culture of cells in indirect contact with PNVP polymers. 
A cartoon illustrating the experimental set up is shown in figure 2.1.B. Basically 
cells were seeded at 5 x 104 cells per well in 10 J..lI of medium into standard 24 well 
Costar™ culture plates. PNVP hydrogels were placed into ThinCert™ PET tissue 
culture inserts with 8 J..lm pores either suspended above the cells in the culture well. 
A TCP control was always included. In the case of experiments performed with 
keratinocytes and HCEC cells the TCP was coated with the appropriate proteins (see 
section 2.2.7 and 2.2.10). Once seeded, cells were placed in the incubator for 1 hour 
and then extra medium was gently added. Cells were cultured in the presence of 
PNVP for 4 days. 
2.5.3 Effect of hydrogel-conditioned media on fibroblast viability. 
PNVP hydrogels were placed into wells in a 24 well plate. I ml of appropriate media 
was added (serum free DMEM or fibroblast culture medium). The plates were placed 
into an incubator at 37°C, 5% C02 for 4 days. The now conditioned media was 
transferred to cells plated out at a density of 5 x 104 cells in fibroblast culture 
medium 24 hours previously. Cells were cultured in PNVP conditioned medium for 
4 days. 
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2.6 Cell viability, proliferation and differentiation assays. 
Materials. 
PBS, 3-( 4,5-0imethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (M TT), Propan-
2-01, concentrated hydrochloric acid (HCI), 2-ethoxyethanol (Cellosolve). 4',6-
Diamidino-2-phenylindole (OAPI), Urea, SOS. 
Acidified Isopropanol 25 ,.d concentrated HCI was added to 20 ml isopropanol. 
This solution was stored until needed. 
DAPI Solution Stock solution consisting of 1 mg.mr l of OAPI in PBS was 
prepared. 10 )..1.1 aliquots were frozen at -20°C until needed. These aliquots were then 
diluted 1: 1000 in PBS immediately prior to experimental use. 
Lysis Buffer 48 g of urea and 0.04 g of SOS were dissolved in 100 ml of PBS. 
MTT solution MTT was dissolved in PBS to a final concentration of 0.5 mg.mr). 
The solution was made fresh for each experiment. 
The plate readers used in these experiments were Oynex Technologies MRXII 
microplate reader attached to a PC running Revelation 2.0 software. Fluorescent 
plate reader Bioteck Flx800 microplate fluorescence reader attached to a PC running 
KC4 v3.3 software. The epifluorescence microscope was obtained from Leica 
Microsystems (UK) Ltd, UK. Photographs were taken with a Hamamatsu Orca 
camera from Hamamatsu Photonics UK Ltd, UK. Openlab 3.1.7 software and 
Openlab filter- and shutter-controlling hardware were obtained from Improvision, 
UK. 
2.6.1 DAPI DNA assay. 
Urea, OAPI and SDS were obtained from Sigma, UK. 
Cells were washed with PBS, 1 ml of lysis buffer was added to the cells and 
incubated for 1 hour at 37°C. Samples were collected into micro-centrifuge tubes. 
100 )..1.1 of sample was added to 100 )..1.1 of DAPI solution and fluorescence was read 
using a fluorescent plate reader (Aex = 360/340 nm Aem = 460/440 nm). 
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2.6.2 Involucrin assay. 
Goat serum, IgG 1 anti-human involucrin, mouse isotype involucrin IgG goat anti-
mouse JgG-FITC conjugate and sodium hydroxide (NaOH) were obtained from 
Sigma, UK. 10% phosphate-buffered formaldehyde was obtained from Genta 
Medical, UK. Methanol was obtained from Fisher, UK. 
At the end of the culture period cells were fixed in 10% buffered formaldehyde for 
10 minutes at room temperature. Cells were then treated on ice with absolute 
methanol for 5 minutes to permeabilise the cell membrane. The cells were then 
washed three times in PBS and incubated in 10% (v/v) solution of goat serum in 
PBS. The goat serum was then removed and the cells were washed in PBS. The 
wells were then incubated for 45 minutes with 18 Ilg.mr l mouse primary antibody 
IgG 1 antihuman involucrin in PBS. In order to control for the binding specificity of 
the primary antibody, control wells were incubated with 18 Ilg.mr l of a mouse IgG 1 
Kappa antibody in PBS. After washing with PBS, all of the wells were incubated 
with a secondary antibody, goat anti-mouse IgG - FITC conjugate (Fab specific) in 
PBS (1 :500) for 45 minutes. To obtain quantitative values, the fluorescent label was 
eluted by the addition of 0.1 M NaOH at 37°C for 1 hour. The fluorescence of 100 III 
of each sample was read in a Bioteck Flx800 microplate fluorescence reader attached 
to a PC running KC4 v3.3 software, using an excitation wavelength 360/340 nm and 
emission wavelength 460/440 nm. 
Microscopy was performed within 24 hours of staining and DAPI-stained plates 
were kept in the dark at 4°C prior to microscopy. Fluorescent emission was 
visualised using a Leica epifluorescence microscope "-ex = 495 nm, "-em = 5 15 nm 
(for FITC/involucrin visualisation) and "-ex = 358 nm, "-em = 461 nm (for 
DAPIInuclei visualisation) and images were captured using a Hamamatsu Orca 
camera attached to an Apple computer (MAC OS 9.2) running Openlab 3.1.7 
software. 
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2.6.3 MTT-eluted stain assay. 
MTT and Cellosolve were obtained from Sigma, UK. Concentrated HCI was 
obtained from VWR. Propan-2-01 was obtained from Fisher, UK. PBS tablets were 
obtained from Oxoid, UK. 
Samples were washed gently with PBS. For 24 well plates I ml of MTT solution was 
used per well, 12 well plates used 1.5 ml of MTT solution per well. The plates were 
incubated with MTT solution for 40 minutes at 37°C, 5% CO2 in a humidified 
atmosphere. The MTT solution was subsequently removed and for fibroblast cultures 
acidified isopropanol was used to elute the formazan product from the cells. For 
keratinocyte, HaCaT and HCEC cultures and experiments where cells were grown in 
direct contact with the PNVP hydrogels, 2-ethoxyethanol was used to elute the 
formazan from the cells. 75 JlI of the sample was placed in a 96 well plate and the 
optical density was read in a Dynex Technologies MRXII microplate reader attached 
to a PC running Revelation 2.0 software at 540 nm and referenced at 630 nm. 
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2.7 Collagen gels. 
Materials. 
NaOH was obtained from sigma, UK. Collagen from Rat tail was obtained from 
Fluka, UK. Glacial acetic acid was obtained from VWR, UK. DMEM and FCS were 
obtained from Biowest Biosera, UK. 
Acetic Acid solution 0.1 M Glacial acetic acid (17.4 M) was diluted in distilled 
water to produce a 0.1 M solution. This was then taken into a class 11 cell culture 
hood and filter sterilised kept in a sterile bottle until needed. 
Collagen I solution (5 mg.mr1) Rat tail type I collagen was placed into a sterile 
bottle/container containing a sterile stirring bar and made up to 5 mg.mr' by adding 
sterile 0.1 M acetic acid. This was kept cool and stirred slowly until all the collagen 
had dissolved, and the stock solution was kept at 4°C until needed (no more than 3 
weeks). 
Sodium Hydroxide solution (1 M) Sodium hydroxide pellets were dissolved in 
distilled water to produce a 1 M solution. This was then taken into a class 11 cell 
culture hood and filter sterilised and then kept in a sterile bottle until needed. 
Collagen gels were prepared with a final collagen concentration of 2.7 mg.mr'. 
3.6 ml of 5 mg.mr' collagen solution was placed into a chilled universal. 2.1 ml 
DMEM was added and gently mixed. 1 M NaOH was added dropwise to neutralise 
the acetic acid. 0.9 ml FCS (containing if needed the appropriate number of cells) 
was then added to the collagen solution and mixed well. 350 ).ll of collagen solution 
was used per well of a 24 well plate. The plate was gently rocked to ensure that the 
gels spread out unifonnly. The gels were placed into an incubator to set. After 24 
hours the gels were released from the side of the wells using a fine pipette tip (p20) 
and 1 ml of medium was added to the wells. 
2.7.1 Fibroblast monoculture collagen gels. 
5 x 104 cells per gel were suspended in the FCS used to make the collagen gel. After 
the gel set I ml of fibroblast culture medium was gently added to the wells. 
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2.7.2 Keratinocyte monoculture collagen gels. 
Collagen gels were prepared as per section 2.7 without cells in the FCS. After the 
gels had set 5 x 104 keratinocytes (P 1 or 2) were placed on the top of the gel in 50 J.l.1 
of Greens medium and allowed to attach for 20 minutes at 37°C. 1 ml of Greens 
medium was then gently added to the wells. 
2.7.3 Fibroblast-keratinocyte co-culture collagen gels. 
Collagen gels were prepared as per section 2.7 with 1.25 x 104 fibroblasts per gel in 
the FCS. After the gels had set 3.75 x 104 keratinocytes (PI or 2) were placed on the 
top of the gel in 50 J.l.1 of Greens medium and allowed to attach for 20 minutes at 
37°C. I ml of Greens medium was then gently added to the wells. 
2.7.4 Effect of j3APN and 4-MU on the contraction of co-cultured collagen gels. 
Co-cultured collagen gels were prepared as per section 2.7.3. Before the gels were 
released from the sides of the wells all the media was removed from the gels. Once 
the gels had been released 1 ml of media supplemented with PAPN 50 - 800 J.l.g.mr l 
or 4-MU 0.125 - 4 mM was added to the wells. Every 24 hours from this point on all 
the media was removed from each well and the collagen gels. The gels were 
photographed for image analysis (see section 2.9) and I ml of fresh PAPN or 4MU 
supplemented media was added. The experiments were run over 6 days. 
2.7.5 Effect of 4-MU on the contraction of mono and co-cultured collagen gels. 
Collagen gels were prepared seeded with mono and co-cultures of fibroblasts and 
keratinocytes as per sections 2.7.1-3. Before the gels were released from the sides of 
the wells all the media was removed from the gels. Once the gels had been released 
1 ml of media supplemented with 2 mM 4-MU was added to the wells. Every 24 
hours from this point on all the media was removed from each well and the collagen 
gels. The gels were photographed for image analysis (see section 2.9) and 1 ml of 
fresh j3APN or 4MU supplemented media was added. The experiments were run 
over 6 days. 
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2.7.6 Effect of PAPN and 4-MU loaded hydrogels on collagen gel contraction. 
4-methyl umbelliferone sodium salt was obtained from Sigma, UK. P(NVP-co-
DEGBAC) and P(NVP-co-DEGBAC-co-AA) xerogels were produced as per section 
2.1.7. PBS was produced as per section 2.2. 
4-methyl umbelliferone solution 4-methyl umbelliferone sodium salt was dissolved 
in PBS (produced as per section 2.2) to produce solutions of I mM and 4 mM these 
solutions were then filter sterilised. 
p-aminopropionitrile fumarate solution 3-aminopropionitrile fumarate was 
dissolved in PBS (produced as per section 2.2) to produce solutions of 1 000 ~g.mrl 
and 200 ~g.mrl these solutions were then filter sterilised. 
Sterile xerogels were placed into 30 ml universals containing 25 ml of PAPN or 4-
MU solution at the appropriate concentration. These were placed onto a slowly 
revolving blood rolling table at room temperature for 2 days, until the gels were 
hydrated. The gels were then suspended in ThinCert™ cell culture inserts above 
collagen gels that had just been released from the sides of the well. 1 ml of Greens 
medium was gently added to each well. After 24 hours the medium was completely 
removed from the wells and the cell culture inserts. The inserts were placed into a 
fresh sterile 24 well plate while the collagen gels were photographed for image 
analysis. The inserts were then re-suspended above the gels and 1 ml of fresh Greens 
medium added. This procedure was repeated every 24 hours for 6 days. 
2.7.7 Effect of 4-MU loaded hydro gels, changed regularly, on collagen gel 
contraction. 
Hydrogels loaded with 4mM 4-MU were produced as per section 2.7.6. 
The hydrogels were suspended in ThinCert™ cell culture inserts above collagen gels 
that had just been released from the sides of the well. 1 ml of Greens medium was 
gently added to each well. After 24 hours the medium was completely removed from 
the wells and the cell culture inserts. The inserts were placed into a fresh sterile 24 
well plate while the collagen gels were photographed for image analysis. The inserts 
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were then re-suspended above the gels and I ml of fresh Greens medium added. This 
procedure was repeated every 24 hours for 6 days with the 4-MU hydrogels being 
changed for fresh 4-MU loaded hydrogels every second day. 
95 
2.8 Preparation of tissue-engineered composites. 
The protocol used was developed within our laboratory and reported by Ghosh 
(Ghosh, Boyce et at. 1997). It was subsequently modified by Chakrabarty 
(Chakrabarty, Dawson et at. 1999). 
2.8.1 Sterilisation of donor skin. 
The skin was received from theatre and stored in PBS supplemented with 
penicillin/streptomycin (penicillin 50 I.U.mrl and streptomycin 50 ~g.mrl) and 
Fungizone (313 Jlg.r l) at 4°C for up to 14 days. The skin was then immersed in a 
sterile mixture of 50% glycerol: 50% PBS (v/v) for 4 hours followed by 85% 
glycerol: 15% PBS for 18 hours. The skin was finally placed into 100% glycerol for 
26 hours. The skin was then sent for further ethylene oxide sterilisation. 
The skin was removed from 100% glycerol (section 2.6.1) and allowed to drip dry 
before any excess glycerol was removed by gently dabbing the skin with absorbent 
paper towel. The skin was the placed into autoclave bags, labelled and sealed with 
autoclave tape. Ethylene oxide sterilisation was performed at the Central Sterile 
Services Department (CSSD) of Leicester Royal Infirmary by the Sterivit™ 
procedure. The bagged skin samples were placed onto racks and exposed to 15% 
ethylene oxide, 85% carbon dioxide (a concentration of 200 mg ethylene oxide per 
litre) at 55°C and a pressure of 5.5 atmospheres for 30 minutes. After sterilisation, 
the samples were stored at room temperature for at least 3 days to allow aeration and 
dissipation of any remaining ethylene oxide gas. Ethylene oxide treated skin was 
then stored, in sealed autoclave bags, at room temperature until needed. 
2.8.2 De-epidermisation of donor skin. 
All procedures were performed in a class 11 culture hood. The sterilised skin was 
removed from the sealed autoclave bags and placed into 100 ml sterile plastic 
containers containing sterile PBS which was then incubated at 37°C for at least 2 
days. The skin was then removed from the PBS solution and placed into 100 ml 
sterile plastic containers containing sterile 1 M sodium chloride solution. The skin 
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was then incubated overnight at 37°C (typically 14 - 18 hours). At this stage there 
was visible separation of the dermis from the epidermis. Epidermis that was still 
attached to the dermis was gently detached by gentle scraping with a blunt-ended 
spatula. The de-epidermised dermis (DED) was then washed twice with PBS and 
incubated in 10% Greens medium at 37°C for a minimum of 48 hours. This had a 
threefold purpose i) ensured that any sodium chloride solution remaining in the DED 
was washed out ii) allowed the DED to become saturated with culture medium and 
iii) provided a rough sterility check for the DED (in the presence of infection, the 
medium becomes more acidic and therefore the phenol red pH indicator in the 
medium changes colour from crimson red to yellow). For anyone experiment, DED 
from a single patient was used and wherever possible cut from the same sheet. This 
was to try to reduce inter-patient variation in skin characteristics and differences in 
thickness. For experimental use the DED was cut into squares with dimensions of 
approximately 1.5 x 1.5 cm and the reticular surface was placed on the bottom of the 
culture well. 
2.8.3 Production of tissue-engineered skin composites. 
Rings and grids were manufactured from medical grade stainless steel by the 
Department of Medical Physics, Royal Hallamshire Hospital, Sheffield. 6-well tissue 
culture plates were Costar™ obtained from Coming Inc., USA. 
Following skin rehydration and de-epidermisation, the DED was cut with a scalpel to 
squares of approximately 1.5 x 1.5 cm and placed into the wells of a six well plate 
with the papillary dermis facing upwards. A chamfered metal ring (internal diameter 
1 cm) was placed in the centre of each piece of DED and was gently pressed down to 
ensure a watertight seal and thus prevent leakage of the cell suspension. 10% Greens 
media was added to the culture well outside the ring to allow the seal to be tested. 
Keratinocytes and fibroblasts were seeded into the centre of the ring (keratinocytes 
3 x 105 in 300 III 10% Greens, fibroblasts 1 x 105 in 200 J.lI 1 0% Greens). The culture 
plates were then incubated at 37°C for 48 hours with the media inside the ring being 
changed twice during this period prior to raising to air-liquid interface (All). After 
48 hours, the media and the seeding rings were removed. A no.22 scalpel blade was 
used to cut around the seeded area and the un seeded DED was discarded. A sterile 
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stainless steel grid was introduced to each well and the composite was placed on this 
grid seeded surface uppermost. Fresh 10% Greens medium, or Greens medium plus 
4-MU was placed into each well until it just touched the reticular surface each 
composite whilst leaving the seeded papillary surface exposed to the air. The 
composites were cultured at 37°C in a humidified 5% CO2 atmosphere for 28 days. 
The cell culture medium was changed every 3 - 4 days. A cartoon illustrating the 
experimental set up for a seeded composite at an ALl is shown in figure 2.2 below. 
Air-liquid interface 
Cell culture medium 
Figure 2.2 Diagram showing schematic for the culture of tissue engineered skin 
composite at an air-liquid interface. 
2.8.4 Effect of 4-MU on contraction of tissue engineered skin composite. 
4-Methyl umbelliferone (4-MU) solution 4-MU sodium salt was dissolved in 
DMEM to produce a stock concentration of 0.1 M. This solution was filter sterilised 
and made fresh for each experiment. 
To examine the effect of 4-MU on the contraction of the skin composite the 
composites were prepared as per section 2.8.3 and the medium was supplemented 
with 4-MU to produce final concentrations of 0.5, I and 2 mM. Every 7 days the 
composites were photographed for image analysis (see section 2.9). 
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2.9 Image analysis. 
The collagen gels and composites were photographed using a Nikon 990 Coolpix 
digital camera. In each case the plate was placed alongside a scale bar so that the 
captured digital image could be calibrated and thus the area of the composite be 
calculated. The camera was placed directly above the plate (without its lid) inside the 
class 11 culture hood to maintain sterility but to minimise distortion of the image. The 
images were imported into ImageJ software and the scale bar used to calibrate the 
image. The zoom facility in the programme was used to increase the size of each 
image to reduce observer error. A computer mouse was used to trace the edge of the 
composite freehand. The software then automatically calculated the area of this plot. 
relative to the calibration derived from the scale bar. The area of the composite on 
day 0 (when it was raised to an air-liquid interface) was designated 100% and all 
changes in area were expressed relative to this initial measurement. 
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2.10 Histology. 
Materials. 
10% phosphate-buffered formaldehyde was obtained from Genta Medical, UK. 
Carazzi's Haematoxylin: 5 g Haematoxylin (Cl 75290) was dissolved in 800 ml 
distilled water, 50 g aluminium potassium phosphate, 0.6 g potassium iodate and 
200 ml glycerol was then added to the solution. The solution was mixed well and 
then filtered. 
Eosin: A 1% w/v solution of eosin (Cl 45280) was adjusted to pH 6.3 with dilute 
HC\. 
Acid/alcohol: I % v/v HCI in 70% ethanol. 
Composites were placed into 10% phosphate-buffered formaldehyde at room 
temperature, which were subsequently embedded in paraffin wax. 5 Ilm sections 
were cut, mounted and stained using haematoxylin and eosin by Dr Christopher 
Lay ton, Department of Histopathology, Northern General Hospital, Sheffield. 
2.10.1 Carazzi's Haematoxylin and Eosin staining. 
This stain was used to show the cellular architecture/interactions within the tissue. 
Haematoxylin stains acidic structures such as cell nuclei purple/blue. Eosin stains 
proteins and other basic structures pink. 
The wax covering the sections was removed by submerging the slides in xylene for 
approximately 10 minutes. The xylene was then removed by taking the slides 
through descending grades of alcohol i.e. 90%, 75% and 50% and then into water. 
The slides were stained with haematoxylin for 3 minutes and then excess stain was 
removed by rinsing the slides in tap water. The haematoxylin stains all cellular 
material not just the nuclei. In order to remove the haematoxylin from the cytoplasm 
of the cell, the slides were differentiated in 1% acid/alcohol for approximately 20 
seconds. Differentiation was confirmed microscopically then sections were washed 
in running tap water. The slides were then stained with eosin for approximately 20 
seconds. Dehydration was achieved by taking the slides through ascending grades of 
alcohol i.e. (50%, 75% and 90%). The slides were then placed back into xylene and 
cover slips were applied. 
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2.10.2 Histological scoring of skin composites. 
In order to assess the effect of 4-MU on the appearance of the reconstructed skin 
composites, a scoring system was used. This was the scoring system used by Miss 
Caroline Harrison and is an adaptation of a previous scoring system devised by Ms. 
R. Dawson, research technician, University of Sheffield; Or C. Lay ton, Department 
of Histopathology, Northern General Hospital, Sheffield and Professor S. MacNeil. 
Scoring was carried out by 5 independent observers within the MacNeil group, who 
each have significant experience examining composite histology. Photomicrographs 
of the H&E stained composites were given a random anonymous reference number. 
Photomicrographs were taken using a Motic digital microscope (85 professional 
series) attached to a PC running Motic Images Advanced 3.1 software. The digital 
photomicrographs were examined on PC monitors by the observers, thus allowing 
the zoom feature to be used during the scoring procedure. 
AREA 
Keratin 
Keratinocyte layer 
Skin scoring system 
DESCRIPTION 
Normal keratin 
Vacuolation within the keratinised layers 
Thin layer of poorly adherent/fragmented keratin 
Non-existent 
SCORE 
A 
B 
C 
D 
Good, organised, thick with differentiation A 
Either parakeratosis or disordered keratinocyte differentiation B 
Thin (2-3 cells), organised, continual C 
Monolayer, patchy D 
Non-existent E 
Dermo-Epidermal Junction 
Fully attached, with rete ridges present A 
Dermis 
Fibroblasts 
Attached but no rete ridges B 
Partial attachment C 
No attachment D 
Increased dermal density 
Normal, organised pattern ofreticular and papillary dermis 
Disorganised, small gaps I holes 
Bland collagen tissue, large gaps I holes 
Disintegrating 
Large number, enhanced proliferation 
Average number 
Few, reduced proliferation I poor survival 
Non-existent 
A 
B 
C 
D 
E 
A 
B 
C 
D 
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2.11 SDS-P AGE electrophoresis and protein staining with 
Coomassie Brilliant Blue TM. 
Materials. 
Tris-HCI, Tris, p-mercaptoethanol, glycerol, bromophenol blue. 30% w/v 
acrylamide/0.8% w/v N,N' -methylene-bis-acrylamide, N,N,N' ,N'· 
Tetremethylethylenediamine (TEMED), ammonium persulphate (APS), glycine, 
glacial acetic acid were obtained from VWR, UK. Coomassie Brilliant Blue R250, 
EDTA, SDS, and SDS-7B molecular weight ladder were obtained from Sigma, UK. 
The proteins used in the SDS· 7B molecular weight ladder were <X2 macroglobulin 
(185 kDa), p-glactosidase (115 kDa), fructose 6-phosphate kinase (84 kDa), 
pyruvate kinase (61.5 kDa), fumarase (55 kDa), lactic dehydrogenase (36 kDa) and 
triose phosphate isomerise (31 kDa). DMEM, DMEM + 10% FCS, FCS Methanol 
was obtained from Fisher, UK. 
Coomassie Brilliant Blue 0.25% (w/v) Coomassie Brilliant Blue™, 40% (v/v) 
methanol, 7% (v/v) acetic acid, deionised water. 
Coomassie Brilliant Blue Destain 40% (v/v) methanol, 7% (v/v) acetic acid, 
deionised water. 
Loading buffer 0.5 ml p-mercaptoethanol, 2 ml glycerol, 1.5 g SDS, 0.0 I g 
bromophenol blue, 0.6 ml 1.25 M Tris HCI pH 6.8, 6.9 ml d&hO. 
Overlay 12.5 ml 1.875 M tris pH 8.8, 36.5 ml deionised water and 1 ml 10% w/v 
SDS. 
Resolving gel (7%) 2.3 ml of 30% w/v acrylamide/0.8% w/v N,N' -methylene-bis-
acrylamide, 2.5 ml of 1.875 M Tris buffer pH8.8, 4.92 ml deionised water, 0.2 ml 
10% w/v SDS, 10 III TEMED and 70 III 10%w/v APS. 
Running buffer 3 g Tris, 14.4 g Glycine, 2 g SDS, 0.75 g EDT A dissolved in 
800 ml of ddH20 and make up the volume to 1000 ml with ddlhO. This was stored 
at 4°C until required. 
Stacking gel 0.76 ml 30% w/v acrylamide/0.8% w/v N,N'-methylene-bis-
acrylamide, 0.5 ml 1.25 M tris pH 6.8, 3.61 ml deionised water, 0.1 ml 10% w/v 
SDS, 5 J.!I TEMED, 25 J.!I 10% w/v APS. 
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AIl samples (OM EM, OMEM + 10% FCS, FCS, and P(NVP-co-DEGBAC) soaked 
in OM EM, OMEM + 10% FCS and FCS) were placed into micro-centrifuge tubes 
with I: 1 v/v loading buffer for 5 minutes at 100°C. The SDS-7B molecular weight 
ladder was also placed into a micro-centrifuge tube with 1: I v/v loading buffer for 5 
minutes at 100oe. 
The resolving gel solution was placed into a multicasting chamber leaving a 3 cm 
gap at the top. Overlay solution was then gently added to fill the chamber and the gel 
was allowed to polymerise for approximately I hour. The overlay was then gently 
poured off and stacking gel solution added. A lane comb was inserted into the 
stacking gel solution to form the gel lanes. The stacking gel was allowed to 
polymerise for approximately 1 hour. Once the stacking gel had polymerised the 
well comb was carefully removed and the denatured samples added. including 
ladder. The electrophoresis unit was placed into the electrophoresis tank and 
submerged in running buffer. The proteins were separated at a constant voltage of 
200 V for 1 hour. The stacking gel was then removed and the resolving gel placed 
into 1 M acetic acid. The acetic acid was removed and the gel placed into Coomassie 
Brilliant Blue™ solution for 1 hour. This solution was removed and destain added. 
The gel was left in destain for 2 hours and then changed. The destain was then left 
overnight (approximately 12 - 18 hours) and changed again. The gel was then placed 
onto a flat bed scanner attached to a PC running Epson scansmart software. 
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2.12 (3-aminopropionitrile «(3APN) release. 
Materials 
2,4,6-trinitrobenzenesulfonate 5% (w/v) in H20 (TNBS), sodium bicarbonate, 3-
aminopropionitrile fumarate (J3APN) and bovine serum albumen (BSA) were 
obtained from Sigma, UK. Concentrated hydrochloric acid was obtained from VWR. 
P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-AA) xerogels were produced as 
per section 2.1.7. PBS was produced as per section 2.2. Plate reader used for J3APN 
release assay was a Bioteck ELx800uv microplate reader attached to a PC running 
KCJunior software optical density was measured at 320 nm and referenced at 
630 nm. 
j3-aminopropionitrile fumarate solution 3-aminopropionitrile fumarate was 
dissolved in PBS (produced as per section 2.2) to produce solutions of 1000 J..lg.mr 1 
and 200 J..lg.mr1• 
Sodium bicarbonate solution 0.1 M solution was produced by dissolving sodium 
bicarbonate pellets in water the pH was then adjusted to p1l8.5 by the addition of 
concentrated hydrochloric acid. 
TNBS solution 0.0 I % solution of TNBS was produced by diluting 2 J.lI of TNBS per 
ml of sodium bicarbonate solution. 
2.12.1 Loading ofPNVP xerogels with J3APN solution. 
Xerogels were placed into 30 ml universals containing 25 ml of J3APN solution at the 
appropriate concentration (200 or 1000 J.lg.mr1). These were placed onto a slowly 
revolving blood rolling table at room temperature for 2 days, until the gels were 
hydrated. 
2.12.2 Release of J3APN from PNVP hydrogels. 
J3APN loaded hydrogels were produced as per section 2.12.1. The hydrogels were 
gently removed from the universal and gently dabbed with absorbent paper to 
remove any excess solution. The hydrogels were then placed into individual wells of 
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a 48 well plate and 1 ml of PBS gently added to each well. After 24 hours the PBS 
was completely removed and stored for later analysis. I ml of fresh PBS was then 
added to each well and this was repeated every 24 hours for 6 days. 
2.12.3 Detection of I3APN in PBS. 
10 III of the PBS stored from 2.12.2 was transferred to a 96 well plate 90 III sodium 
carbonate buffer was added. SO III of TNBS solution was added to each well and the 
plate left in the dark at room temperature for 2 hours. The absorbance was read at 
320 nm in a Bioteck ELx800uv microplate reader attached to a PC running KCJunior 
software. The absorbance was then converted to ~APN concentration using the 
calibration graph shown in figure 2.3 below. 
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Figure 2.3 Final I3APN calibration curve, samples diluted down to final 
concentrations using Na(C03) 2 buffer pH 8.S (n=6). All data expressed as mean ± 
SEM. 
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2.13 4-methyl umbelliferone (4-MU) release. 
Materials. 
4-methyl umbelliferone sodium salt was obtained from Sigma, UK. P(NVP-co-
DEGBAC) and P(NVP-co-DEGBAC-co-AA) xerogels were produced as per section 
2.1.7. PBS was produced as per section 2.2. The plate reader used for 4-MU release 
assay was a Bioteck Flx800 microplate fluorescence reader attached to a PC running 
KC4 v3.3 software. (t..ex = 360/340 nm t..em = 460/440 nm). 
4-methyl umbelliferone solution 4-methyl umbelliferone sodium salt was dissolved 
in PBS (produced as per section 2.2) to produce solutions of I mM and 4 mM. 
2.13.1 Loading of PNVP xerogels with 4-MU solution. 
Xerogels were placed into 30 ml universals containing 25 ml of 4-MU solution at the 
appropriate concentration (1 or 4 mM). These were placed onto a slowly revolving 
blood rolling table at room temperature for 2 days, until the gels were hydrated. 
2.13.2 Release of 4-MU from PNVP hydrogels. 
4-MU loaded hydrogels were produced as per section 2.13. I. The hydrogels were 
gently removed from the universal and gently dabbed with absorbent paper to 
remove any excess solution. The hydrogels were then placed into individual wells of 
a 48 well plate and I ml of PBS gently added to each well. After 24 hours the PBS 
was completely removed and stored for later analysis. 1 ml of fresh PBS was then 
added to each well and this was repeated every 24 hours for 6 days. 
2.13.3 Detection of 4-MU in PBS. 
25 J.lI of the PBS stored from 2.13.2 was transferred to a 96 well plate. To this was 
added 175 J-lI of PBS, the fluorescence was then read using an excitation wavelength 
of 360/340 nm and emission wavelength of 460/440 nm in a Bioteck Flx800 
microplate fluorescence reader attached to a PC running KC4 v3.3 software. The 
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fluorescence was then converted to 4-MU concentration using the calibration graph 
shown in figure 2.4. 
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Figure 2.4 Calibration curve used for drug release experiments. Excitation 
wavelength 360/340 nm, emission monitored 460/440 nm. Data expressed as mean ± 
SEM of n=6 samples. 
2.14 Statistics. 
Statistics used during this project were Students ' T-Test and I-way ANOVA with 
Bonferroni Correction. Statistical significance was assessed by p<O.OS. GraphPad 
InStat 3.06 software from GraphPad software Inc, USA was used for statistical 
analysis. 
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3. Synthesis and characterisation of 
poly(vinylpyrrolidinone) polymers. 
3.1 Functionalised oligomers. 
The production of oligoNVP's with functional end groups could aid the chemical 
incorporation of drugs and other compounds that could aid wound healing and/or 
reduce skin graft contraction. Functionality could also improve the biocompatibility 
of hydrogel membranes synthesised using these oligomers possibly aiding cell 
attachment and thus increasing the number of possible applications of these 
hydrogels. 
3.1.1 Synthesis of oligoNVP. 
Figure 3.1 shows the IH NMR spectrum of oligoNVP synthesised in bulk. GPC 
measurements of the oligoNVP gave a weight average molecular weight (Mw) of 
251 g.mor l with a polydispersity of 1.02 indicating that the oligomers formed 
primarily as dimers with a small proportion oftrimers being produced. Reducing the 
amount of initiator in the reaction system and possibly adding a small amount of 
solvent to retard the reaction slightly could increase the chain length. The wide peaks 
are indicative of the presence of polymer instead of mono mer. 
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Figure 3.1 IH NMR spectrum ofoligoNVP in CHCb. 
3.1.2 OligoNVP functionalised with benzene dithiobenzoate. 
An attempt to produce oligoNVP using RAFT polymerisation using BOTB as the 
RAFT agent gave the NMR spectrum shown in figure 3.2. The yield was 1.63% 
unfortunately this meant that after structural verification there was insufficient 
sample for further GPe analysis. This low yield meant that this synthesis route 
would not be practical for the large quantities of oligomers needed for subsequent 
membrane synthesis. Again the wide peaks seen in this spectrum are indicative of the 
presence of polymeric species. 
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Figure 3.2 IH NMR in MeOH of oligoNVP polymerised in the presence of the 
RAFT agent BDTB. 
3.1.3 OligoNVP fuoctiooalised with silyl eool ether. 
The polymerisation ofNVP in the presence of the silyl enol ether MPTMSE gave the 
NMR spectrum shown in figure 3.3. The GPC analysis of this functionalised 
oligoNVP gave Mw of 266 g.mor 1 with a polydispersity of 1.04. This is indicative 
of the presence ofNVP dimers and trimers again larger oligomeric fragments would 
be required for membrane synthesis. 
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Figure 3.3 'H NMR spectrum in CDCh ofNVP polymerised with MPTMSE. 
3.1.4 Summary of results. 
Living polymerisation routes were used in an attempt to maintain a narrow 
polydispersity. The synthesis of oligomers via RAFT polymerisation with benzyl 
dithiobenzoate was unsuccessful, both in the presence and absence of the solvent 
dioxane due to very low conversions. The synthesis of the NVP oligomers 
functionalised with the silyl enol ethers was also unsuccessful, again due to the 
unstable radical resulting in very low conversions, both in the presence and absence 
of the solvent toluene. The NVP radical is not very stable and it is therefore likely 
that in the presence of solvent the radical transferred to the solvent molecules. 
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3.2 Synthesis and characterisation of NVP based membranes. 
The ultimate aim of this project is the production of PNVP based hydrogel 
membranes. The synthesis of functional oligomers was unsuccessful so membrane 
synthesis was attempted using the monomer I-vinyl-2-pyrrolidinone. 
3.2.1 Synthesis and characterisation of NVP-co-EGDMA membranes. 
Initially membranes were synthesised in the presence of dimethyl sulfoxide (DMSO) 
as a solvent. These membranes were easy to handle and peel away from the PET 
backing sheet after polymerisation. However once swollen in ethanol, to remove 
unreacted monomer, initiator etc., and phosphate buffered saline (PBS) for biological 
testing the membranes became extremely difficult to handle. This was reflected in 
the equilibrium water content (EWC). These hydrogels had a EWC of 98.25% ± 
0.155% as shown in table 3.1 and illustrated in figure 3.4 below resulting in 
problems handling these membranes. 
Table 3.1 EWC measurements. Measurements performed on polymers swollen in 
PBS. Dried at 50°C in a vacuum oven for 24 hours (n=6). Measurements expressed 
as mean ± standard error of mean (SEM). 
Polymer Ewe in PBS @ room SEM I 
temperature I % % 
NVP 1 wt% EGDMA +DMSO 98.3 0.2 
NVP 1 wt% EGDMA 96.2 0.3 
NVP 2 wt% EGDMA 92.3 0.6 
NVP 1 wt% DEGBAC 92.2 0.1 
NVP 2 wt% DEGBAC 89.3 0.2 
NVP 3 wt% DEGBAC 86.1 0.5 
NVP 4 wt% DEGBAC 81.7 0.4 
NVP 1 wt% DEGBAC 1 wt% AA 89.5 0.1 
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Figure 3.4 Effect of synthesis conditions, presence of solvent, crosslinker, 
crosslinker concentration and addition of acrylic acid on equilibrium water content 
of membranes swollen in phosphate buffered saline measurements expressed as 
mean ± SEM (n=6). 
To reduce the EWe the next batch of membranes were synthesised in bulk, i.e. 
without solvent. This did reduce the EWe to 96.18% and raise the membrane 
material properties. However they still did not have the handle-ability required of a 
wound dressing. Increasing the concentration of EGDMA (1-5 wt%) in the 
membranes produced opaque, phase separated membranes as illustrated in figure 3.5. 
Once hydrated these membranes were significantly stiffer than the original 1 wt% 
EGDMA membranes. However, they had little material integrity and flaked easily 
when removed from liquid. Therefore the only membrane where EWe 
measurements were possible was the NVP 2 wt% EGDMA membrane. 
113 
1% 20/0 3% 4% 
Figure 3.5 NVP-co-EGDMA membranes swollen in ethanol. EGDMA concentration 
expressed as wt% in the monomer feed. 
I3C Solid state NMR analysis of the I wt% EGDMA membrane revealed a surprising 
amount of unreacted vinyl groups still present, see figure 3.6 below 
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Figure 3.6 l3C NMR spectrum of NVP-co-EGDMA membrane containing I wt% 
EGDMA. The presence of the peak at 110 ppm (*) is indicative of unreacted vinyl 
groups still present in the polymer membrane. 
3.2.2 Synthesis and characterisation of NVP-co-DEGBAC membranes. 
The crosslinker was changed to diethyleneglycol bisallylcarbonate (DEGBAC) in an 
attempt to produce membranes with increased material properties. This crosslinker 
was also chosen because of the potential for degradation inherent in the carbonate 
groups. As the aim of this part of the study was the improvement of the material 
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properties these membranes were synthesised solely in bulk. Increasing the amount 
of crosslinker in these DEGBAC crosslinked membranes produced clear colourless 
membranes. The membranes containing 3 wt% DEGBAC and above shattered 
during the ethanol swelling procedure with the 3 and 4 wt% membranes producing 
pieces of sufficient size for EWC measurements to be performed. However for those 
membranes for which EWC measurements were possible the NVP-co-DEGBAC 
membranes showed reduced water contents compared to NVP-co-EGDMA 
membranes. The I wt% DEGBAC had an EWC of 92.2% ± 0.1 % and the EWC 
reduced with increasing crosslinker concentration. The 2 wt% DEGBAC had an 
EWC of 89.3% ± 0.2 and 3 wt% DEGBAC had an Ewe of 86.1 % ± 0.5% and 
4 wt% DEGBAC had an EWe of 81.7% ± 0.4%. These are illustrated in table 3.1 
and figure 3.4. The 5 wt% DEGBAC membrane shattered into pieces so small that 
Ewe measurements were not possible. Figure 3.7 shows the I3C solid state NMR 
spectrum from the analysis performed on the 1 wt% DEGBAe membrane, once 
again unreacted vinyl groups are present in the spectrum. 
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Figure 3.7 IJC NMR spectrum of P(NVP-co-DEGBAC) membrane containing 
I wt% DEGBAC. The presence of the small peak at 110 ppm (*) is indicative of 
unreacted vinyl groups still present in the polymer membrane. 
A small amount (1 wt%) of acrylic acid (AA) was added to the NVP 1 wt% 
DEGBAC membrane to see if this altered the release profile of either of the anti-
contraction agents under investigation see chapter 5. This produced a clear, 
colourless membrane which became slightly hazy when swollen in PBS indicating a 
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certain amount of phase separation within the membranes. The addition of the AA 
reduces the EWC still further. All EWC measurements can be found in table 3.1 and 
figure 3.4. Again the I3C solid state NMR spectrum in figure 3.8 reveals the presence 
of unreacted vinyl groups in the membranes. 
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Figure 3.8 I3C NMR spectrum of P(NVP-co-DEGBAC-co-AA) membrane 
containing I wt% DEGBAC and I wt% AA. The presence of the small peak at 
110 ppm (*) is indicative of unreacted vinyl groups still present in the polymer 
membrane. 
3.2.3 Mechanical testing of NVP based membranes. 
Compression testing of the hydrogels that were considered for biological 
characterisation confirmed that the hydrogels had Young' s moduli (E) suitable for 
the proposed wound dressing application. The data for these experiments are shown 
in table 3.2. For those samples which were tested to failure an ultimate compressive 
stress (UCS) was calculated. Some samples did not fail over the 2 mm test distance 
possibly due to differences in sample thickness. Those that did not fail were 
excluded from UCS calculations and this lead to different replicate numbers for each 
polymer. 
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Table 3.2 Material properties, E and UCS. Measurements performed in compression 
on polymers swollen in PBS in air over a distance of 2 mm at a strain rate of 
01 mm S·I 
Polymer Elastic SEM / Ultimate Compressive SEM / 
Modulus / MPa Stress / MPa MPa 
MPa 
NVP 1 wt% EGDMA 
+DMSO Not done Not done 
NVP 1 wt% EGDMA 0.16 0.02 0.03 0.00 
(n=4) (n=3) 
NVP 1 wt% DEGBAC 0.22 0.02 0.29 0.08 
(n=4) (n=2) 
NVP 1 wt% DEGBAC 0.24 0.02 Unable to obtain 
1 wt%AA (n=3) (n=3) 
3.2.3 Degradation of P(NVP-co-DEGBAC) based membranes 
Degradation of P(NVP-co-DEGBAC) hydrogels was initially determined by 
examining the change in equilibrium water content (EWC), the data is shown in 
figure 3.9. Previous studies of carbonate crosslinked PNVP's (Bruining. Koole et al. 
1999; Liu and Rimmer 2002b) suggest that these polymers should degrade rapidly 
via carbonate hydrolysis, so initially measurements were taken every 24 hours. 
However it rapidly became apparent that these polymers did not degrade over the 
time period studied. The Ewe stayed fairly constant over the 10 day period. At this 
point the number of samples left and difficulties keeping the samples at 37°C meant 
that the experiment was continued at room temperature. Degradation from this point 
on was assessed visually, and no apparent degradation was observed after 1 year. 
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Figure 3,9 Effect of crosslinker concentration on the degradation of P(NVP-co-
DEGBAC) hydrogels swollen in PBS at 37°C. Degradation assessed using EWC 
measurements, measurements expressed as mean ± SEM (n=6). 
3.2.4 Synthesis ofNVP-co-DEGBAC membranes incorporating J3APN. 
In any drug delivery application controlled release is essential. Too little drug and 
the desired effect is not achieved and too much drug could be harmful to the cells 
and tissues involved. The incorporation of a known amount of the anti-contraction 
agents would hopefully allow an appropriate therapeutic concentration to be 
released. Experiments have shown that (3APN at a concentration of 200 Ilg.mrl is 
effective at reducing contraction of the reconstructed skin model (Chapter 6). Initial 
experiments were performed attempting to incorporate (3APN, in the form of the 
water soluble salt 3-aminopropionitrile fumarate «(3APN.F), into the PNVP-co-
DEGBAC membranes. 
Initially membranes were synthesised where (3APN.F at various concentrations was 
mixed into the monomer blend before injection into the mould. These membranes 
were very difficult to peel off the PET sheets. With increasing concentrations of 
(3APN.F the membranes became increasingly golden in appearance. This was 
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presumed to be the organic pAPN.F. The pAPN.F had a tendency to locate around 
the edges of the membrane. A large number of bubbles were seen in the membranes. 
Due to this and the presence of small pAPN.F crystals still present in the monomer 
blend prior to injection, a range of solvents was then tested to improve the 
incorporation of the pAPN.F into the P(NVP-co-DEGBAC) membranes. 
Table 3.3 Table showing the solubility, assessed visually, of 3-aminopropionitrile 
fumarate in 1 ml of solvent. 
Solvent Solubility Solvent Solubility 
10% EtOH In Insoluble DMF Insoluble 
DMSO 
20% EtOH in Insoluble Dioxane Insoluble 
DMSO 
30% EtOH in Insoluble THF Insoluble 
DMSO 
40% EtOH In Insoluble IPA Insoluble 
DMSO 
50% EtOH In Insoluble Acetonitrile Insoluble 
DMSO 
60% EtOH in Insoluble DEGBAC Insoluble 
DMSO 
70% EtOH in Insoluble Methanol Insoluble 
DMSO 
80% EtOH in Insoluble AA Soluble 
DMSO 
90% EtOH in Insoluble NVP Insoluble 
DMSO 
10% H20 in NVP Insoluble 17% H20 in NVP Insoluble 
15% H20 in NVP Insoluble 20% H20 in NVP Soluble 
With pAPN.F soluble in water a small amount of water (l ml per membrane) was 
added to the monomer blend prior to injection. When these membranes still proved 
unsuitable 20 wt% water was added to the monomer blend. Acrylic acid was also 
added to the monomer blend. 
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These membranes still had a golden tinge especially at high concentrations of 
pAPN.F and a large amount of bubbles were still visible in the membranes. The 
membranes containing 20 wt% water were easy to peel off the PET backing sheets 
and extremely pliable. The addition of Acrylic acid to the P(NVP-co-DEGBAC) 
membranes resulted in bubbles and localisation of the pAPN.F around the edges of 
the membrane. It was then thought that PAPN could be loaded into dried hydrogel 
membranes (xerogels) from a known concentration in phosphate buffered saline see 
chapter 7. 
3.2.4 Summary of results 
The synthesis of poly(vinylpyrrolidinone) based hydrogels membranes using a 
mixture of I-vinyl-2-pyrrolidinone, crosslinker and initiator ± solvent was successful 
and produced membranes with material properties suitable for use as a wound 
dressing. Changing the crosslinker from EGDMA to DEGBAC and removing 
solvent from the reaction reduced the water content sufficiently to produce a tough 
flexible hydrogel. The addition of acrylic acid to the P(NVP-co-DEGBAC) 
membranes reduced the EWC still further with a corresponding increase in Young's 
modulus. Young's moduli were achieved of between 0.16 MPa ± 0.02 MPa and 0.24 
MPa ± 0.02 MPa when tested at a strain rate of O. t mm.s- I (6 mm.min- I ) for the 
polymers synthesised in bulk. These values compare favourably with those seen in 
the literature. Cauich-Rodriguez et al. (1996a) synthesised a poly(vinylalcohol) -
poly(vinylpyrrolidinone) blend with similar material properties. The Young's moduli 
were dependent on the heat treatment received by the polymer but were between 
0.15 MPa ± 0.07 MPa and 1.51 MPa ± 1.00 MPa at a strain rate of 5 mm.min- I . The 
addition of gluteraldehyde to these polymers had no effect on the Young's modulus 
of these polymers (Cauich-Rodriguez, Deb et al. 1996b). The introduction of 
carbonate groups into the membranes via the change in crosslinker from EGDMA to 
DEGBAC did not produce the expected highly degradable hydrogel. A small amount 
of unreacted vinyl groups could still be found in the \3C solid state NMR spectra of 
all the hydrogels. 
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Synthesising P(NVP-co-DEGBAC) membranes where (3APN.F was incorporated 
into the monomer blend prior to injection into the polymerisation mould proved to be 
unsuccessful due to the insolubility of (3APN.F in NVP and the other components of 
the monomer mix. A large amount of water was needed to ensure that the (3APN.F 
remained dissolved in the monomer blend. However in all the membranes where 
(3APN.F was added the (3APN.F had a tendency to localise around the edges of the 
membrane and an unacceptable amount of bubbles were formed during curing. Even 
the addition of acrylic acid to the membranes did not solve this problem. 
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4. Effect of PoJy(vinyJpyrrolidinone) membranes on cell 
viability. 
Experiments in this section were performed with the cells in direct contact with the 
polymers and also in indirect contact. The poor material properties of the P(NVP-co-
EGDMA) polymers meant that to force contact between the polymer and the cells 
the polymers had to be placed inside ThinCert™ inserts. The commonly used 
method of seeding cells inside a stainless steel ring did not work in this situation as 
the weight of the ring cut straight through the P(NVP-co-EGDMA) polymer. 
The P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-AA) polymers are stiff 
enough to be able to support the stainless steel ring. Initial experiments were 
performed to investigate if cells could attach to the P(NVP-co-DEGBAC) polymers 
however problems with seepage from the rings due to the smoothness of the polymer 
surfaces made these experiments difficult to perform and so they were abandoned 
early on. 
4.1 Effect of Poly(vinylpyrrolidinone) membranes on cell viability -
direct contact versus indirect contact. 
4.1.1 Cytotoxicity of P(NVP-co-EGDMA) membranes. 
Initial experiments were performed where P(NVP-co-EGDMA) hydrogels were 
placed in direct contact with human dermal fibroblasts in the presence of serum. 
These experiments are summarised in figure 4.2 below. Student's unpaired T-Test 
was used to determine significant (p<O.05) stimulation or inhibition in cell viability 
as assessed using the MTT-ESTA assay. A large number of experiments were 
required to get a clear picture due to the variation in viabilities encountered during 
these initial experiments. The fibroblasts used were from different donors and 
different passage numbers and the P(NVP-co-EGDMA) membranes came from 
multiple batches. None of these variables affected the range of results obtained. 
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Figure 4.2 Pie charts illustrating the percentage of experiments where cell viability 
was stimulated, inhibited or not affected by A) Direct contact or B) Indirect contact 
with P(NVP-co-EGDMA) hydrogels. Stimulation or inhibition represented a 
statistically significant (p<0.05) difference in cell viability from tissue culture plastic 
control n=20 (3 replicates per experiment). 
The results obtained from cells cultured in direct contact with the polymer can be 
viewed with some suspicion. It can be seen clearly in figure 4.3 how the cells 
(stained blue with MTT in this picture) are found at the bottom of the inserts (A) and 
at the interfaces between the pieces of polymer and the polymer-insert interface. 
These clumps of cells are viable but do not look normal when examined visually as 
shown in figure 4.4.A. However fibroblasts grown in indirect contact with the 
hydrogel have a normal morphology comparable to fibroblasts grown on TCP alone 
as shown in figure 4.4.C. 
Figure 4.3 Photograph of human dermal fibroblasts cultured in direct contact with 
P(NVP-co-EGDMA) for 4 days in ThinCert™ inserts in the presence of serum. Cells 
are stained purple with MTT and can clearly be seen on the bottom of the Insert (A) 
and in small clumps at the interface between the polymer and insert (B). 
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Figure 4.4 Photograph of human dennal fibroblasts cultured in the presence of serum 
for 4 dW A) in direct contact with the P(NVP-co-EGDMA) membrane in 
ThinCert inserts B) grown on TCP in indirect contact with the P(NVP-co-
EGDMA) membrane and C) Photograph of fibroblasts grown on TCP only. In all 
photographs cells are stained purple with MTT 
4.1.2 Cytotoxicity of P(NVP-co-DEGBAC) membranes. 
Poor mechanical properties (see chapter 3) meant that the P(NVP-co-EGDMA) 
polymer would be unsuitable for the final application of a wound dressing and so 
another crosslinking agent diethyleneglycol bisallylcarbonate (DEGBAC) was 
investigated. Again cytotoxicity studies were perfonned with the polymer in both 
direct and indirect contact with human dermal fibroblasts in media containing 10% 
FCS. These experiments are summarised in the pie charts in figure 4.5. As in figure 
4.2 Student's unpaired T-Test was used to detennine significant (p<0.05) stimulation 
or inhibition in cell viability as assessed using the MTT -EST A assay. 
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Figure 4.5 Pie charts illustrating the percentage of experiments where cell viability 
was stimulated, inhibited or not affected by A) Direct contact or B) Indirect contact 
with P(NVP-co-DEGBAC) hydrogels. Stimulation or inhibition was detennined 
within each experiment by a statistically significant (p<0.05) difference in cell 
viability from TCP control n=5 (3 replicates per experiment). 
Once again the cells are found around the edges of the polymer and underneath the 
polymer growing on the PET membrane on the bottom of the insert. Cells that have 
attached to the membrane, see figures 4.6 and 4.7, again do not look normal however 
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these cells have wetted to the surface and are less rounded than those attached to the 
P(NVP-co-EGDMA) membrane. 
Figure 4.6 Photograph of human dermal fibroblasts cultured in the presence of serum 
for 4 da.(;1 A) in direct contact with the P(NVP-co-DEGBAC) membrane in 
ThinCert inserts B) grown on tissue culture polystyrene in indirect contact with 
the P(NVP-co-DEGBAC) membrane and C) Photograph of fibroblasts grown on 
tissue culture polystyrene only. In all photographs cells are stained purple with MTT. 
Figure 4.7 Photograph of human dermal fibroblasts cultured in direct contact with 
the P(NVP-co-DEGBAC) membrane for 4 days using forced contact by seeding in 
the centre of a stainless steel ring in the presence of serum. Cells are stained with 
MTT and are found primarily growing on the TCP surrounding the polymer (A) 
however a few can be seen on the hydrogel (B). 
4.1.3 Cytotoxicity of P(NVP-co-DEGBAC-co-AA) membranes. 
I wt% acrylic acid (AA) was subsequently incorporated into the P(NVP-co-
DEGBAC) membranes in an attempt to modify the release of PAPN from the 
polymers see chapter 7. Cytotoxicity studies performed on these polymers where 
human dermal fibroblast cells were placed in direct and indirect contact with the 
polymer in both the presence and absence of serum are summarised in figure 4.8. 
Fibroblasts cultured in direct contact with the polymers P(NVP-co-DEGBAC-co-
AA) polymers once again preferred to grow on the PET insert membrane than on the 
hydrogels. Figure 4.9 shows human dermal fibroblasts stained with MTT growing on 
the insert instead of on the P(NVP-co-DEGBAC-co-AA) hydrogels. 
125 
_ Stimulation 
_ Inhibition 
I I No effect 
Figure 4.8 Pie charts illustrating the percentage of experiments where cell viability 
was stimulated, inhibited or not affected by A) direct contact with the polymer, B) 
indirect contact with the polymer in the presence of serum, stimulation or inhibition 
was taken to mean a statistically significant (p<O.05) difference in cell viability from 
TCP control within each experiment n=3 (3 repeats per experiment) 
Figure 4.9 Photograph of human dermal fibroblasts cultured in direct contact with 
P(NVP-co-DEGBAC-co-AA) for 4 days in ThinCert™ inserts in the presence of 
serum. Cells are stained purple with MTT and can clearly be seen on the bottom of 
the insert. 
4.1.4 Cytotoxicity of P(NVP-co-DEGBAC) membranes on a variety of skin and 
epithelial cells. 
Whilst fibroblasts are suitable for generic cytotoxicity testing they are by no means 
the only cell type found in skin. These polymers will hopefully be used in a wound 
healing application; therefore the polymers will primarily come into contact with 
keratinocytes. Primary normal human keratinocytes and a keratinocyte cell line, the 
HaCaT cellline along with a human cornea epithelial cellline (HCEC) were cultured 
in optimised medium for each cell type in direct and indirect contact with the 
P(NVP-co-DEGBAC) polymer. The results are shown in table 4.1 with 
photomicrographs of cell morphology shown in table 4.2. 
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_ Stimulation 
_ Inhibition 
Table 4.1 Effect of PNVP on viability of HaCaT, HECE and Keratinocyte cells. Cells were grown in direct and 
indirect contact with PCNVP-co-DEGBAC} for 4 days. Results shown are the means ± SEM of 3 experiments (3 
replicates per experiment). *p< 0.05, **p< 0.0 I , ***p< 0.001 
I I No effect 
HCEC Keratinocytes HaCaT's 
Direct 
Contact 
Indirect 
Contact 
n=3 
n=3 
100% 
n=3 n=3 
67% 
100% 
127 
Table 4.2 photographs of primary normal human keratinocytes, HaCaT's and human cornea epithelial cells stained with MTT after being grown 
in direct or indirect contact with P(NVP-co-DEGBAC) and on tissue culture polystyrene with no P(NVP-co-DEGBAC) present in optimised 
medium. 
Direct 
Contact 
Indirect 
Contact 
Tissue 
Culture 
Polystyrene 
Keratinocytes HaCaT's HCEC 
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4.2 Effect of PNVP membranes on cell viability - The effect of 
serum. 
The ability to successfully culture cells in serum free conditions is an ambition of 
many laboratories due to fears over the disease transmission between species i.e. 
bovine spongioform encephalitis (BSE) and its human analogue Creutzfeld Jacob 
Disease (CJD). Hong et al. (1997) showed that poly(vinylpyrrolidinone) hydrogels 
crosslinked with diethyleneglycol dimethacrylate (DEGDMA) could increase the 
viability of 3T3 cells cultured in serum free conditions to approximately 90% of their 
viability in cultures containing serum. However the crosslinker used in the polymer 
synthesis was shown to moderate this with some crosslinkers proving toxic. The 
indirect contact system was used to see if the crosslinkers used in these experiments, 
i.e. EGO MA, OEGBAC and OEGBAC + AA had a similar effect. 
Initial experiments were performed using the P(NVP-co-EGOMA) and P(NVP-co-
DEGBAC) polymers hence for these polymers there are many more experiments for 
analysis than with the P(NVP-co-DEGBAC-co-AA) hydrogels which were 
developed at a much later stage in this project. The latter were developed to modify 
the release of ~APN.F towards the end of the project and therefore there were fewer 
of these for examination. Table 4.3 shows the effect of these hydrogels on the 
viability of human dermal fibroblasts grown in both serum containing and serum free 
medium. 
Table 4.3 Effect of PNVP membranes with different crosslinkers on the viability of human dermal fibroblasts in the 
presence and absence of 10% foetal calf serum in the culture media. Experiments were performed using the indirect 
contact culture system. Stimulation or inhibition was determined by a statistically significant (p<0.05) difference in 
cell viability compared to the same cells grown on tissue culture plastic. (3 repeats per experiment) 
_ Stimulation 
_ Inhibition 
I I No effect 
P(NVP-co-EGDMA) P(NVP-co-D EG BAC) P(NVP-co-DEGBAC-co-AA) 
n= 18 n=3 
55% 
100% 
+ 
Serum 
n=14 n=3 
100% 
Serum 
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4.3 Investigation into the mechanism of action of PNVP based 
hydrogels on human dermal fibroblasts. 
4.3.1 The effect of conditioned polymers and media. 
A number of theories as to what was causing the increase in cell viability had by this 
point been proposed. Thus it was hypothesised that the polymer could be breaking 
down and directly stimulating the cells in some way, the polymer could be acting as 
a mitogen sponge or buffer, the polymer could be acting as a filtration unit and 
cleaning the culture medium of metabolic waste or the polymer could be collecting 
mitogens and forcing the cells into overdrive to produce more. An experiment was 
designed to look at these theories using both P(NVP-co-EGDMA) and P(NVP-co-
DEGBAC) and see which, if any, was most reasonable, again the indirect contact 
system was used. The flow chart in figure 4.10 illustrates how the experiment works. 
It was thought that if the polymers were loosely binding something during the initial 
culture period, stage 1, then when the polymer was placed straight back above new 
cells in stage 2 then the action of the pre-cultured polymer would be different to that 
of the new PNVP. The premise for stage 3 is that if the NVP was removing 
something from the culture system and if it was not tightly bound to the NVP then it 
would wash out into the media. If it was a mitogen(s) then the media would 
encourage cell growth however if it was waste metabolites then cell growth would be 
inhibited. The PNVP was placed back into culture to see if the washing step during 
stage 2 again altered the effect of the polymer on the viability of the cells. The MTT-
EST A assay was used to determine cell viability. 
Stage 1 
r 
I' ""'\ 
NVP placed into indirect contact with fibroblasts, 
seeded 24 hours previously for 4 days in both the 
presence and absence of serum. 
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I 
!Half of the NVP from stage 1 placed into indirec~ 
contact with fibroblasts seeded 24 hours 
previously for 4 days. Fresh NVP also added as a 
control to cells cultured in both the presence and 
absence of serum. 
I' Half ofthe NVP from stage 1 placed into fresh 
fibroblast culture medium for 4 days. Fresh NVP 
also added as a control in both the presence and 
absence of serum. 
Stage 2 
'-
Stage 3 
, / 
1 
NVP from stage 2, including the fresh NVP ""'\ 
placed into indirect contact with fibroblasts 
seeded 24 hours previously for 4 days. Cells 
cultured in both the presence and absence of 
serum. 
I 
tNvp conditioned medium from stage 2, includin~ 
the fresh NVP conditioned medium placed into 
indirect contact with fibroblasts seeded 24 hours 
previously for 4 days. Cells cultured in both the 
presence and absence of serum. 
, / 
Figure 4.10 Flow chart illustrating the organisation of the experiment designed to investigate how the PNVP polymers were affecting cell 
viability. 
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Stage 1 of this experiment shown in figu re 4.1 1 illustrates the effect that P(NVP-co-
EGDMA) and P(NVP-co-DEGBAC) have on fibroblast viabi lity using the indirect 
contact method assessed using the MTT-ESTA assay. Cells were grown in both the 
presence and absence of serum. Only the P(NVP-co-EGDMA) hydroge l significantly 
increased fibroblast viability in these three experiments and this was only in the 
presence of serum. 
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Figure 4.11 Effect of PNVP on fibroblast viability. Cells were grown in indirect 
contact with PNVP for 4 days in the presence and absence of serum. Results shown 
are the means ± SEM of 3 experiments (3 replicates per experiment). Significance 
was assessed using Student' s T-Test *p< 0.05, **p< 0.0 I, ***p< 0.00 I. 
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Stage 2 of this experiment shown in figure 4.12 illustrates the effect that P(NVP-co-
EGDMA) and P(NVP-co-DEGBAC) polymers that have previously been in indirect 
contact with fibroblasts for 4 days have on the viability of a new set of fibroblasts. 
The experiment was again performed in both the presence and absence of serum. 
Fresh hydrogels kept in fibroblast culture medium, either in the presence or absence 
of serum were also present. At no point during this part of the experiment was there 
any significant difference in cell viability between the old and new PNVP' s. The 
presence or absence of serum also had no effect. 
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Figure 4.12 Effect of PNVP on fibroblast viability. Cells were grown in indirect 
contact with PNVP for 4 days in the presence and absence of serum. Results shown 
are the means ± SEM of 3 experiments (3 replicates per experiment). Significance 
was assessed using Student's T-Test *p< 0.05, **p< 0.01 , ***p< 0.001. 
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Stage 3 of this experiment shown in figure 4.13 illustrates the effect that P(NVP-co-
EGDMA) and P(NVP-co-DEGBAC) polymers that have previously been in indirect 
contact with fibroblasts for 4 days and subsequently washed for 4 days, have on the 
viabil ity of a new set of fibroblasts. The experiment was again performed in both the 
presence and absence of serum. Cell viability was significantly increased when the 
washed polymers were placed in indirect contact with cells in the presence of serum. 
These polymers had no significant effect on cell viability in the absence of serum. 
Again there is no difference between the old and new polymers. 
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Figure 4.13 Effect of PNVP on fibroblast viabi lity. Cells were grown in indirect 
contact with washed PNVP for 4 days in the presence and absence of serum. Results 
shown are the means ± SEM of 3 experiments (3 replicates per experiment). 
Significance was assessed using Student' s T-Test *p< 0.05, **p< 0.01 , ***p< 0.001. 
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Stage 3 of this experiment shown in figure 4.14 illustrates the effect that medium 
used to wash P(NVP-co-EGDMA) and P(NVP-co-DEGBAC) polymers that have 
previously been in indirect contact with fibroblasts for 4 days and medium used to 
wash fresh PNVP have on the viability of a new set of fibroblasts. The experiment 
was again performed in both the presence and absence of serum. In all cases when 
the polymers have been placed into serum free medium the cell viability is increased. 
There is no difference between the media used to wash the new polymers and the 
pre-cultured polymers suggesting that the effect of the polymers on cell viability is 
not due to the entrapment of some factor from the culture medium. I f this was the 
case and the polymer was removing some mitogen from the culture system then this 
increase in cell viability would be greater in the medium used to wash the pre-
cultured polymers. Therefore it could be suggested that something is being washed 
from the polymer itself. This is not seen as clearly when serum is present. Only the 
new P(NVP-co-EGDMA) polymer had any significant effect on cell viability in the 
presence of serum. 
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Figure 4.14 Effect of PNVP conditioned medium on fibroblast viability. Cells were 
grown in indirect contact with PNVP conditioned medium for 4 days in the presence 
and absence of serum. Results shown are the means ± SEM of 3 experiments (3 
replicates per experiment). Significance was assessed using Student's T-Test *p< 
0.05 , **p< 0.01 , ***p< 0.001. 
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Throughout the experiment the equilibrium water content of the samples was 
monitored . The equilibrium water contents of the hydrogels were measured at the 
start and end of each stage. These hydrogels were treated exactly the same way as 
the hydrogels used for the cell culture part of this experiment above. However at no 
time did these hydrogels come into contact with cells. Each piece of hydrogel was 
placed into I ml of fibroblast culture medium, both in the presence and absence of 
serum and kept in an incubator at 37°C for the same length of time as the hydrogels 
placed into indirect contact with the fibroblasts. At no time over the 12 days of the 
experiments was any significant difference in equilibrium water content observed 
within any of the stages of the experiment with the results shown in figure 4.15 
below. 
New PNVP End Stage 3 
Old PNVP End Stage 3 
New PNVP End Stage 2 
Old PNVP End Stage 2 
Start Stage 213 
End Stage 1 
Start Stage 1 
o 20 40 60 
_ P(NVP-co-EGDMA) 
_ P(NVP-co-DEGBAC) 
80 100 
Equilibrium water content I % 
Figure 4.15 Effect of pre-culture and washing of the polymer on the equilibrium 
water content of P(NVP-co-EGDMA) and P(NVP-co-DEGBAC) hydrogels. Results 
expressed as mean ± SEM of n=6 samples. There was no significant difference in the 
equilibrium water contents for each polymer observed over the course over the 12 
days of the experiment. 
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4.3.2 Investigation into protein binding to PNVP hydrogels. 
A possible mechanism by which the PNVP hydrogels could affect the viability of 
fibroblasts would be through the binding and / or release of proteins and growth 
factors. SDS-PAGE electrophoresis with subsequent protein staining with Brilliant 
Blue ™ was used to briefly investigate this possibility. 
Figure 4.16 7% Polyacrylamide SDS-PAGE gel stained with Brilliant Blue to 
identify proteins. A - SDS-7B ladder, B - Serum free DMEM, C - DMEM + 10% 
FCS D - FCS, E - P(NVP-co-DEGBAC) soaked in Serum free DMEM, F - P(NVP-
co-DEGBAC) soaked in DMEM + 10% FCS, G - P(NVP-co-DEGBAC) soaked in 
FCS. 
4.4 Summary of results. 
After the synthesis of PNVP based hydrogels biological characterisation was 
attempted. It became apparent early on that the P(NVP-co-EGDMA) polymers did 
not have sufficient strength to support the stainless steel rings commonly used in this 
laboratory to force contact between cells and substrates. It was therefore necessary to 
develop an alternate methodology to force this contact. The use of ThinCert ™ 
inserts was determined to be the best way forward, as this system also gave the 
opportunity to examine the effect of these polymers when placed in indirect contact 
with cells. 
Examination of the effects of PNVP based polymers synthesised for this study on the 
viability of human dermal fibroblasts showed that it was difficult to grow cells in 
direct contact with the polymers. Those cells that did manage to attach did not 
appear when viewed down a microscope to be viable. Those cells that did manage to 
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escape from direct contact with the polymers preferred to grow elsewhere i.e. the 
tissue culture plastic on the bottom of the wells or the PET membrane on the bottom 
of the ThinCert™ inserts. This could explain the discrepancy between the MTT-
EST A viability data and the appearance of the cells when grown in direct contact 
with the polymers. The lack of cell adhesion to these polymers can perhaps be 
explained by the extremely high water contents of these polymers. The high 
hydrophilicity would make protein adsorption to the surfaces extremely difficult and 
the lack of adsorbed proteins would decrease the sites available for cell attachment. 
Haigh et al. (2002) showed that the EWC of hydrogels had an effect on fibroblast 
adhesion and the state of the water in the hydrogels was also a factor. Hydrogels with 
an EWC of 30% appeared to have the optimum conditions for fibroblast attachment 
and spreading. Levels of attachment were lower on polymers with a EWC of greater 
than 30%. Also the presence of free water in the hydrogels was only observed at 
EWC's greater than 25% and this was necessary for cell attachment and spreading 
(Haigh, Fullwood et al. 2002). 
In nearly all cases where fibroblasts were cultured in indirect contact with the 
hydrogels the viability, assessed using the MTT-ESTA assay, was either unaffected 
by the presence of the polymers or increased. This correlates with the visual analysis 
of cell morphology. The fibroblast viability when grown in indirect contact with the 
PNVP based polymers ranged from 46 - 530% of control viability in the presence of 
serum and 15 - 242% of control viability without serum. The average increase in 
viability was 22.5% ± 24.6% for the P(NVP-co-EGDMA) polymer in the presence of 
serum (n= 18 not significant, Students paired T -Test) and 27.2% ± 16.6% in the 
absence of serum (n= 14 not significant, Students paired T -Test), overall the P(NVP-
co-EGDMA) polymer increased the average viability by 24.5% ± 15.4% regardless 
of the presence or absence of serum. The P(NVP-co-DEGBAC) polymer increased 
the average viability of fibroblasts grown in indirect contact with the polymer by 
19.5% ± 11.8% in the presence of serum (n=14 p<0.05, Students paired T-Test) and 
19.2% ± 19.2% in the absence of serum (n=18 p<O.OI, Students paired T-Test) and 
regardless of the presence or absence of serum the average increase in cell viability 
was 19.4% ± 7.0%. Overall PNVP based hydrogels increased cell viability by 22.1 % 
± 8.5% regardless of the presence of serum and crosslinker used (n=64 p<O.O I, 
Students paired T-Test). PNVP hydrogels increased the average cell viability by 
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21.2% ± 14.6% in the presence of serum and 23.1 % ± 8.8% in the absence of serum. 
The P(NVP-co-DEGBAC-co-AA) hydrogels had no significant effect on cell 
viability in both the presence and absence of serum when human dermal fibroblasts 
were grown in indirect contact with the polymer. 
Attempts were made to grow primary human keratinocytes, the HaCaT keratinocyte 
cell line and a human cornea epithelial cell line (HCEC) in both direct and indirect 
contact with the P(NVP-co-DEGBAC) polymer. The MTT-ESTA assay was again 
used to assess cell viability along with visual observation of cell morphology. In all 
cases when the cells were grown in direct contact cell viability was decreased. 
HCEC cells and keratinocytes cannot be grown successfully on tissue culture plastic 
(TCP) alone. For successful culture HCEC cells need to be grown on TCP coated 
with a mixture of extracellular matrix proteins (collagen I, bovine serum albumen 
and fibronectin). Keratinocytes need to be grown on TCP coated with collagen I. 
HaCaT cells can be grown successfully on uncoated TCP. The P(NVP-co-
DEGBAC) had no significant effect on the viability ofkeratinocytes and HCEC cells 
grown for 4 days in indirect contact with the polymer in all three experiments. In two 
out of the three experiments the P(NVP-co-DEGBAC) hydrogel had no significant 
effect on the viability of HaCaT cells grown in indirect contact with the polymer. In 
one out of the three experiments where HaCaT cells were grown in indirect contact 
with the P(NVP-co-DEGBAC) hydrogel a significant decrease in cell viability was 
observed. 
Attempts to explain how these hydrogels affected the viability of human dermal 
fibroblasts involved investigating the action of both conditioned polymers and 
polymer conditioned media. The polymer could be breaking down. The polymer 
could be removing mitogens or toxins and metabolic waste from the media. These 
could either be released later or removed from the system completely, forcing the 
cells into overdrive. These results showed that polymers once placed in indirect 
contact with fibroblasts for 4 days and then immediately placed into indirect contact 
with another batch of fibroblasts had no significant effect on the viability of this 
second batch of fibroblasts in both the presence and absence of serum. However if 
these polymers were washed before being placed back into indirect contact with the 
fibroblasts in the presence of serum an increase in viability was seen, but there was 
140 
no significant difference between the old and new PNVP's. In the absence of serum 
there was no significant difference between the cells cultured in the presence or 
absence of PNVP or between the old and hew PNVP's. The conditioned media from 
the old PNVP's also had no significant effect on cell viability in the presence of 
serum. Medium conditioned using new P(NVP-co-EGDMA) did significantly 
increase the fibroblast viability in the presence of serum, whilst the P(NVP-co-
DEGBAC) conditioned media had no significant effect on cell viability in the 
presence of serum. In the absence of serum all of the conditioned media significantly 
stimulated cell viability, but there was no difference between the old and new 
PNVP's or between the crosslinkers. These results could suggest that the polymer 
itself directly affects cell viability rather than the entrapment and / or release of 
metabolic waste or mitogens. If the polymers were trapping metabolic waste or 
mitogens there would be a difference in the effect of the pre-cultured polymers and 
the new polymers. This is not observed in either the presence or absence of serum. It 
is interesting to note that by day 12 it is the conditioned media that increases cell 
viability in the absence of serum. However in the presence of serum it is the presence 
of the washed polymers that increases cell viability. It is also interesting to note that 
the unwashed polymers had no effect on cell viability in stage 2. There was no 
significant effect on the water content throughout the course of the experiments 
indicating that over the 12 days of the experiments there was no significant bulk 
degradation. So whilst it appears that the polymers are directly stimulating cell 
viability this is not due to polymer degradation at a scale large enough to be detected 
via equilibrium water content measurements. 
Protein adsorption studies were inconclusive as no bands could be seen in the 
channels into which the polymers were placed. It could therefore be suggested that 
either the polymers are not binding any proteins or that any proteins bound are bound 
so tightly that the electrical field, Tris Hel, SDS, and p-mercaptoethanol are not 
sufficient to separate the proteins from the polymers. 
The P(NVP-co-EGDMA) hydrogel whilst non-cytotoxic does not have sufficient 
material properties for use as a wound dressing, however two hydrogels have now 
been developed that have sufficient material properties for use as a wound dressing, 
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P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-AA). These hydrogels are also 
non-cytotoxic when cells are grown in indirect contact with the polymers but also 
largely non-fouling, an ideal property in a wound dressing. These hydrogels can also 
stimulate cell viability and this effect is especially potent in serum free conditions. 
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5. The effect of ~-aminopropionitrile and 4-methyJ 
umbelliferone on 
differentiation. 
cell viability, proliferation, and 
In the current experiments cell viability was assessed as before using the M TT-
EST A assay. Keratinocyte proliferation was assessed by investigating the total DNA 
content of cultures treated with the anti-contraction agents. Keratinocyte 
differentiation was assessed by investigating involucrin expression in treated 
cultures. Involucrin is a soluble cytoplasmic protein which is crosslinked by 
transglutaminase during the production of the cornified envelope formed during 
keratinocyte differentiation. It is expressed in a rang~ of stratified squamous epithelia 
and is expressed in the suprabasal layers of stratified squamous epithelium (Griffin 
and Harris 1992; Carroll, Albers et al. 1993). According to Griffin et al. (1992) 
involucrin is normally expressed in vivo when cells have lost the ability to divide and 
is therefore considered a marker of terminal keratinocyte differentiation. 
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5.1 Effect of J3APN on cell viability, proliferation and differentiation. 
5.1.1 Effect of ~APN OD cell viability. 
In these experiments the cytotoxic effects of ~-aminopropionitrile (~APN) on 
fibroblasts and keratinocytes was investigated using the MTI -EST A assay . Cells 
were cultured in monolayer in appropriate media supplemented with ~APN at 
concentrations of 0-800 J..I.g.mr l . Cells were cultured individually and in a 3: 1 co-
culture of keratinocytes and fibroblasts for 7 days and the results are shown in figure 
5.1 below. These data show that PAPN at concentrations of between 50 and 
800 J..I.g.mr I does not have a significant effect on the viabi lity of these cells. 
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Figure 5.1 Effect of increasing concentrations of PAPN on viability of fibroblasts, 
keratinocytes and 3: 1 co-culture of keratinocytes and fibroblasts. Viability assessed 
using MTI-ESTA assay. Data expressed as mean ± SEM of n=3 experiments (3 
replicates per experiment). ~APN had no significant affect on cell viability at 
concentrations between 50 and 800 J..I.g.mr l . 
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5.1.2 Effect of J3APN on keratinocyte proliferation. 
In these experiments the effect of J3APN on the proliferation of keratinocytes was 
investigated by measuring total DNA in the cultures. Cells were cultured in 
monolayer in Greens medium supplemented with PAPN at concentrations of 0-
800 Ilg.mr l for 7 days. DNA content was measured by lysing the cells with a buffer 
made from SOS, Urea and PBS and then treating the lysate with DAPI. The results 
are shown in figure 5.2 below. DAPI is a fluorescent stain which binds strongly to 
DNA. These data show that J3APN at concentrations of between 25 and 800llg.mrl 
does not have a significant effect on the proliferation of keratinocytes. 
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Figure 5.2 Effect of increasing concentrations of J3APN on the proliferation of 
keratinocytes. Proliferation was assessed by measuring total DNA. Data expressed as 
mean ± SEM of n=3 experiments (3 replicates per experiment). PAPN had no 
significant affect on cell proliferation at concentration between 25 and 800 Ilg.mr l as 
assessed by Students' T-Test. 
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5.1.3 Effect of J3APN on keratinocyte differentiation. 
In these experiments the effect of J3APN on the differentiation of keratinocytes was 
investigated by immunolabelling of the involucrin expression in the cultured cells. 
Cells were cultured in monolayer in Greens medium supplemented with PAPN at 
concentrations of 0-800 J.lg.mr l for 7 days. Photomicrographs were subsequently 
taken of the fixed cells which were co-stained with DAPI to enable identification of 
the cell nucleus. These are shown in figure 5.4 below. After the photomicrographs 
were taken the fluorescence from the cells was read in a plate reader to allow the 
results to be quantified. The graphs obtained from these results are shown in figure 
5.3. To allow for differences in cell number between weIls, the fluorescence from the 
involucrin was divided by the fluorescence from the DAPl staining for each well. 
These results shown in figure 5.3.C show the involucrin per well divided by the 
DNA per well gives an index of differentiation for the remaining cells. These data 
shows that at concentrations of 0-400 J.lg.mr l J3APN does not significantly affect 
keratinocyte differentiation. At the highest concentration investigated, 800 J.lg.mr l , a 
significant increase in keratinocyte differentiation was seen. 
Figure 5.3 Effect of increasing concentrations of PAPN on the differentiation of 
keratinocytes over 7 days. Data expressed as mean ± SEM of n=3 experiments (3 
replicates per experiment) A) DAPI fluorescence staining showing proliferative ce lls 
present expressed as a % of the TCP control. B) Involucrin staining showing 
terminally differentiating cells expressed as a % of the TCP control. C) In C the 
amount of involucrin per cell is estimated by showing the relative involucrin per well 
(expressed with respect to the TCP control) divided by the relative amount of DNA 
per well (expressed with respect to the TCP control). 
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Figure 5.4 Photomicrographs of keratinocytes treated with j3APN at concentrations 
of 0-800 Ilg.mr J for 7 days. Cells were immunolabelled with OAPI to show the cell 
nuclei and a FITC conjugated antibody for anti -involucrin. 
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5.2 Effect of 4-MU on cell viability, proliferation and differentiation. 
5.2.1 Effect of 4-MU on cell viability. 
In these experiments the cytotoxic effects of 4-methyl umbelliferone (4-MU) on 
human skin cells, fibroblasts and keratinocytes was investigated using the MTT-
ESTA assay. Cells were cultured in monolayer in appropriate media supplemented 
with 4-MU at concentrations of 0-8 mM. Cells were cultured individually and in a 
3: 1 co-culture of keratinocytes and fibroblasts for 7 days. The results are shown in 
figure 5.5 below. It can be clearly seen that at concentrations of 4-MU greater than 
or equal to 1 mM the cell viability was significantly reduced. Having cells in co-
culture did not protect against the cytotoxic effects of the 4-MU. 
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Figure 5.5 Effect of increasing concentrations of 4-MU on viability of human skin 
cells, fibroblasts , keratinocytes and 3: I co-culture of keratinocytes and fibroblasts. 
Viability assessed using MTT-ESTA assay. Data expressed as mean ± SEM of n=3 
experiments (3 replicates per experiment). * indicates significant difference in 
optical density from untreated culture (Student's paired T test). *p<0.05 **p<O.O 1 
***p<O.OO I. 
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5.2.2 Effect of 4-MU on keratinocyte proliferation. 
In these experiments the effect of 4-MU on the proliferation of keratinocytes was 
investigated by measuring total DNA in the cultures. Cells were cultured in 
monolayer in Greens medium supplemented with 4-MU at concentrations of 0-4 mM 
for 7 days. DNA content was measured by lysing the cells with a buffer made from 
SOS, Urea and PBS and then treating the resulting lysate with DAPt. The results are 
shown in figure 5.6 below. DAPt is a fluorescent stain which binds strongly to DNA. 
It can clearly be seen that at concentrations of greater than 0. 125 mM a significant 
inhibition in keratinocyte proliferation is seen. 
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Figure 5.6 Effect of increasing concentrations of 4-MU on the proliferation of 
keratinocytes. Proliferation was assessed by measuring total DNA, data expressed as 
mean ± SEM of n=3 experiments (3 replicates per experiment). * indicates 
significant difference in relative fluorescence from untreated culture (Student' s 
paired T test) *p<0.05. 
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5.2.3 Effect of 4-MU on keratinocyte differentiation. 
In these experiments the effect of 4-MU on the differentiation of keratinocytes was 
investigated by immunolabelling of the involucrin expression in the cultured cells. 
Cells were cultured in monolayer in Greens medium supplemented with 4-MU at 
concentrations of 0 - 4 mM for 7 days. Photomicrographs were subsequently taken 
of the fixed cells which were co-stained with OAPI to enable identification of the 
cell nucleus. These are shown in figure 5.8 below. After the photomicrographs were 
taken the fluorescence from the cells was read in a plate reader to allow the results to 
be quantified. The graphs obtained from these results are shown in figure 5.7. To 
allow for differences in cell number between wells, the fluorescence from the 
involucrin was divided by the fluorescence from the OAPI staining for each well. 
These results shown in figure 5.7.C show the involucrin per well divided by the 
DNA per well gives an index of differentiation for the remaining cells. The 
photomicrographs in figure 5.8 clearly show the reduction in keratinocyte number as 
the concentration of 4-MU in the cell culture medium increases. This corresponds 
with an increase in the index of differentiation calculated for each cell. There is seen 
to be a significant increase in the index of differentiation when the keratinocytes 
were treated with medium containing 2 mM 4-MU. 
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A 
B 
C 
Figure 5.7 Effect of increasing concentrations of 4-MU on the differentiation of 
keratinocytes over 7 days. A) DAPI fluorescence staining showing proliferative cells 
present expressed as % TCP control. B) Involucrin staining showing terminally 
differentiating cells expressed as % TCP control. C) Amount of involucrin per 
proliferative cell. Data expressed as mean ± SEM of n=3 experiments (3 replicates 
per experiment). * indicates significant difference in relative fluorescence from 
untreated culture (Student ' s paired T test) *p<O.OS. 
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1 mM 4-MU 2 mM 4-M U 
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Figure 5.8 Photomicrographs of kerat inocytes treated with 4-MU at concentration 
of 0 - 4 mM cells were immunolabelled with OAPI to show the cel l nuclei and a 
FITC conjugated antibody for involucrin. 
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5.4 Summary of results 
The aim of this project is the synthesis and characterisation of a polymer membrane 
that could subsequently be used to deliver anti-contraction agents. Two potential 
anti-contraction agents were identified from previous work carried out in Professor 
MacNeil's laboratory and from surveying the literature j3APN had recently been 
investigated for use as an anti-contraction agent in this group by Miss Caroline 
Harrison (Harrison, Gossiel et al. 2006a; Harrison, Gossiel et al. 2006c). However up 
until this point no cytotoxicity testing had been undertaken with j3APN. 4-MU has 
been shown to reduce hyaluronan production by cells (Rilla, Pasonen-Seppanen et al. 
2004; Rilla, Siiskonen et al. 2005; Nagira, Nagahata-Ishiguro et al. 2007). It was also 
associated with a reduction in keratinocyte differentiation and hence was postulated 
that it may also affect keratinocyte contraction of the reconstructed skin. Once again 
there was no information available about the cytotoxic effect of this drug on 
keratinocytes. 
These experiments showed that j3APN had no significant effect on the viability of 
monolayer cultures of dermal fibroblasts and keratinocytes in both single and a 3: 1 
co-culture of keratinocytes to fibroblasts. Similarly j3APN had no significant effect 
on either the proliferation or differentiation of keratinocytes. Conversely 4-MU 
significantly reduced the viability of monolayer cultures of fibroblasts and 
keratinocytes in both single and a 3: I co-culture of keratinocytes to fibroblasts at 
concentrations of 1 mM or greater. There was also a significant reduction in cell 
proliferation in monolayer keratinocyte cultures treated with 4-MU at concentration 
of 0.125 mM or greater. Differentiation was also reduced in these cultures however 
once this was corrected for the effects of 4-MU on cell number it was evident that 
the degree of differentiation of the remaining cells was increased. Thus in summary 
prior information on j3APN (Harrison, Gossiel et al. 2006a; Harrison. Gossiel et al. 
2006c) showed it to have potential as an anti-contraction agent while 4-MU had not 
previously been tested with respect to skin contraction. However it was evident from 
the data from these results that in studying 4-MU the drug was clearly cytotoxic to 
skin cells and therefore could only be examined over a relatively narrow range of 
concentrations. 
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6. Effect of J3-aminopropionitrile and 4-methyl 
umbelliferone on contraction. 
Two contraction models were used to examine the efficacy of PAPN and 4-MU on 
contraction. The first model was a simple collagen gel model and the second was a 
more physiologically relevant reconstructed skin model. 
6.1 Contraction of collagen gels. 
6.1.1 Contraction of collagen gels populated with fibroblasts and keratinocytes. 
As mentioned earlier the majority of research into skin contraction is performed on 
fibroblast populated collagen gels. It was therefore necessary to establish a more 
physiologically relevant collagen gel model to enable better characterisation of the 
drugs under consideration. To this end collagen gels were produced and seeded with 
human dermal fibroblasts and normal human keratinocytes in either mono or co-
culture. The cells were either placed directly into the gel or on top of a precast gel. In 
all cases the final cell number was 5 x 104 cells. In keratinocyte containing 
experiments Greens medium was used to feed the cells. Fibroblast culture medium 
was used in fibroblast mono-culture experiments and the experiments were run for 5 
days. In co culture experiments a 3: 1 ratio of keratinocytes (P I or P2) to fibroblasts 
(P3-9) were used. This is to mimic the seeding densities used in the production of the 
reconstructed skin. Image analysis was used to measure the area of the gels at 24 
hour time points and the results are shown in figure 6.1. 
Collagen gels without any cells present did not contract over the time period 
examined. Collagen gels where fibroblasts or keratinocytes were seeded on top of 
the gel contracted the least whilst gels populated with both cell types contracted the 
most. The gels where fibroblasts were seeded inside the gel contracted steadily over 
the culture period however when keratinocytes were seeded inside the gels a sharp 
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reduction in surface area was observed over the first 24 hours and very little 
contraction seen during the following time periods. Unfortunately the error bars for 
the co-culture gels are large and it is not possible to draw any firm conclusion from 
these experiments. However it is clear that both cell types can contract collagen I 
gels. When keratinocytes are placed inside the gels or cultured with fibroblasts these 
gels tend to contract to a greater extent than gels populated with fibroblasts alone. 
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Figure 6.1 Graph showing how the cellular composition of collagen gels affects 
collagen gel contraction over 5 days. Data expressed as mean ± SEM of n=2 
experiments (3 replicates per experiment) for all experiments except keratinocytes on 
and fibroblasts on (n= I). Collagen gels without any cells present did not contract 
over the time period examined. Collagen gels where fibroblasts or keratinocytes 
were seeded on top of the gel contracted the least whilst gels populated with both 
cell types contracted the most. 
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6.1.2 Effect of j3APN on collagen gel contraction. 
These experiments show the effect of j3APN supplemented medium on the 
contraction of collagen gels populated with a 3: 1 ratio of keratinocytes and 
fibroblasts. The medium contained J3APN at concentrations of between 50 and 
800 )lg.mr l . Unfortunately J3APN does not seem to affect the contraction of 
collagen gels populated with both cell types as shown in figure 6.2 below. 
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Figure 6.2 Effect of increasing concentrations of J3APN on contraction of collagen 
gels over a period of 6 days. Data expressed as mean ± SEM of n=3 experiments (3 
replicates per experiment). On day 6 J3APN had no significant affect on the 
contraction of collagen gels at concentrations between 50 and 800 )lg.mr l as 
assessed using I-way ANOV A + Bonferroni correction. 
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6.1.3 Effect of 4-MU on contraction of collagen gels 
Figure 6.3 shows the effect of 4-MU supplemented medium on the contraction of 
collagen gels populated with a J: I ratio of keratinocytes and fibroblasts. The 
medium contained 4-MU at concentrations of between 0.125 and 4 mM. 4-MU at 
concentration of 1 mM and greater significantly reduced the contraction of the 
collagen gels. However figure 5.5 illustrates that in monolayer co-cultures at 
concentrations of 1 mM or greater 4-MU is significantly toxic. This cytotoxic effect 
may also affect collagen gel contraction. It could be that the reduced cell number is 
responsible for the reduction in contraction. 
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Figure 6.3 Effect of increasing concentrations of 4-MU on contraction of collagen 
gels over a period of 6 days. Data expressed as mean ± SEM of n=3 experiments (3 
replicates per experiment). On day 6 4-MU has no significant affect on the 
contraction of collagen gels at concentrations between 0.125 and 0.5 mM. A 
significant difference in contraction at day 6 was observed in collagen gels treated 
with 4-MU at concentrations of 1 mM and greater. * indicates significant difference 
in area from untreated collagen gels (I-way ANOV A + Bonferroni correction.). 
*p<0.05 **p<O.O 1 ***p<O.OO I. 
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6.1.4 Effect of 4-MU on contraction of fibroblast populated collagen gels. 
Work in the laboratory of Dr. Mike Edwards at Glasgow (data not shown and 
unpublished at this time) suggests medium supplemented with 2mM 4-MU would 
reduce the contraction of fibroblast populated collagen gels. Collagen gels were 
prepared containing 5 x 104 fibroblasts and cultured in 4-MU supplemented medium 
for 6 days. Every 24 hours the medium was completely replaced and the gels 
photographed for later image analysis. The data is shown in figure 6.4 below. 
Unfortunately, whilst there was a trend to suggest that 4-MU could reduce the 
contraction of fibroblast populated collagen gels the variation in the data meant that 
statistical significance was not obtained. 
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Figure 6.4 Effect of 2 mM 4-MU on contraction of collagen gels populated with 
fibroblasts over a period of 6 days. Data expressed as mean ± SEM of n=3 
experiments (3 replicates per experiment). 4-MU has no significant effect on the 
contraction of collagen gels populated with human dermal fibroblasts as assessed 
using I-way ANOV A + Bonferroni correction at day 6. 
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6.1.5 Effect of 4-MU on contraction of keratinocyte populated collagen gels. 
5 x 104 keratinocytes were seeded on top of pre-cast collagen gels and cultured in 
Greens medium supplemented with 2 mM 4-MU for 6 days. Every 24 hours the 
medium was completely replaced and the gels photographed for later image analysis. 
The data is shown in figure 6.5 below. Unfortunately, again whilst there was a trend 
to suggest that 2 mM 4-MU could reduce the contraction of keratinocyte populated 
collagen gels the variation in the data meant that statistical significance was not 
obtained at day 6. A significant difference in contraction was observed despite the 
large errors between days 3 and 5. Suggesting that 4-MU at a concentration of2 mM 
does significantly reduce the contraction ofkeratinocyte populated collagen gels. 
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Figure 6.5 Effect of 2 mM 4-MU on contraction of collagen gels populated with 
keratinocytes over a period of 6 days. Data expressed as mean ± SEM of n=3 
experiments (3 replicates per experiment). 4-MU has no significant effect on the 
contraction of collagen gels populated with keratinocytes as assessed using I-way 
ANOV A + Bonferroni correction at day 6. However a significant difference in 
contraction was observed between days 3 and 5. 
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6.1.4 Effect of 4-MU on contraction of collagen gels populated with fibroblasts 
and keratinocytes. 
Effect of 4-MU at a concentration of 2 mM on contraction of collagen gels populated 
with both fibroblasts and keratinocytes was also investigated. 5 x 104 cells were 
seeded in a 3: I ratio of keratinocytes to fibroblasts. The fibroblasts were seeded 
inside the gel and the keratinocytes on top. These gels were cultured Greens medium 
supplemented with 2 mM 4-MU for 6 days. Every 24 hours the medium was 
completely replaced and the gels photographed for later image analysis. The data is 
shown in figure 6.6 below. Unfortunately, again whilst there was a trend to suggest 
that treatment of the collagen gels with 2 mM 4-MU could reduce the contraction of 
collagen gels the variation in the data meant that statistical significance was not 
obtained. 
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Figure 6.6 Effect of 2 mM 4-MU on contraction of collagen gels populated with a 
3: I ratio of keratinocytes: fibroblasts over a period of 6 days Data expressed as mean 
± SEM of n=3 experiments (3 replicates per experiment). 4-MU has no significant 
effect on the contraction of collagen gels populated with keratinocytes as assessed 
using I-way ANOV A + Bonferroni correction at day 6. 
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6.2 Reconstructed skin model 
The reconstructed skin model has been established for many years in Prof. 
MacNeil's group. Although it has many uses, in this project it was used to model 
contraction. It has been clearly shown by Harrison (Harrison, Gossiel et al. 2006c), 
Thomton (Thomton, Harrison et al. Provisionally accepted) and Chakrabarty 
(Chakrabarty, Heaton et al. 2001) how this model can be used to see how various 
potential anti-contraction agents affect contraction. Statistics performed on these data 
were a 2-way ANOV A + Bonferroni correction. These statistics were chosen to 
allow comparison between these data and the data of Harrison et al. (Harrison, 
Gossiel et al. 2006c). 
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6.2.1 The effect of J3APN on contraction of reconstructed skin. 
These experiments (carried out by Miss Caroline Harrison) show the effect of I3APN 
supplemented medium on the contraction of collagen gels after 28 days culture at an 
air-liquid interface in Greens medium. The culture medium contained I3APN at 
concentration of 50, 100 and 200 J.lg.mr l . Whilst I3APN had no significant effect on 
the contraction of collagen gels (see figure 6.2) Greens medium supplemented with 
200 ).lg.mr l I3APN significantly reduced the contraction of the reconstructed skin 
composite shown below in figure 6.7. 
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Figure 6.7 Effect of I3APN on contraction of the reconstructed skin model n=3 
experiments (3 replicates per experiment). * indicates significant difference in 
surface area from untreated composite (2-way ANOV A + Bonferroni correction). 
*p<0.05 **p<O.O 1 ***p<O.OO 1. No significant difference between I3APN treated and 
untreated DED (p>0.05). Data courtesy of Miss Caroline Harrison (Harrison, Gossiel 
et al. 2006c). I3APN supplemented medium (200 ).lg.mr l ) significantly reduced the 
contraction of the reconstructed skin composite. 
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6.2.1 The effect of 4-MU on contraction of reconstructed skin. 
These experiments show the effect of 4-MU supplemented medium on the 
contraction of the reconstructed skin model after 28 days culture at an air-liquid 
culture in Greens medium. The medium contained 4-MU at concentration of 0.5, I 
and 2 mM. The data is shown in figure 6.8 below. Greens medium supplemented 
with 4-MU at concentration of I mM or greater significantly reduced the contraction 
of the reconstructed skin composite. 
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Figure 6.8 Effect of 4-MU on contraction of the reconstructed skin model n=3 
experiments (3 replicates per experiment). * indicates significant difference in 
surface area from untreated composite (I-way ANOVA + Bonferroni correction). 
*p<0.05 **p<O.Ol ***p<O.OOl. There was no significant difference between 4-MU 
treated and untreated DED (p>O.05). Medium supplemented with 4-MU at 
concentrations of 1 mM and greater significantly reduced the contraction of the 
reconstructed skin. 
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6.2.2 Effect of 4-MU on histology of reconstructed skin. 
The effects of medium supplemented with 4-MU at concentrations of 0, 0.5, 1 and 
2 mM are shown in figure 6.9 below. Composites were cultured for 28 days at an air-
liquid interface in Greens medium. Samples were subsequently fixed, embedded, 
mounted, and stained with Haematoxylin and Eosin (H&E). These sections were 
then photographed and sent for blind scoring. The results of the scoring are shown in 
the graphs in figure 6.10. To enable fair scoring with the small number of samples 
two micrographs, randomly numbered, for each condition were sent for blind scoring 
to 5 independent observers within the MacNeil group who each have significant 
experience in examining composite histology. The scoring system used is shown in 
chapter 2.10.2. 
Figure 6.9 Effect of 4-MU on histology of the reconstructed skin model after 28 days 
culture at air-liquid interface. A) 0 mM 4MU, B) 0.5 mM 4-MU, C) 1 mM 4-MU D) 
2mM4-MU. 
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Figure 6.10 Graphs showing the qualitative assessment of histology. A) Assessment of keratin layer, B) assessment of the keratinocyte layers, C) 
assessment of the quality of the dermo-epidermal junction, D) assessment of the quality of the dermis, E) assessment of fibroblast number in the 
composites. Two photomicrographs for each condition were assessed blind by 5 independent members of the MacNeil group and scored 
according to the system shown in section 2.10.2_ Graphs have been drawn to illustrate the number of times a photograph was categorised as A, 
B, C, D or in the case of the quality of the keratinocyte layer and th~ dermis E. 
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At low concentrations of 4-MU very little disruption to the keratin layer is seen with 
the majority of the photomicrographs categorised as normal (A). As the 
concentration of the 4-MU in the culture medium increases more of the 
photomicrographs are categorised as having either a thin layer of poorly adherent / 
fragmented keratin (C) or as having no keratin (D). The same trend is observed when 
assessing the quality of the keratinocyte layer. An increased number of 
photomicrographs were placed in the worst categories i.e. being categorised as 
having a patchy monolayer of keratinocytes (D) or having no keratinocytes (E) with 
increasing concentrations of 4-MU in the culture medium. 
Increasing the concentration of 4-MU in the culture medium also decreases the 
quality of the dermo-epidermal junction. Again as the concentration of the 4-MU in 
the culture medium increases more photomicrographs were categorised as having 
partial (C) or no attachment (0) between the epidermis and dermis than when there 
was no 4-MU in the culture medium. At the highest concentration investigated, 
2 mM, 8 out of the 10 photo micrographs assessed were classified as having no 
attachment between the dermis and epidermis. 
Increasing the concentration of 4-MU in the culture medium does not appear to have 
any effect on the quality of the dermis with the majority of the photomicrographs 
categorised as having normal, organised collagen. 
Increasing the concentration of the 4-MU in the culture medium does appear to have 
a profound effect on the fibroblast number. Even at low concentrations of 4-MU 
more photomicrographs were placed into the reduced proliferation (C) or no 
fibroblasts present (D) categories than in the normal proliferation (B) category. At 
the highest concentration of 4-MU investigated, 2 mM, 7 out of the 10 
photomicrographs were classified as having no fibroblasts. 
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6.3 Summary of Results. 
Initially the collagen gel model was used to examine the efficacy of the two anti-
contraction agents under investigation, P-APN and 4-MU. The fibroblast populated 
collagen gel model is a cheap, simple model commonly used to study skin graft 
contraction. However, it does have its limitations; these include the presence of only 
one cell type, the lack of dermal architecture and basement membrane. The lack of 
dermal architecture and basement membrane cannot be easily rectified. A second cell 
type, the keratinocyte, can relatively easily be introduced into the collagen gels. It 
was therefore necessary to determine how the addition of keratinocytes into 
fibroblast populated collagen gels affected contraction. Collagen gels were produced 
with fibroblasts and keratinocytes in single and co-culture. All of the collagen gels 
produced had an initial seeding density of 5 x 104 cells. Whilst there was no 
significant difference observed due to low replicate numbers and large errors the 
collagen gels seeded with both cell types tended to contract more than those seeded 
with a single cell type. The collagen gel model with fibroblasts seeded in the gel and 
keratinocytes seeded on top of the gel in a 3:1 ratio (keratinocytes : fibroblasts) was 
therefore used to evaluate the efficacy of the two anti-contraction agents. 
PAPN had no effect on the contraction of collagen gels populated with both 
fibroblasts and keratinocytes. The 4-MU significantly reduced collagen gel 
contraction at concentrations of I mM or greater. Collagen gels populated with 
single or co-cultures of fibroblasts and / or keratinocytes were also treated with 4-
MU at a concentration of 2 mM. Unfortunately due to variation in the 4-MU treated 
collagen gels no statistical significance was obtained at day 6. However, in the 
keratinocyte populated gels a significant reduction in contraction was seen between 
days 3 and 5 despite the considerable variation present in the data. 4-MU also 
significantly reduced the contraction of the reconstructed skin model at 
concentrations of 1 mM or greater. Harrison et al. (Harrison, Gossiel et al. 2006c) 
had previously shown that PAPN at concentrations of 200 I-lg.mr l can significantly 
reduce contraction in the same reconstructed skin model. Table 6.1 summarises the 
effects of PAPN and 4-MU at various concentrations on the contraction of collagen 
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gels populated with single and co-cultures of fibroblasts and keratinocytes, and the 
reconstructed skin mode l. 
Table 6.1 Effect of PAPN and 4-MU at various concentrations on the contraction of 
the reconstructed skin model and collagen gels populated with single and co-cultures 
of fibroblasts and keratinocytes. 
Drug Model used Cells used, Effect on contraction 
PAPN Collagen I 3: 1 co-c u lture No significant effect 
50-800 Ilg.mrl gels 
4-MU Collagen I 3: 1 co-culture 1 mM and 4 mM significantly 
0.125-4 mM gels reduced contraction 
4-MU Collagen I Fibroblasts No significant effect 
2mM gels 
4-MU Collagen I Keratinocytes No significant effect 
2mM gels 
4-MU Collagen I 3: 1 co-culture No significant effect 
2mM gels 
PAPN* Reconstructed Fibroblasts & 200 ~g.mrl PAPN significantly 
50-200 Ilg.mrl skin keratinocytes reduced contraction 
4-MU Reconstructed Fibroblasts & 1 mM and 2 mM significantly 
0.5-2 mM skin keratinocytes reduced contraction 
* Data courtesy of MIss Carohne Harnson (Harrison, Gosslel et al. 2006c). 
Whilst the 4-MU significantly reduced the contraction of the reconstructed skin 
model it is important to make sure that there is no significant change to the histology 
of the reconstructed skin. H&E were used to stain the sections cut from the 
reconstructed skin composites after 28 days culture at an air-liquid interface. 
Photomicrographs of these sections were sent for independent blind scoring to 5 
members of the MacNeil group who each have significant experience examining 
composite histology. The photomicrographs appear to show a dramatic change in the 
quality of the epidermis, both in the quality of the keratinised layer and in the 
keratinocytes, as the concentration of 4-MU in the medium increases. Again the 
quality of the dermo-epidermal junction decreases with increasing concentration of 
4-MU. No difference was observed in the quality of the dermis at any of the 
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examined concentrations of 4-MU. However, the fibroblast number reduced 
dramatically when the composites were treated with 4-MU at concentrations of 1 
mM or greater. Harrison et al. (2006c) also showed that treatment of the 
reconstructed skin with 200 J.lg.mr l PAPN had no significant effect on the composite 
morphology. 
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7. Release of J3-aminopropionitrile and 4-methyl 
umbelliferone from poly(vinylpyrrolidinone) hydrogels and 
their effect on collagen gel contraction. 
The aim of this project was the development of a hydrogel wound dressing that could 
potentially be used to prevent / reduce skin graft contracture. A noncytotoxic poly 
(vinylpyrrolidinone) (PNVP) hydrogel has been developed with suitable material 
properties for use as a wound dressing. Two potential anti contraction agents have 
been identified, J3-aminopropionitrile (J3APN) and 4-methyl umbelliferone (4-MU). 
J3APN has been shown to be effective in reducing contraction of the reconstructed 
skin model (See chapter 6.2.1) but was unsuccessful in reducing the contraction of 
the collagen gel model (See chapter 6.1.2). 4-MU reduced contraction in both the 
collagen gel and reconstructed skin models (See chapter 6). 
Initial experiments to quantify J3APN release into aqueous media for this project 
involved attempted extraction of the J3APN from the aqueous media, (cell culture 
medium and PBS) into organic solvent, chloroform, for gas chromatography. 
Unfortunately the extraction proved unsuccessful, the J3APN was still present in the 
aqueous media even after treatment of the aqueous medium with potassium 
carbonate in an attempt to free the J3APN from the fumarate. The presence of J3APN 
in the aqueous solution was confirmed by the reaction of the amine group with 2,4,6-
trinitrobenzenesulfonic acid (TNBS). This yellow solution reacts with the amine to 
form an orange derivative as follows. 
+,,0 
O-""n0 N ~S ~O~ + I ~ +_ 
N NO 
1- 11 
o 0 
Figure 7.1 Reaction scheme for the reaction of 2,4,6-trinitrobenzenesulfonic acid 
with a primary amine (Hermanson 1996). 
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The TNBS assay has been used for many years to measure the free amino groups in 
proteins (Habeeb 1966). It can also be used as a qualitative check for the presence of 
amines, sulfuydryls, or hydrazides (Hermanson 1996). Further studies showed that 
this TNBS assay could be used to monitor the release of the I3APN into amine free 
aqueous media. 
In monitoring the release of 4-MU into various aqueous media advantage was taken 
of the fluorescent properties of the 4-MU. Friedberg and Shihabi (1997) use 4-MU 
conjugated to glucosaminide as a synthetic substrate to monitor the activity of N-
acetyl-l3-glucosaminidase. The product of this reaction is 4-MU and UV absorption 
or fluorescence spectroscopy techniques can be used to quantify the amount of 4-MU 
in solution. This assay has also been used by Calvitti et at. (2004). Lovdahl et at. 
(1994) used a HPLC method to quantify the amount of 4-MU in Williams E Media 
and dog plasma. However, this method was not explored in this study due to 
potential difficulties in the extraction of the 4-MU into acetonitrile. 
7.1 Drug release assay development. 
7.1.1 Assay development for monitoring PAPN release. 
The TNBS assay is used to determine the presence of free amino groups in amino 
acids and peptides. Initial experiments were performed with a protein control, BSA, 
to ensure that the assay worked. Initial experiments as illustrated in figure 7.2.A 
showed that the assay was more sensitive to I3APN than to BSA. It is thought that 
this is due to the protonated nitrogen in the PAPN causing the PAPN to be a more 
reactive species than the primary amines the assay was designed to measure. Further 
experiments were conducted to establish by what factor the experimental samples 
would need to be diluted by to prevent the saturation seen in figure 7.2.A. Dilutions 
of both the PAPN solutions in PBS and the TNBS solution were tried. This showed 
that dilution of the TNBS solution did not affect the concentration at which 
saturation occurred it only lowered the sensitivity of the assay. Dilution of the PAPN 
samples from a known concentration by 1: 1 0 did produce a curve suitable for use. 
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This means that the maximum detectable J3APN concentration for these experiments 
is 120 J..lg.mr l as shown in figure 7.2.B. 
A variety of other aqueous media were also tried to see which would be the best for 
a) releasing the J3APN into and b) diluting the samples by. Media tried were distilled 
water, PBS, PBS + 10% FCS, serum free DMEM, fibroblast culture medium, and 
Greens medium. The serum free DMEM, fibroblast culture medium, and Greens 
medium were investigated both with and without phenol red. In all cases except 
water and PBS the assay did not detect the presence of J3APN. This was thought to 
be due to the presence of the amino acids in these media. The phenol red also 
quenched the majority of the signal from the TNBS (data not shown). It was found 
that the best medium for the J3APN release assay was therefore PBS due to the 
similarities between this medium and the cell culture medium. The best medium for 
the sample dilution was the carbonate buffer used to make the TNBS solution used 
in the assay (data not shown). In all cases the experiments were performed using a 96 
well plate, absorption was measured using a U.V. plate reader at 320 nm. 
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Figure 7.2 Development of the calibration curve for detection of I3APN in phosphate 
buffered saline (PBS) by TNBS. A) Detection of I3APN and BSA (n=6), B) Final 
I3APN calibration curve, samples diluted down to final concentrations using Na(CO-
3)2 buffer pH 8.5 (n=6). All data expressed as mean ± SEM. 
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7.1.2 Assay development for monitoring 4-MU release. 
The assay for detection of 4-MU is already fairly well established using the 
fluorescence of the 4-MU solution with an excitation wavelength of 360 nm and 
emission of 440/460 nm. Initial experiments were performed to ensure the 
concentration dependent peaks stated in the literature were not affected by the 
various potential media that the 4-MU could be dissolved in Figure 7.3.A. Media 
examined included distilled water, phosphate buffered saline (PBS), PBS + 10% 
foetal calf serum (FCS), serum free DMEM, fibroblast culture medium and Greens 
medium. The serum free DMEM, fibroblast culture medium and Greens medium all 
contained phenol red. This shows that it is possible to directly measure the release of 
the 4-MU into the Greens medium that was used for the cell culture experiments. 
Samples also have to be diluted 1:8 producing the curve shown in figure 7.3.B. This 
allows a maximum directly measurable concentration of 0.15 mM. 
Q) 
o 
c::: 
20000 
15000 
~ 10000 
IJ) 
~ 
o 
::::l 
U. 
5000 
o 
70000 
60000 
50000 
~ 40000 c::: 
Q) 
o 
IJ) 
~ 
o 
::::l 
u::: 
30000 
20000 
10000 
o 
o 2 
0.00 
175 
----ddH20 
-.- PBS 
-A- Serum Free DMEM 
-.- DMEM + 10% FCS 
Greens + 10% FCS 
4 6 8 10 12 14 16 18 20 
4-MU concentration I mM 
8 
0.05 0.10 0.15 
4-MU concentration I mM 
Figure 7.3 Calibration curves for A) 4-MU dissolved in a variety of different 
solvents. 8) Calibration curve used for drug release experiments. Excitation 
wavelength 360 nm, emission monitored at 440/460 nm. Data expressed as mean ± 
SEM of n=6 samples. 
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7.2 Release of (3APN and 4-l\lU from PNVP based bydrogels. 
7.2.1 Release of PAPN from PNVP hydrogels. 
These experiments show the cumulative release of PAPN into 1 ml of PBS from 
P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-AA) hydrogels loaded with 
PAPN at initial concentrations of 1000 J.lg.mr1 and 200 J.lg.mr1 over a period of 6 
days at room temperature. Graphs show cumulative release over this period. At each 
time point all the PBS was removed from the samples and fresh PBS added. This 
was to mimic the situation seen in the collagen gel contraction experiments in 
chapter 7.3. 
7.2.1.1 P(NVP-co-DEGBAC) hydrogels. 
Figure 7.4 shows the cumulative release of PAPN into PBS over a period of 6 days 
at room temperature from P(NVP-co-DEGBAC) hydrogels. Xerogels, dehydrated 
hydrogels, were swollen in PBS containing PAPN at concentration of 200 J.lg.mr l 
and 1000 J.lg.mr1 for 48 hours. The swollen gels were then allowed to air dry for } 
hour to remove any excess solution before being placed into individual wells of a 48 
well plate. 1 m} of PBS was then added and the plate closed to reduce evaporation. 
At each time point the PBS was completely removed, stored for later analysis and 
fresh PBS added to mimic the conditions of the collagen gel contraction experiment 
described in chapter 7.3. The concentration of PAPN in the PBS was measured at 
each time point and added to the previous days total to obtain the cumulative release. 
It can be seen that in the gels loaded from a solution of 200 J.lg.mr1 PAPN after 48 
hours the majority of the PAPN has been released. The total volume of the swollen 
gel is approximately 500 J.lI and therefore it is important to note that the 
concentration of the final solution would not be the same as the concentration of the 
loading solution i.e. a final cumulative concentration of 200 J.lg.mr1 would not be 
expected. If all the PAPN is being released from a gel loaded from 200 J.lg.mr l a 
maximum achievable concentration would be approximately 100 J.lg.mr1 which is 
close to the value of 70 J.lg.mr1 seen in figure 7.4. The gel loaded from 1000 J.lg.mr l 
could potentially achieve a maximum concentration of approximately 500 J.lg.mr l 
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however this is not seen in figure 7.4 with the maximum concentration of 160 Ilg.mr 
I being obtained. Again most of the drug appears to be released over the first 48 
hours of the experiment. This is further illustrated by the fractional release graphs 
shown in figure 7.5. Figure 7.5.A shows that approximately 80% of the ~APN is 
released within the first 48 hours from the P(NVP-co-DEGBAC) hydrogel loaded 
from a 200 Ilg.mrl solution. Figure 7.5.B shows that a similar quantity of the ~APN 
was also released within the first 48 hours from the P(NVP-co-DEGBAC) hydrogel 
loaded from a 1000 Ilg.mrl solution. The fractional release data have been fitted 
with curves of the form y=kxn. This allows the rate constant (k) and diffusional 
exponent (n) to be calculated. Both of these curves are a fairly good fit with R2 
values of 0.844 and 0.791 respectively. The diffusional exponents derived from these 
graphs, 0.233 ± 0.054 and 0.186 ± 0.023 respectively are much lower than the value 
of 0.5 generally expected for Fickian release or the value of 0.45 expected for 
Fickian release from cylindrical samples. They are close to the values of 0.13, 0.19 
and 0.23 obtained for the release of 5-FU from PNVP based hydrogels by Liu et al. 
(2002b). 
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Figure 7.4 Release of ~APN into phosphate buffered saline from P(NVP-co-
DEGBAC) hydrogels over a period of 6 days at room temperature. After reaction 
with TNBS for 2 hours at room temperature absorbance was read at 340 nm and 
referenced at 630 nm. Data expressed as mean ± SEM of n=6 samples. 
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Figure 7.S Fractional release of PAPN into phosphate buffered saline from P(NVP-
co-DEGBAC) hydrogels loaded from A) 200 J..lg.mr1 B) 1000 J..lg.mr1 PAPN 
solutions over a period of 6 days at room temperature. Fractional release plotted 
from release data used for figure 7.4 plotted as concentration at time t / final 
concentration. Data expressed as mean ± SEM of n=6 samples. 
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7.2.1.2 PNVP-co-DEGBAC-co-AA hydrogels. 
Figure 7.6 shows the cumulative release of PAPN into PBS over a period of 6 days 
at room temperature from P(NVP-co-DEGBAC-co-AA) hydrogels. Xerogels were 
swollen in PBS containing PAPN at concentrations of 200 J.lg.mr l and 1000 J.lg.mr l 
for 48 hours. The swollen gels were then allowed to air dry for 1 hour to remove any 
excess solution before being placed into individual wells of a 48 well plate. 1 ml of 
PBS was then added and the plate closed to reduce evaporation. At each time point 
the PBS was completely removed, stored for later analysis and fresh added to mimic 
the conditions of the collagen gel contraction experiment described in chapter 7.3. 
The concentration of PAPN in the PBS was measured at each time point and added 
to the previous days total to obtain the cumulative release. It can be seen that in the 
gels loaded from a solution of 200 J.lg.mr l PAPN after 24 hours the majority of the 
PAPN has been released. Again it is important to note that the concentration of the 
final solution would not be the same as the concentration of the loading solution i.e. 
a final cumulative concentration of 200 J.lg.mr l would not be expected. If all the 
PAPN is being released from a gel loaded from 200 J.lg.mr l a maximum achievable 
concentration would be approximately 100 J.lg.mr l which is again close to the value 
of 70 J.lg.mr l seen in figure 7.6. The gel loaded from 1000 J.lg.mr l could potentially 
achieve a maximum concentration of approximately 500 J.lgmr l however once again 
this is not seen in figure 7.6 with the maximum concentration of 150 J.lg.mr l being 
obtained. In this case as with the P(NVP-co-DEGBAC) gels most of the drug 
appears to be released over the first 48 hours of the experiment. This is further 
illustrated by the fractional release graphs shown in figure 7.7. The P(NVP-co-
DEGBAC-co-AA) hydrogel loaded from a 200 J.lg.mr l solution releases 
approximately 70% of the PAPN within the first 24 hours as illustrated in figure 
7.7.A. Figure 7.7.B shows that approximately 80% of the PAPN is released within 
the first 24 hours from the P(NVP-co-DEGBAC-co-AA) hydrogel loaded from a 
1000 J.lg.mr l solution. The fractional release profiles obtained from the P(NVP-co-
DEGBAC-co-AA) hydrogels loaded from 200 and 1000 /J.g.mr l solutions of PAPN 
give diffusional exponents of 0.171 ± 0.05 and 0.133 ± 0.02 respectively. These 
curves have R2 values of 0.791 and 0.927 respectively. These values again are much 
lower than the value of 0.5 generally expected for Fickian release or the value of 
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0.45 expected for Fickian release from cylindrical samples. Again, they are close to 
the values of 0.13, 0.19 and 0.23 obtained for the release of 5-FU from PNVP based 
hydrogels by Liu et al. (2002b). The addition of the acrylic acid to the P(NVP-co-
DEGBAC) hydrogel did alter the diffusion exponents. The exponents obtained for 
the P(NVP-co-DEGBAC-co-AA) hydrogels releasing PAPN were reduced compared 
to the exponents for the P(NVP-co-DEGBAC) hydrogels releasing PAPN from both 
loading solutions. 
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Figure 7.7 Fractional release of PAPN into phosphate buffered saline from P(NVP-
co-DEGBAC-co-AA) hydrogels over a period of 6 days at room temperature. 
Fractional release plotted from release data used for figure 7.6 plotted as 
concentration at time t / final concentration. 
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7.2.2 Release of 4-MU from PNVP hydrogels. 
These experiments show the cumulative release of 4-MU into phosphate buffered 
saline from P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-AA) hydrogels 
loaded with 4-MU at initial concentrations of I mM or 4 mM over a period of 6 days 
at room temperature. Graphs show cumulative release over this period. At each time 
point all the PBS was removed from the samples and fresh PBS added. This was to 
mimic the situation seen in the collagen gel contraction experiments in chapter 7.3. 
7.2.2.1 PNVP-co-DEGBAC hydrogels. 
Figure 7.8 shows release of 4-MU into Greens medium containing 10% FCS over a 
period of 6 days at 37°C from P(NVP-co-DEGBAC) hydrogels. Xerogels were 
swollen in PBS containing 4-MU at concentration of I mM and 4 mM for 48 hours. 
The swollen gels were then allowed to air dry in sterile conditions for I hour to 
remove any excess solution before being placed into individual wells of a 48 well 
plate. I ml of medium was then added and the plate closed. At each time point the 
medium was completely removed and stored for later analysis and fresh medium 
added to mimic the conditions of the collagen gel contraction experiment described 
in chapter 7.3. The concentration of 4-MU in the PBS was measured at each time 
point and added to the previous days total to obtain the cumulative release. It can be 
seen that in the gels loaded from a solution of 1 mM 4-MU after 24 hours the 
majority of the 4-MU has been released. Again it is important to note that the 
concentration of the final solution would not be the same as the concentration of the 
loading solution i.e. a final cumulative concentration of I mM would not be 
expected. If all the 4-MU is being released from a gel loaded from I mM solution a 
maximum achievable concentration would be approximately 0.5 mM which is near 
to the value of 0.3 mM seen in figure 7.8. The gel loaded from 4 mM could 
potentially achieve a maximum concentration of approximately 2 mM however 
figure 7.8 shows a value of approximately 1.5 mM is obtained. In this case as with 
the gels loaded from a I mM solution most of the drug appears to be released over 
the first 24 hours of the experiment. This is further illustrated by the fractional 
release graphs shown in figure 7.9. Figure 7.9.A shows that approximately 80% of 
the 4-MU is released within the first 24 hours from the P(NVP-co-DEGBAC) 
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hydrogel loaded from a I mM 4-MU solution. Figure 7.9.B shows that a similar 
quantity of the 4-MU was also released within the first 24 hours from the P(NVP-co-
DEGBAC) hydrogel loaded from a 4mM 4-MU solution. Both of these curves are 
not a good fit with R2 values of 0.682 and 0.730 respectively. The diffusional 
exponents derived from these graphs, 0.074 ± 0.03 and 0.107 ± 0.03 respectively are 
indicative of non Fickian release. These values again are much lower than the value 
of 0.5 generally expected for Fickian release or the value of 0.45 expected for 
Fickian release from cylindrical samples. Again, they are close to the values of 0. 13, 
0.19 and 0.23 obtained for the release of 5-FU from PNVP based hydrogels by Liu et 
al. (2002b). 
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Figure 7.9 Fractional release of 4-MU into Greens medium from P(NVP-co-
DEGBAC) hydrogels over a period of 6 days at 37°C. Fractional release plotted from 
release data used for figure 7.8 plotted as concentration at time t / final 
concentration. 
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7.2.2.2 PNVP-co-DEGBAC-co-AA bydrogels. 
Figure 7.10 shows the cumulative release of 4-MU into Greens medium containing 
10% FCS over a period of 6 days at 37°C from P(NVP-co-DEGBAC-co-AA) 
hydrogels. Xerogels were swollen in PBS containing 4-MU at concentration of 1 
mM and 4 mM for 48 hours. The swollen gels were then allowed to air dry for 1 
hour in sterile conditions to remove any excess solution before being placed into 
individual wells of a 48 well plate. 1 ml of medium was then added and the plate 
closed. At each time point the medium was completely removed and stored for later 
analysis and fresh added to mimic the conditions of the collagen gel contraction 
experiment described in section 7.3. The concentration of 4-MU in the PBS was 
measured at each time point and added to the previous days total to obtain the 
cumulative release. It can be seen that in the gels loaded from a solution of 1 mM 4-
MU after 24 hours the majority of the 4-MU has been released. Again it is important 
to note that the concentration of the final solution would not be the same as the 
concentration of the loading solution i.e. a final cumulative concentration of 1 mM 
would not be expected. If all the 4-MU is being released from a gel loaded from 1 
mM a maximum achievable concentration would be approximately 0.5 mM which is 
close to the value of 0.3 mM seen in figure 7.10. The gel loaded from 4 mM could 
potentially achieve a maximum concentration of approximately 2 mM however 
figure 7.1 0 shows a value of approximately 1 mM 4MU is obtained. In this case as 
with the gels loaded from a 1 mM solution most of the drug appears to be released 
over the first 24 hours of the experiment. This is further illustrated by the fractional 
release graphs shown in figure 7.11. Figure 7.11.A shows that approximately 80% of 
the 4-MU is released within the first 24 hours from the P(NVP-co-DEGBAC) 
hydrogel loaded from a 1 mM 4-MU solution. Figure 7.11.B shows that a similar 
quantity of the 4-MU was also released within the first 24 hours from the P(NVP-co-
DEGBAC) hydrogel loaded from a 4 mM 4-MU solution. Again both of these curves 
are not a good fit with R2 values of 0.676 and 0.716 respectively. The diffusional 
exponents derived from these graphs, 0.074 ± 0.03 and 0.1 01 ± 0.03 respectively are 
indicative of non-Fickian release. Again these values are close to those obtained for 
the release of 5-FU from PNVP hydrogels (Liu and Rimmer 2002b). The addition of 
the acrylic acid to the P(NVP-co-DEGBAC) hydrogel had no effect on the release of 
the 4-MU. 
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Figure 7.10 Release of 4-MU into phosphate buffered saline from P(NVP-co-
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Fluorescence was measured using excitation of 360 nm and measuring emission at 
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Figure 7.11 Fractional release of 4-MU into Greens medium from P(NVP-co-
DEGBAC-co-AA) hydrogels over a period of 6 days at 37°C. Fractional release 
plotted from release data used for figure 7.10 plotted as concentration at time t / final 
concentration. 
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7.3 Effect of PNVP hydrogels loaded with PAPN or 4MU on collagen 
gel contraction. 
In these experiments the gels were prepared as per chapter 2.7.6. Even though the 
PAPN had no effect on the contraction of collagen gels in chapter 6.1 PAPN loaded 
gels were still included in these experiments. 
7.3.1 Effect of P(NVP-co-DEGBAC) hydrogels loaded with PAPN or 4-MU on 
contraction of collagen gels. 
The graph shown in figure 7.12 illustrates the effect of P(NVP-co-DEGBAC) 
hydrogels loaded with PAPN and 4-MU on the contraction of collagen gels over a 
period of 6 days. The initial contraction seen in the first 24 hours is thought in part to 
be due to the innate elastic properties of the collagen gels with only a small 
contribution from the cells. All of the treated collagen gels contracted significantly 
less over the initial 24 hours than the control. Over the following 24 hours only the 
hydrogel loaded from a 4 mM solution of 4-MU significantly reduced the 
contraction. The hydrogels had no effect on contraction at any further time points. It 
is interesting to note that the hydrogel itself significantly reduced contraction in the 
absence of drug over the initial 24 hours. 
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Figure 7.12 Effect of PAPN and 4-MU loaded P(NVP-co-DEGBAC) hydrogels on 
contraction of co-cultured collagen gels over 6 days. Results shown are mean ± SEM 
of n=3 experiments (3 replicates per experiment). * indicates a significant difference 
in area from untreated collagen gels (I-way ANOV A + Bonferroni correction). 
*p<0.05 **p<O.O I ***p<O.OO 1. 
7.3.2 Effect of P(NVP-co-DEGBAC-co-AA) hydrogels loaded with PAPN or 4-
MU on contraction of collagen gels. 
The graph shown in figure 7.13 illustrates the effect of P(NVP-co-DEGBAC-co-AA) 
hydrogels loaded with PAPN and 4-MU on the contraction of collagen gels over a 
period of 6 days. The initial contraction seen in the first 24 hours is thought in part to 
be due to the innate elastic properties of the collagen gels with only a small 
contribution from the cells. Unlike the P(NVP-co-DEGBAC) hydrogels the P(NVP-
co-DEGBAC-co-AA) hydrogels have no significant effect on the contraction of 
collagen gels by themselves. The hydrogels loaded with PAPN from a I 000 ~g.mrl 
solution significantly reduce contraction during the first 24 hours as do the hydrogels 
loaded from a 1 mM solution of 4-MU. The hydrogel loaded from a 4 mM solution 
of 4-MU significantly reduced the contraction of the collagen gels compared to the 
untreated gels up to day 2. 
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Figure 7.13 Effect of PAPN and 4-MU loaded P(NVP-co-DEGBAC) hydrogels on 
contraction of co-cultured collagen gels over 6 days. Results shown are mean ± SEM 
of n=3 experiments (3 replicates per experiment) * indicates significant difference in 
area from untreated collagen gels (I-way ANOVA + Bonferroni correction). 
*p<0.05 **p<O.OI ***p<O.OOl. 
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7.4 Effect of 4 mM 4-MU loaded PNVP hydrogels, changed every 
two days, on collagen gel contraction. 
The graph shown in figure 7.14 illustrates the effect of PCNVP-co-DEGBAC) and 
P(NVP-co-DEGBAC-co-AA) hydrogels loaded with 4 mM 4-MU on the contraction 
of collagen gels over a period of 6 days. In these experiments the hydrogel was 
removed every two days and fresh 4 mM 4-MU hydrogel added. Replacing the 
P(NVP-co-DEGBAC) hydrogel with fresh 4 mM 4-MU hydrogel every two days 
significantly reduces the contraction compared to the untreated control over the full 6 
day period. The P(NVP-co-DEGBAC-co-AA) hydrogel significantly reduces the 
contraction over 5 of the 6 days. However the large error bars on day 6 prevent 
significance being obtained. There was no significant difference observed between 
the two hydrogels. 
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Figure 7.14 Effect of PNVP based hydrogels loaded with 4 mM 4-MU on 
contraction of co-cultured collagen gels over 6 days. Hydrogels changed every 2 
days. Results shown are mean ± SEM of n=3 experiments (3 replicates per 
experiment) * indicates significant difference in area from untreated collagen gels 
(2-way ANOV A + Bonferroni correction). *p<O.05 **p<O.O I ** *p<O.OO I. 
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7.5 Summary of results. 
After the synthesis and characterisation of the hydrogels the evaluation of the 4-MU 
and PAPN drug release profiles were obtained. The TNBS (2,4,6-
trinitrobenzenesulfonic acid) assay, an assay for detection and quantification of 
primary amines in peptide solutions was modified to allow detection and 
quantification of PAPN in phosphate buffered saline. This is not ideal but it was not 
possible to detect the PAPN in cell culture media containing solutions. This was 
thought to be due to the presence of amino acids in the media and proteins in the 
foetal calf serum. The 4-MU was detected using fluorescence and could be 
accurately detected in various media, water, PBS, PBS + 10% FCS, serum free 
DMEM, DMEM + 10% FCS and Greens medium + 10% FCS. 
PAPN was loaded into P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-AA) 
xerogels (dehydrated hydrogels) from solutions of p-aminopropionitrile fumarate in 
PBS with concentrations of 200 J.lg.mr l and 1000 J.lg.mr l , Prior to release 
experiments the swollen gels were air dried to remove any excess solution and then 
placed into 1 ml of PBS. There was very little difference observed in the release 
behaviour of the I3APN loaded into P(NVP-co-DEGBAC) from 200 J.lg.mr l and 
1000 J.lg.mr l solutions. Both loading concentrations resulted in non-Fickian 
diffusion of the PAPN from the hydrogels as indicated by diffusion exponents of 
0.231 and 0.186 for the 200 J.lg.mr l and 1000 J.lg.mr l solutions respectively. The 
release profiles for PAPN loaded into P(NVP-co-DEGBAC-co-AA) from 200 J.lg.mr 
I and 1000 J.lg.mr l solutions were markedly different. The addition of the acrylic 
acid to the P(NVP-co-DEGBAC) hydrogel lowered the diffusion exponent. 
Diffusion exponents of 0.171 and 0.133 were calculated for the release of the I3APN 
from the P(NVP-co-DEGBAC-co-AA) hydrogels loaded from 200 J.lg.mr l and 
1000 J.lg.mr l solutions of 3-aminopropionitrile fumarate. 
4-MU was loaded into P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-AA) 
xerogels from solutions of 4-methyl umbelliferone sodium salt in PBS with 
concentrations of 1 mM and 4 mM. Prior to release experiments the swollen gels 
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were air dried to remove any excess solution and then placed into I ml of PBS. 
There was very little difference observed in the release profiles for the P(NVP-co-
DEGBAC) hydrogels loaded from the I mM and 4 mM 4-MU solutions. The release 
profiles calculated for these hydrogels gave diffusional exponents of 0.074 and 0.107 
for the 1 mM and 4 mM loaded hydrogels. With both hydrogels an initial burst 
release was observed during the first 24 hours where 80% of the 4-MU was released. 
The hydrogel loaded from the I mM solution released the remaining 20% of 4-MU 
over the following 48 hours. Similarly the hydrogel loaded from the 4 mM solution 
released the remaining 20% of 4-MU over the following 24 hours. The addition of 
the acrylic acid to the P(NVP-co-DEGBAC) hydrogel had no effect on the release of 
the 4-MU. Diffusional exponents calculated for the release of the 4-MU from the 
1 mM and 4 mM P(NVP-co-DEGBAC-co-AA) hydrogel were 0.074 and 0.101 
respectively. 
Table 7.1 summarises the diffusion exponents calculated for the release of PAPN 
and 4-MU from the PNVP based hydrogels. The acrylic acid was added to the 
P(NVP-co-DEGBAC) hydrogel in an attempt to modify the release of the PAPN 
from the hydrogel. The calculated diffusion exponents show that adding the acrylic 
acid to the hydrogel reduced the diffusion exponent. The addition of the acrylic acid 
to the P(NVP-co-DEGBAC) hydrogel has no effect on the calculated diffusion 
exponents for the release of the 4-MU. All of the diffusional exponents are in the 
same range as those observed by Liu et al. (2002b) for the release of 5-fluorouracil 
from PNVP based hydrogels. However the 5-FU was part of the crosslinker used in 
the hydrogel synthesis. Its release was therefore governed not only by diffusion but 
by crosslinker degradation (Liu and Rimmer 2002b). It was not possible to 
physically incorporate the PAPN or 4-MU into the hydrogels and therefore the 
release mechanism despite the similarities in diffusion exponents cannot be the same. 
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Table 7.1 Summary of diffusion exponents 
P(NVP-co-DEGBAC) P(NVP-co-DEGBAC-co-AA) 
J3APN / 200 0.232 ± 0.05 0.171 ± 0.05 
J..1gmr l 1000 0.186 ± 0.02 0.133 ± 0.02 
4-MU / 1 0.074 ± 0.03 0.073 ± 0.03 
mM 4 0.107 ± 0.03 0.101 ± 0.03 
Collagen gels were then used to evaluate the effects of these drug loaded hydrogels 
on contraction. The hydrogels examined were P(NVP-co-DEGBAC) and P(NVP-co-
DEGBAC-co-AA) hydrogels loaded with J3APN from solutions of 200 J..1g.mr l and 
1000 J..1g.mr1 and 4-MU from solutions of 1 mM and 4 mM. Hydrogels swollen in 
PBS in the absence of the J3APN and 4-MU were used as controls. The P(NVP-co-
DEGBAC) hydrogels loaded from a 4 mM solution of 4-MU produced a significant 
decrease in the contraction of the collagen gels up to day 2 of the experiment. In all 
cases the contraction of the collagen gels treated with the P(NVP-co-DEGBAC) 
hydrogel was significantly reduced at the 1 day time point. This was unexpected as 
the J3APN loaded hydrogels appeared to reduce contraction whilst J3APN by itself 
had no effect on the collagen gels. The P(NVP-co-DEGBAC-co-AA) hydrogels, 
loaded from a 1000 J..1g.mr l solution of J3APN and 1 mM solution of 4MU produced 
a significant decrease in the contraction of the collagen gels up to day 1 of the 
experiment. However the P(NVP-co-DEGBAC-co-AA) hydrogel loaded from a 
4 mM solution of 4-MU produced a significant decrease in the contraction of the 
collagen gels up to day 2. 
Reduction in collagen gel contraction was only observed up to day 2 when treated 
with any combination of hydrogel and anti-contraction agent. The hydrogels loaded 
from solutions of 4 mM 4-MU however appeared to be the most promising. It was 
therefore proposed to change the hydrogel every two days. Again all the media was 
removed at each 24 hour time point. It should be noted that the cells in the collagen 
gels will not be exposed to a constant concentration of 4-MU. It was shown in 
figures 7.9 and 7.11 that approximately 80% of the 4-MU is released from both the 
P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-AA) hydrogels with most of the 
remaining 4-MU released over the following 24 hours. This means that on the day 
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when the hydrogels are changed the cells will be exposed to a much higher 
concentration of 4-MU than on the days where the hydrogels are not changed. 
Changing the hydrogel every two days resulted in a significant reduction in collagen 
gel contraction when the gels were treated with both the P(NVP-co-DEGBAC) and 
the P(NVP-co-DEGBAC-co-AA) hydrogels loaded from a 4 mM 4-MU solution at 
the majority of the time points up to 6 days. 
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8. Discussion. 
The overall aim of this project was to develop a novel poly(N-vinylpyrrolidinone) 
(PNVP) based hydrogel wound dressing which could be used to release anti-
contraction agents to prevent or reduce skin graft contracture. 
To achieve this a series of specific objectives were identified I) to evaluate the 
material properties and cellular toxicity of novel PNVP hydrogels. 2) To examine the 
cytotoxicity of the identified anti contraction agents. PAPN and 4-MU, 3) to 
determine whether PAPN and 4-MU could reduce contraction in a collagen gel 
model, 4) to determine if 4-MU could prevent or reduce contraction in the 
reconstructed skin model, 5) to examine the loading and release of PAPN and 4-MU 
into and from PNVP hydrogels and 6) to examine to what extent the drug loaded 
hydrogels would reduce the contraction of the collagen gel and reconstructed skin 
models. 
A novel PNVP hydrogel was produced with material properties suitable for use as a 
wound dressing. Cytotoxicity testing showed that whilst cells could not be grown on 
the hydrogel this hydrogel was not cytotoxic. If human dermal fibroblasts were 
grown in indirect contact with the hydrogel then cell viability could be stimulated. 
Cytotoxicity testing of PAPN showed that this drug at the concentrations identified 
was also not cytotoxic. PAPN also had no affect on keratinocyte proliferation or 
differentiation at the concentrations identified. Cytotoxicity testing of 4-MU showed 
that this drug over the concentrations examined could significantly reduce cell 
viability and keratinocyte proliferation and differentiation. Despite or perhaps 
because of these cytotoxic effects 4-MU significantly reduced the contraction of both 
collagen I gels and the reconstructed skin model. PAPN was not shown to have any 
effect on the contraction of collagen I gels but previous work in this laboratory had 
shown PAPN to be effective in reducing the contraction of the reconstructed skin 
model. The water soluble salts of PAPN and 4-MU were loaded into the PNVP 
hydrogels and the release of the drugs from the hydrogels monitored. The drugs were 
released from the hydrogels in a predictable manner over a 48 hour period. The 4-
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MU loaded hydrogels were then shown to significantly reduce the contraction of 
collagen I gels when the hydrogels were changed every two days. 
In this thesis initially attempts were made to produce PNVP oligomers with differing 
functionalities. This was in an attempt to produce PNVP polymers with a greater 
range of applications. Unfortunately attempts to produce functionalised NVP 
oligomers had low yields and these synthesis routes proved impractical for the large 
quantities needed for hydrogel synthesis. Therefore PNVP hydrogel membranes 
crosslinked with either ethyleneglycol dimethacrylate (EGDMA) or diethyleneglycol 
bisallylcarbonate (DEGBAC) were synthesised and their material and biological 
properties evaluated. The P(NVP-co-EGDMA) hydrogels with 1 wt% crosslinker did 
not have material properties suitable for use as a wound dressing. The polymers, 
even when synthesised in the absence of solvent, once swollen in phosphate buffered 
saline (PBS) had an elastic modulus (E) of 0.16 MPa ± 0.02 MPa and ultimate 
compressive strength (UCS) of 0.03 MPa with an equilibrium water content (EWC) 
of 96.2% ± 0.3%. Increasing the amount of EGDMA in the hydrogel resulted in an 
opaque, phase separated polymer that disintegrated easily. Increasing the EGDMA 
content in the polymer to 2 wt% produced a polymer with an EWC of 92.3% ± 0.6%. 
Unfortunately it was not possible to get an elastic modulus or ultimate compressive 
strength for this polymer. Changing the crosslinker to DEGBAC reduced the EWC 
to 92.2% ± 0.1 % and gave an E = 0.22 MPa ± 0.02 MPa and UCS=0.29 MPa ± 
0.08 MPa. Once again increasing the DEGBAC concentration in the monomer blend 
reduced the EWC to 81.7% ± 0.4% for the 4 wt% DEGBAC hydrogel. 
These properties compare favourably with those seen in the literature for hydrogels. 
The viscoelastic nature of hydrogels makes the experimental determination of their 
material properties difficult. Values can be calculated for the elastic modulus, 
ultimate compressive or tensile strength, and the strain at failure. However these 
values will be dependent on the strain rate and temperature at which the experiment 
was performed. All experiments performed for this project were performed at a 
strain rate of 0.1 mm.s- I , this is equivalent to 6 mm.min- I , Cauich-Rodriguez et al. 
(1996a) produced a PNVP - PVA hydrogel with similar material properties, 
E = 0.15 MPa ± 0.07 MPa. Unfortunately it was not possible to obtain published 
EWC data for these polymers. The hydrogels produced by Hong et al. (1997) do not 
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have published mechanical data, however data about the EWC's of these polymers 
have been published. The polymers produced by Hong et al. were primarily 
synthesised from NVP and the majority of these contained a small am'ount of HEMA 
as well as a crosslinking agent (divinyl glycol, diallyl ether, ethyleneglycol 
dimethacrylate, diethyleneglycol dimethacrylate or tetraethyleneglycol 
dimethacrylate). All of these polymers had similar EWC's (95.0% - 98.3%) to the 
P(NVP-co-EGDMA) hydrogels produced for this thesis which had EWC's of 92.3% 
- 98.3%. Increasing the amount of another hydrophilic monomer, HEMA, in the 
Hong polymers from 1 wt% to 2 wt% whilst using 0.25 wt% diethyleneglycol 
dimethacrylate as the crosslinking agent increased the EWC from 95.0% to 98.3%. 
The P(NVP-co-DEGBAC) based hydrogels had much lower EWC's (81.7 - 92.2%) 
than those seen in the Hong et al. polymers. The EWC values seen for the P(NVP-
co-DEGBAC) based polymers are similar to those obtained by Lopes et al. (2003) 
for their PNVP-gelatin interpenetrating networks. The EWC's obtained for these 
networks ranged from 89.8% for the highest PNVP concentration (70% PNVP : 30% 
gelatin) to 90.2% for the lowest PNVP concentration (30% PNVP : 70% gelatin). 
However the PNVP crosslinked network produced as a control had an EWC of 
89.9% whilst the crosslinked gelatin control had an EWC of 83%. Potassium 
persulphate was used to crosslink the PNVP instead of a larger molecule such as 
EGDMA or DEGBAC and PNVP was used to form the networks instead of the 
monomer NVP used to produce the polymers in this thesis and the studies mention 
previously. 
Generally, the reactivity ratios for polymerization ofNVP and methacrylates do not 
favour the formation of instantaneous polymer compositions that are similar to the 
feeds. This can lead to heterogeneous materials. For example the reactivity ratios for 
copolymerization with furfuryl methacrylate (FM) have been approximated as 
rF A = 3.92 and rNVP = 0.004 (Zaldivar, Peniche et al. 1993). Copolymerization 
with glycidyl methacrylate (GMA) gave values of rGMA = 4.32 - 4.53 and 
rNVP = 0.0075 - 0.0147 (Wen, Xiaonan et al. 1992). The result of this large 
disparity between the pairs of reactivity ratios means that at high conversion 
heterogeneous materials contain regions of high crosslink density connected by long 
linear chains. On the other hand the reactivity ratios obtained by polymerization of 
a-allyl or p-allyl carbonates are much closer. For example Liu et al. (2000) 
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determined that for 5-fluoruracil diallylcarbonates that were copolymerized with 
NVP: ra.-allyl = 0.32 and rNVP = 0.97 and r~-allyl = 0.61 and rNVP = 1.3 (Liu and 
Rimmer 2002b). Therefore, the use of a bisallylcarbonate as a crosslinker in the 
synthesis of hydrogels, by the radical polymerization of NVP should lead to 
materials with more homogeneous distributions of crosslinks. Clearly changes in the 
distribution of crosslinks have a large effect on the properties i.e. EWC, E and UCS, 
of the hydrogels. 
Literature reports (Bruining, Koole et al. 1999) suggested that crosslinking the 
PNVP with a carbonate based crosslinker could produce a highly degradable 
hydrogel which would not be suitable for use as a wound dressing. Bruining et al. 
(1999) reported the synthesis and degradation of a carbonate crossl inked PNVP 
based hydrogel. The novel carbonate crosslinker used in the study was much longer 
than the DEGBAC used in this project and whilst both molecules have two carbonate 
groups the groups on the novel crosslinker appear to be more accessible and 
therefore more susceptible to hydrolysis. This may explain why the polymers 
synthesised by Bruining et al. degraded over time spans varying from under one day 
to polymers which were still stable after one week in studies performed at 3~C in 
PBS. To ensure that the P(NVP-co-DEGBAC) hydrogels would be stable 
degradation studies were performed on these hydrogels. EWC measurements were 
used to monitor hydrogel degradation. If significant degradation was occurring then 
the EWC would increase. No significant increase in EWC was observed over the 12 
days of the experiments. This would suggest that within the limits of the EWC 
measurements no appreciable degradation was occurring. 
Degradable hydrogels are especially useful in drug delivery and tissue engineering 
applications. Controlling degradation behaviour is one of the critical issues in 
biomaterials research. Generally biomaterials need to be cleared from the body once 
they complete their roles in the body, and degradable materials are ideal for this 
purpose. These polymers are usually viewed as superior materials; however, they 
have to be approached with caution. The effects of the degradation products on 
surrounding tissues has to be assessed. Changes in pH associated with the 
degradation of 'traditional' biodegradable polymers such as poly(lactic acid) or 
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poly(glycolic acid) can have an adverse effect on the viability of surrounding tissues. 
The rates of degradation also have to be evaluated as do the effects of degradation on 
the material properties ofthe polymer. 
The cytotoxicity of these hydrogels was then investigated. Cytotoxicity studies of 
PNVP based materials reported in the literature shows that PNVP is non cytotoxic 
and has even been shown to increase cell viability particularly in fibroblasts 
(Robinson, Sullivan et al. 1990; Vijayasekaran, Chirila et al. 1996; Hong, Chirila et 
al. 1997; Hong, Chirila et al. 1998; Risbud, Hardikar et al. 2000; Lopes and 
Felisberti 2003; Sen and Avci 2005; Devine, Devery et al. 2006; Saxena, Mozumdar 
et al. 2006). However this appears to be the first comprehensive cytotoxicity study 
using these polymers. 
The MTT assay was used to assess the viability of cells cultured in both direct and 
indirect contact with the hydrogels. Initial studies performed with the P(NVP-co-
EGDMA) hydrogel confirmed that PNVP based hydrogels can increase cell viability. 
Fibroblasts grown in direct contact with the P(NVP-co-EGDMA) polymer did not 
appear to adhere well to the polymer. Cells were seen either growing on the bottom 
of the ThinCert™ insert or in small aggregates on the polymer. In both cases the 
cells stained purple after incubation with MTT indicating that they are viable. The 
very high water content of this polymer provides a probable explanation for the lack 
of cell adhesion. For cells to be able to attach successfully to a surface, proteins i.e. 
fibronectin, laminin or vitronectin first have to adsorb to the surface (Nuttelman, 
Mortisen et al. 2001). In the case of this polymer the polymer is so highly hydrated 
that proteins would probably find it difficult to adsorb and therefore the cells would 
be less likely to attach to the polymers. In experiments where fibroblasts were grown 
in indirect contact with the P(NVP-co-EGDMA) hydrogel an increase in viability 
was seen. When fibroblasts were grown in direct contact with the P(NVP-co-
DEGBAC) hydrogel there was no increase in fibroblast viability. Again the cells 
preferred to grow on the bottom of the ThinCert™ insert rather than on the hydrogel. 
Whilst these cells stained blue when incubated with MTT indicating that they are 
viable, observations of cell morphology showed that whilst cell attachment to the 
polymer appears to be increased compared to the P(NVP-co-EGDMA) polymer, 
fibroblasts do not appear to be able to successfully adhere to the polymer. Again the 
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high water contents of these polymers may inhibit protein adsorption to the polymer 
surface and therefore inhibit cell attachment to the polymers. When fibroblasts were 
grown in indirect contact with the P(NVP-co-DEGBAC) hydrogel a significant 
increase in fibroblast viability was seen. In all of the experiments where fibroblasts 
were grown in direct contact with P(NVP-co-DEGBAC-co-AA) hydrogels cell 
viability was significantly inhibited. Growing fibroblasts in indirect contact with the 
P(NVP-co-DEGBAC-co-AA) hydrogels had no significant effect on cell viability in 
all three experiments. Again when the fibroblasts were grown in direct contact with 
the P(NVP-co-DEGBAC-co-AA) hydrogel the viable fibroblasts were found 
growing on the bottom of the ThinCert™ insert. 
A variety of human epithelial cells, Keratinocytes, HaCaT cells (an immortalised 
keratinocyte cells line) and a human corneal epithelial cell line, were also grown in 
direct and indirect contact with the P(NVP-co-DEGBAC) hydrogel. At no point was 
a significant increase in cell viability seen when any of the cells were grown in either 
direct or indirect contact with the polymer. Growing keratinocytes in direct contact 
with the hydrogel resulted in a significant inhibition in cell viability in two out of the 
three experiments. However in the other experiment there was no significant 
difference in cell viability observed. In all three experiments where keratinocytes 
were grown in indirect contact with the polymer no significant difference in cell 
viability was observed compared to the control. HaCaT's showed similar behaviour 
to the keratinocytes when grown in direct contact with the P(NVP-co-DEGBAC) 
polymer. Two out of the three experiments showed reduced cell viability compared 
to the control. When HaCaT cells were grown in indirect contact with the hydrogel 
two out of the three experiments showed no significant difference in cell viability 
between the cells grown with the polymer and those grown without. One of the three 
experiments had significantly reduced cell viability. In all of the experiments where 
HCEC cells were grown in direct contact with the P(NVP-co-DEGBAC) hydrogel 
cell viability was significantly reduced compared to the control. Conversely in all 
three experiments where HCEC cells were grown in indirect contact with the 
polymer there was no significant difference in cell viability. Reports of PNVP based 
hydrogels increasing cell viability have primarily used murine 3T3 fibroblast cells 
(Hong, Chirila et al. 1997; Risbud, Hardikar et al. 2000). Risbud (2000) also used 
SiHa epithelial cells and saw a similar increase in viability when these cells were 
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cultured on PNVP-chitosan hydrogels. The results reported in this thesis from the 
growth of human dermal fibroblasts in both direct and indirect contact with the 
PNVP polymers confirm the results of Hong et al. (1997) and Risbud et al. (2000). 
However Risbud et al. (2000) also successfully cultured epithelial cells on PNVP-
chitosan hydrogels. However the culture of epithelial cells on P(NVP-co-DEGBAC) 
hydrogels during the course of this project was unsuccessful. Devine et al. (2006) 
also saw an increase in the viability of hepatoma cells grown with a P(NVP-co-AA) 
polymer crosslinked with EGDMA .. 
Growing fibroblasts in indirect contact with PNVP based polymers can increase cell 
viability. Hong et al. (1997) suggest that when fibroblasts are grown in serum free 
conditions in the presence of PNVP crosslinked with diethyleneglycol 
dimethacrylate cell viability could be increased to approximately 90% of that seen 
when fibroblasts are cultured in the presence of serum. This was shown to be 
dependent on both the concentration of the crosslinker in the polymer and the 
concentration of the polymer in the culture medium. To investigate this fibroblasts 
were grown in both the presence and absence of serum in indirect contact with the 
three PNVP based polymers, P(NVP-co-EGDMA), P(NVP-co-DEGBAC) and 
P(NVP-co-DEGBAC-co-AA). In all cases there was no significant difference 
observed in the effects of the polymers on cell viability in the presence or absence of 
serum in the culture medium. This indicates that the effect of the PNVP hydrogels on 
fibroblasts is independent of the presence of serum. Risbud et al. (2000) also showed 
that the presence of the polymer was not always required to see an increase in cell 
viability. Culture medium incubated with the PNVP-chitosan polymer could also 
increase cell viability. This was also shown to be concentration dependent with 
medium containing up to 30% conditioned medium increasing cell viability. 
The ability of the PNVP hydrogels to increase cell viability was unexpected, 
especially when the polymers were in indirect contact with the cells. Therefore a 
series of experiments were performed to investigate how the PNVP hydrogels 
affected the cell viability. A number of theories were proposed to explain how the 
PNVP hydrogels could affect fibroblast viability when the polymers were placed in 
indirect contact with the cells. 1) the polymers could be removing cell metabolic 
waste from the culture medium, 2) the polymers could also be removing mitogens 
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from the culture medium in essence forcing the cell metabolism into overdrive to 
compensate, 3) the polymer could be directly stimulating the cells i.e. degradation 
products could be released from the polymer and directly interact with the cells. 
Hong et aI. (1997), Risbud et a!. (2000) and Devine et aI. (2006) all report an 
increase in cell viability when cells were grown with PNVP based polymers. 
However none of these authors were able to explain how this effect occurs. These 
experiments proved inconclusive with significance only obtained when washed 
polymers were placed into indirect contact with cells in the presence of serum. In the 
absence of serum it was the polymer conditioned media that produced a significant 
increase in cell viability. This could suggest that foetal calf serum may affect the 
mechanism by which PNVP can affect fibroblast viability. The direct stimulation of 
fibroblasts by the polymer would appear to be a promising route for further study. 
At this point it was clear that a poly(vinylpyrrolidinone) hydrogel had been 
synthesised with material properties suitable for use as a wound dressing. The 1 wt% 
DEGBAC P(NVPpcopDEGBAC) hydrogel was flexible, malleable and strong. 
Increasing the crosslinker concentration produced harder, more brittle polymers 
unsuitable for use as wound dressings. Although these hydrogels proved to be non-
cytotoxic, cells were unable to grow successfully on the polymers. This is not 
necessarily a bad property in a wound dressing as cells will not be lost when the 
dressing is changed. Attempts to investigate how the polymers affect fibroblast 
viability proved inconclusive and therefore further work would be required to 
determine the mechanism by which PNVP hydrogels affect cell viability when not in 
direct contact with the cells. The results did suggest however that the polymer may 
be directly interacting with the cells, perhaps via degradation products. 
The second objective was to examine the cytotoxicity of the two identified anti 
contraction agents, p-aminopropionitrile (PAPN) and 4-methyl umbelliferone (4-
MU). PAPN is a specific nonpcompetitive Iysyl oxidase inhibitor (Arem, Madden et 
aI. 1975) and therefore inhibits collagen crosslinking. PAPN, at a concentration of 
200 J.1g.mr l has been shown to reduce the contraction of tissue engineered skin 
(Harrison, Gossiel et aI. 2006c). Redden et aI. (2003) showed that I mM PAPN 
significantly reduced contraction of fibroblast populated collagen gels. Nelson et aI. 
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(1988) showed that fibroblasts treated with 0.25 and 0.5 mM PAPN had reduced 
migration however no differences in cell proliferation or collagen synthesis were 
observed, however Harrison et al. (2006c) showed that PINP production was 
significantly increased, indicating increased collagen synthesis, in both fibroblast 
and fibroblast / keratinocyte monolayer cultures treated with 200 JAg.mr! pAPN. The 
effects of PAPN on cell viability and keratinocyte proliferation and differentiation 
were therefore investigated as part of this project. PAPN at concentrations of 
between 50-800 JAg.mr! had no significant effect on the viability of fibroblast and 
keratinocyte mono and co-cultures. At the same concentrations PAPN had no 
significant effect on keratinocyte proliferation or differentiation. 
4-methyl umbelliferone (4-MU) has not previously been identified as a potential 
anti-contraction agent in the literature. 4-MU is a specific inhibitor of hyaluronan 
(HA) synthesis (Rilla, Pasonen-Seppanen et al. 2004). HA affects cell adhesion, 
migration, proliferation and differentiation (Rilla, Siiskonen et al. 2005). Treatment 
of keratinocytes with 0.5 mM 4-MU has been shown to strongly, but reversibly 
reduce cell proliferation (Rilla, Pasonen-Seppanen et al. 2004). The effects of 4-MU 
on cell viability and keratinocyte proliferation and differentiation were therefore 
investigated as part of this project. At a concentration of greater than 1 mM 4-MU 
significantly reduced the viability of fibroblasts and keratinocytes in both single and 
co-cultures. At concentrations of 0.125 mM or greater 4-MU significantly reduced 
keratinocyte proliferation, at concentrations of greater than 0.5 mM 4-MU also 
significantly reduced keratinocyte differentiation. Ideally the effects of 4-MU on 
keratinocyte migration should also be evaluated. 
The cytotoxic effects of 4-MU cannot be ignored. Whilst literature reports suggest 
that these effects are reversible when the 4-MU is removed from the cells (Rilla, 
Pasonen-Seppanen et al. 2004) this was not investigated as part of this project. If the 
treatment of the healing wound with 4-MU results in significant cell death then 
wound healing would be delayed. As mentioned previously when epithelialisation is 
delayed beyond three weeks the incidence of hypertrophic scarring increases from 
33% to 78% (Papini 2004). In addition to concerns about delayed wound healing the 
mode of cell death would be crucial. If the cells die via necrosis and continue dying 
205 
whilst being treated with 4-MU this could lead to chronic inflammation. However. if 
the cells undergo a programmed cell death i.e. apoptosis then chronic inflammation 
would not occur. The presence of pro-inflammatory cytokines in the wound bed 
serve as some of the earliest signals to activate local fibroblasts and keratinocytes 
(Martin 1997). However prolonged inflammation delays wound healing still further 
and is associated with abnormal scarring (Singer and Clark 1999; Bayat, McGrouther 
et a!. 2003). According to Eming et a!. although the underlying mechanisms for the 
differences in the outcome of scarring is not well understood, there is substantial 
experimental and clinical evidence that differences in scarring reflect an altered 
inflammatory and/or cytokine profile between individuals or in a disease state 
(Eming, Krieg et a!. 2007). Whilst the aim of this project is to reduce skin graft 
contracture it would not be beneficial to the patient to replace one type of scarring 
with another. 
The third objective was to evaluate the efficacy of PAPN and 4-MU on contraction. 
The simple collagen I gel model, based on the commonly used fibroblast populated 
collagen gel model has been widely used since its introduction by Bell and Ivarsson 
in 1979 (2006) to model wound contraction. However skin and therefore burns 
wounds consist of more than one cell type, as well as the fibroblasts present in the 
dermis, keratinocytes, endothelial cells, melanocytes, neutrophils and macrophages 
are among the many cell types that can be found in skin and in the wound bed. 
Whilst fibroblast populated collagen gels are simple and convenient they are not 
particularly physiologically relevant. Therefore keratinocytes were introduced into 
the collagen gels. Oshita et a!. (2006) showed that the introduction of keratinocytes 
into fibroblast populated collagen gels increases contraction. However even the 
introduction of keratinocytes into the fibroblast populated collagen gels cannot 
compensate for the inherent lack of dermal architecture and basement membrane. 
Therefore a second model based on sterilised human dermis was also used to 
evaluate the efficacy of the 4-MU in reducing contraction. This model has been used 
for many years in Professor MacNeil's group. It has been shown that in this model it 
is the keratinocyte that it primarily responsible for contraction (Ralston, Lay ton et al. 
1997; Chakrabarty, Heaton et a!. 2001; Harrison, Gossiel et a!. 2006c). 
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Harrison et a!. (2006c) showed that treatment of this reconstructed skin composite 
with PAPN at a concentration of 200 Ilg.mrl significantly reduced its contraction 
over the 28 days that the experiments were performed over. However PAPN at 
concentrations of between 50 - 800 Ilg.mr1 had no effect on the contraction of 
collagen gels populated with both fibroblasts and keratinocytes. 1 mM f3APN had 
been sho\\n to significantly reduce the contraction of fibroblast populated collagen 
gels by Redden et a!. (2003). A 1 mM solution of f3APN is equivalent to 
256.3 Ilg.mrl, which is slightly higher than the concentration used by Harrison et a!. 
to reduce contraction of the reconstructed skin composite. However this 
concentration is within the range of concentrations examined in this project. 
Previous unpublished data from the group of Dr. Mike Edwards at Glasgow 
University showed that contraction of fibroblast populated collagen gels was 
significantly reduced when these gels were treated with a 2 mM solution of 4-MU. 
However 4-MU does not appear to have been thoroughly investigated as a potential 
therapeutic anti-contraction agent. Collagen gels were therefore prepared containing 
either fibroblasts, keratinocytes or a 3: 1 co-culture of keratinocytes : fibroblasts. 
These gels were treated with 2 mM 4-MU for 6 days. Unfortunately the variation in 
the data obtained from these experiments meant that a statistically significant 
reduction in contraction was only seen at days 3-5 in the keratinocyte populated gels. 
The fibroblast and co-culture collagen gels had no significant reduction in 
contraction. 4-MU successfully reduced contraction in both collagen gels and the 
reconstructed skin model. In collagen gels seeded with both fibroblasts and 
keratinocytes and treated with a concentrations of 4-MU ranging from 0 - 4 mM 
contraction was significantly reduced when the gels were treated with 4-MU at 
concentrations of I mM or greater. When the reconstructed skin model was treated 
with 4-MU at concentrations of 1 mM or greater a statistically significant reduction 
in contraction was seen. Analysis of the histology obtained from these composites 
showed that whilst the quality of the composite decreased with increasing 
concentration of 4-MU, the deterioration in composite quality only became 
significant in composites treated with 2 mM 4-MU. The only exception to this was a 
significant decrease in fibroblast number identified in the composite treated with 1 
mM4-MU. 
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At this point in the project a PNVP hydrogel had been developed with material 
properties suitable for use as a wound dressing. I3APN and 4-MU both appear to be 
promising candidates for use as anti-contraction agents. The next stage in the project 
was the incorporation of these drugs into the hydrogel, this proved to be challenging. 
Initially attempts were made to physically incorporate the I3APN in the form of 3-
aminopropionitrile fumarate into the mono mer blend prior to curing. This was 
unsuccessful, producing hydrogels with a large number of bubbles and large amounts 
of golden brown flecks. These were presumed to be I3APN and were found around 
the edges of the polymer plaque when it was removed from the oven and mould. 
Acrylic acid and water were added to the NVP monomer blend in an attempt to 
dissolve the I3APN. However this still proved unsuccessful. Therefore once the 
P(NVP-co-DEGBAC) and PCNVP-co-DEGBAC-co-AA) hydrogels had been 
washed in ethanol, discs were cut out and dried at 60°C for 48 hours to produce 
xerogels. These xerogels were then rehydrated in PBS containing two different 
concentrations of the water soluble salts of the two drugs, 3-aminopropionitrile 
fumarate and 4-methyl umbelliferone sodium salt. 
The fifth part of this project involved measuring the release of the drugs from the 
hydrogels. To achieve this, assays were required to measure the release of the drugs 
from the hydrogels. To this end an assay for the measurement and detection of 
proteins and amino acids the 2,4,6-trinitrobenzenesulfonic acid (TNBS) assay was 
used to detect I3APN release. The TNBS assay was modified slightly to allow for the 
differences in reactivity between the rJAPN and amino acids. Measurement of 4-MU 
concentration is widely used when monitoring enzymatic activity (Ritger and Peppas 
1987a). In monitoring enzymatic activity a strongly fluorescent molecule, such as 4-
MU, can be conjugated to the natural substrate of the enzyme. The degradation of 
these synthetic substrates by the enzyme releases the 4-MU giving a quantitative 
measurement of activity. 
The exponential relation MrlM",=kt" proposed by the group of Peppas (Ritger and 
Peppas 1987a; Ritger and Peppas 1987b) for the release of solutes from polymeric 
materials was used to analyse the release of the drugs from the polymers. Where 
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MrlM", is the fractional release of the drug from the polymer Mt=mass of drug 
released at time t and M", is the total mass of the drug releases by time infinity. k is 
the rate constant and n is the diffusional exponent. It is the value of the diffusional 
exponent that indicates if the drug is being released by Fickian diffusion (n=0.5) or if 
there is some interaction between the solute and the polymer. For cylindrical 
samples, such as the ones used in this study, Ritger states that for Fickian diffusion 
n=0.45, for anomalous (non-Fickian) transport n= 0.45<n<0.89 and for Case-JI 
transport n=0.89 (Liu and Rimmer 2002b). 
The release profiles obtained for the release of both drugs from both of the PNVP 
based hydrogels allowed diffusional exponents of between 0.073 and 0.232 to be 
calculated. These coefficients are similar to those obtained by Liu and Rimmer 
(2002b) for the release of 5-FU from PNVP based hydrogels. In this paper (Liu and 
Rimmer 2002b) the low values of these exponents was attributed to Fickian 
diffusion, and the interaction of the diffusate with the polymer chain. The 
degradat!on of the crosslinker also played a major role in the release of the 5-FU 
from the PNVP hydrogel. There appeared to be no degradation occurring in these 
polymers over the time frame studied and the PAPN and 4-MU were not covalentIy 
bound to the hydrogels. Therefore this last explanation does not hold for this system. 
Further investigation would be required to explain the mechanisms of both drug 
uptake and release. Unfortunately swelling studies were not performed as part of this 
project. These would be needed to accurately compare the loading of the drugs into 
the PNVP polymers to the loading of other drugs into other hydrogels. 
Acrylic acid was also added to the P(NVP-co-DEGBAC) polymer to see if the 
release of the PAPN could be modified. The diffusional exponents obtained for the 
release of the PAPN from the P(NVP-co-DEGBAC-co-AA) hydrogels were as 
expected lower than the exponents calculated for the plain P(NVP-co-DEGBAC) 
hydrogel with values ranging from 0.073 to 0.171. Again these values are similar to 
those calculated by Liu et al. (2002b). Unfortunately at this time it has not been 
possible to obtain diffusional exponents for the release of other drugs from similar 
materials other than those quoted already. The acrylic acid had no effect on the 
release of the 4-MU from the hydrogels. Whilst there are slight variations in the 
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release of the drugs from the hydrogels the majority of the drugs are released from 
the hydrogels over the first 24 hours. Typically about 80% of the drug (both PAPN 
and 4-MU) is released over this time period. Most of the rest of the drugs were 
released over the following 24 hours. 
The final part of this project was to examine to what extent the drug loaded 
hydrogels would reduce contraction in the collagen gel and reconstructed skin 
models. When the PNVP based hydrogels loaded with j3APN and 4-MU were placed 
above collagen gels seeded with both fibroblasts and keratinocytes for six days there 
was no significant difference in the collagen gel contraction at day 6. The P(NVP-co-
DEGBAC) hydrogels themselves and the P(NVP-co-DEGBAC) hydrogels loaded 
from 200 and 1000 Jlg.mr l solutions of PAPN and ImM solution of 4-MU also 
reduced contraction at 24 hours. Only the P(NVP-co-DEGBAC-co-AA) hydrogels 
loaded from a 1000 Jlg.mr l solution of PAPN and a 1 mM solution of 4-MU 
significantly reduced collagen gel contraction at 24 hours. However, collagen gel 
contraction was significantly reduced at both 24 and 48 hours when both hydrogels 
loaded from a 4 mM solution of 4-MU were placed in indirect contact with the gels. 
It was therefore decided to change the PNVP based hydrogels loaded from a 4 mM 
solution of 4-MU every two days over the course of the six day experiment. This 
resulted in a significant reduction in collagen gel contraction over the full six day 
period for the 4-MU loaded P(NVP-co-DEGBAC-co-AA) hydrogel. Unfortunately 
large error bars on day 6 for the 4-MU loaded P(NVP-co-DEGBAC) hydrogel meant 
that a statistically significant reduction in contraction was only seen until day 5. 
Time constraints meant that it was not possible to evaluate the effect of the drug 
loaded hydrogels on the reconstructed skin model. 
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9. Conclusions. 
In conclusion the aim of this project was the synthesis of a hydrogel wound dressing 
for the prevention / reduction of skin graft contracture. Two novel 
poly(vinylpyrrolidinone) based hydrogels have been synthesised P(NVP-co-
DEGBAC) and P(NVP-co-DEGBAC-co-AA). Both of these hydrogels have material 
properties suitable for use as a wound dressing. 
1. Both of the novel the P(NVP-co-DEGBAC) and P(NVP-co-DEGBAC-co-
AA) hydrogels are non-cytotoxic and have even shown an ability to increase 
the viability of dermal fibroblasts which are grown in close proximity. 
Generally cells will grow up to the hydrogels but not on the hydrogels. This 
non fouling property could be useful in reducing additional trauma to healing 
wound beds caused by the changing of the dressings. 
2. PAPN has also been shown to have no significant toxicity associated with its 
use. Treatment of skin cells with PAPN at concentrations of between 50 and 
800 Jlg.mr l had no significant effect on cell viability, keratinocytc 
proliferation or differentiation. However, treatment of skin cells with 4-MU 
showed significant toxicity associated with concentrations of 0.125 mM or 
greater. 
3. At concentrations of greater than 1 mM 4-MU successfully reduced 
contraction in collagen gels populated with co-cultures of fibroblasts and 
keratinocytes. When collagen gels were populated with either fibroblasts or 
keratinocytes and treated with 2 mM 4-MU a reduction in contraction was 
seen but this was not significant. Despite reports in the literature that PAPN 
can reduce the contraction of fibroblast populated gels the PAPN had no 
effect on the contraction of collagen gels populated with a co-culture of 
fibroblasts and keratinocytes. 
4. When the reconstructed skin model was treated with 4-MU at concentrations 
of greater than 1 mM a significant reduction in contraction was seen. This 
corresponded to a reduction in the quality of the reconstructed skin. At the 
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lowest concentration used (0.5 mM) there did not appear to be a significant 
reduction in quality but at the highest concentration used (2 mM) there was 
very little epidermis and what epidermis was visible was not attached to the 
dermis with no fibroblasts present in the dermis. 
5. Both ~APN and 4-MU can be loaded into the PNVP based hydrogels and 
released in a predictable manner over 2-3 days. The addition of AA to the 
P(NVP-co-DEGBAC) hydrogels had very little effect on the release of the 
~APN from the hydrogel. 
6. PNVP hydrogels loaded with ~APN at concentrations had no effect on the 
contraction of collagen gels populated with a co-culture of fibroblasts and 
keratinocytes over 7 days. PNVP hydrogels loaded from 1 mM and 4 mM 
solutions also had no effect on the contraction of collagen gels populated 
with a co-culture of fibroblasts and keratinocytes over 7 days. However 
PNVP hydrogels loaded from a 4 mM solution of 4-MU significantly reduced 
collagen gels contraction over six days when the hydrogel was changed every 
two days. 
These data suggest that this hydrogel could potentially be used as a wound dressing 
to reduce skin graft contracture in bums patients. 
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10. Further work. 
Further work would be required to evaluate the effect of the drug loaded hydrogel on 
the reconstructed skin model. In addition to this further experiments would need to 
be carried out to look at a range loading concentrations of the drugs. Further studies 
looking at manipulating the drug release profiles of the PAPN could also be 
performed. This could involve increasing the acid content of the hydrogels either by 
increasing the concentration of acrylic acid in the gels or by the incorporation of 
other acid functional molecules such as itaconic acid which has two acid groups into 
the hydrogels. 
A more detailed study of degradation would also be advantageous perhaps using size 
exclusion chromatography (SEC), high performance liquid chromatography (HPLC) 
or by measuring the difference in the dry weight of the polymer over a set time 
period. These studies could shed light on I) if degradation products could be 
influencing cell viability and 2) the mode of drug release from the hydrogels. 
The hydrogels produced in this thesis were produced by a thermal curing method. 
This resulted in hydrogels, once hydrated, that were up to 3 mm thick. This would 
result in a very bulky dressing. To reduce the thickness of the hydrogel it could be 
possible to produce the hydrogels using a UV, IR or other curing system. 
Finally, to take this work to the clinic it would be necessary to conduct animal in 
vivo toxicity tests of the hydrogel, drugs and hydrogel with drugs. For this to be 
successful the hydrogels would also have to be able to be produced in a suitably 
clean environment i.e. in a suite of clean rooms. 
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